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Outline
OUTLINE OF THE THESIS
Molecular  interactions,  although  rich  in  information,  have  up  till  now  not  been 
considered much in metabolomics studies. This thesis focuses on the study of molecular 
interactions of metabolites in biofluids by Nuclear Magnetic Resonance (NMR), which is 
uniquely suited for measurement of interactions in such complex mixtures as biofluids as 
it  provides  qualitative  and  quantitative  information  in  a  non-destructive  manner  at 
molecular/atomic detail.
In Chapter 1 is discussed the role of biofluids in the body and how they report on the 
physiology of the body, through their molecular composition. Biofluids being mixtures of 
molecules of various size and charge, require methods to measure the analytes either 
separately  or  in  the  whole  crude sample.  The latter  approach is  chosen for  studying 
molecular interactions and NMR is the favored technique. We also discuss the role of 
human serum albumin (HSA), the most abundant protein in blood plasma and present in 
almost all biofluids in human. Moreover, an introduction to the NMR is presented with a  
specific focus on chemical shift and bulk magnetic susceptibility (BMS).
Chapter 2 give theoretical explanation and demonstrate experimental use  of signal 
frequency shift caused by protein-induced bulk magnetic susceptibility to determine total 
protein content in blood plasma. Fatted Human Serum Albumin (fHSA), fatted Bovine 
Serum Albumin (fBSA) and Human Serum Albumin (HSA) were employed to represent 
most plasma proteins, as they are like HSA all globular proteins. A linear relationship 
between the chemical shift change and the protein concentration was confirmed in the 
blood plasma mimics with different albumins added. Within each of the mimics equal 
slopes were found for exchange-free metabolites. The total protein concentration in blood 
plasma can be determined with good accuracy as evident from comparison with standard 
colorimetry  measurement  used  in  clinic.  The  error  in  the  proposed  BMS method  is 
estimated to be ≤ 5 %, which is comparable to the ~4 % error of the standard colorimetric 
method used in the clinic. 
Chapter 3 is about metabolites-HSA interactions in blood plasma. Because HSA is the 
most abundant and main transporter protein in blood plasma it is of interest to understand 
how its presence affects the concentration of free metabolites. These aspects were studied 
in  blood  plasma  and  blood–plasma  mimics.  The  mimics  consisted  of  metabolites 
commonly observed by NMR in blood plasma and HSA or fatted HSA, all at their normal 
concentration. Experiments were performed in the presence of fatty acids (FAs), the main 
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HSA ligand, to find out their impact on metabolites-HSA interactions. Also, ultrafiltration 
was evaluated, the method usually employed for separation of metabolites from blood-
plasma proteins. And chemical shift change due to sample dilution was used to identify 
metabolites interacting in fast exchange rate and their respective dissociation constant.
In  Chapter 4 specific fatty acids (FAs), namely myristic acid (C14) and stearic acid 
(C18),  were  used  to  determine  their  impact  on  metabolite-HSA interaction.  The  free 
metabolites  concentration  was  followed  at  different  FA-HSA ratios.  Due  to  poor  FA 
solubility, the samples become diluted simultaneously upon increasing the FA-HSA ratio. 
Thus, the effect of dilution on free metabolite concentration was also followed.
Chapter 5 deals with the formation of complexes between metabolites, bivalent metal 
ions and HSA. This chapter focuses on composition of the prostatic fluid that is affected 
as  part  of  malignant  growth  and  transformation.  Here  chemical  shift  and  transverse 
relaxation were measured and calculated for different composition.
2
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CHAPTER 1
Introduction
Marc Jupin, Sybren Wijmenga
Keywords: Biofluids, Metabolomics, Sample preparation, Analytical techniques, Serum 
albumin, NMR principles, Bulk magnetic susceptibility.
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BIOFLUIDS
The human body is composed for ~70 % of water mixed with other molecules to form 
human biofluid. These molecules are of various size and charge, e.g. ions, amino acids, 
nucleotides, fatty acids, peptides and proteins. Biofluids are found inside cells as well as 
in the extra-cellular spaces. Biofluids are used for transport, energy supply and protection 
(e.g., blood plasma, cerebrospinal fluid, amniotic fluid, breast milk), for excretion (e.g., 
urine,  sweat,  bile),  for  enzymatic  process  (e.g.,  saliva,  tears,  prostatic  fluid),  but  a 
biofluid can also have several of these categories of functions (e.g., blood plasma). The 
body  actively  maintains  a  nearly  constant  internal  environment,  a  process  known as 
homeostasis.  For instance, the kidneys as organ maintain the ion concentration in blood, 
while at the molecular level protein, ion, metabolite etc. transport across membranes is 
actively regulated. This implies that biofluids like blood reflect the physiology of the 
body. Another aspect is that biofluids can be infected by parasites and/or become vectors 
of transmitted diseases, like the acquired immune deficiency syndrome (AIDS). Because 
samples  (saliva,  urine  or  blood)  can  be  collected  fairly  easily,  the  time-dependent 
fluctuations of metabolites due to various stimuli can be easily studied. Thus, studying 
biofluids can be a source of great knowledge about the body's state and for identification 
of diseases. One finds today several research fields involved in detecting various aspects 
of  the  composition  of  biofluids,  e.g.,  immunology,  transcriptomics,  proteomics, 
lipidomics  and  metabolomics.  Information  extracted  in  these  different  fields  can  be 
merged to obtain a global view of the biological system [1], resulting in a recent offshoot: 
systems biology [2]. In this chapter and the rest of the thesis we focus on metabolomics.
METABOLOMICS/METABONOMICS
The term metabolomics contains the word metabolome which stands for the collection 
of  metabolites in a biological system, while the suffix ‘omics’ stands for the field of 
study in biology.  Thus,  metabolomics is  the study of  the quantitative complement of 
metabolites in a biological system and of changes in metabolite concentrations or fluxes 
related  to  genetic  or  environmental  perturbations  [3].  Metabolites  come  from  the 
metabolism of molecules, i.e. the processes that will either construct and produce new 
molecules (anabolism) or breakdown molecules and produce energy (catabolism). They 
usually refer to low molecular weight molecules like amino acids or sugars. Metabolism 
occurs in cells for the purpose of living, growing and performing special functions (e.g.,  
prostate epithelial cells  secrete citrate  [4]). By reflecting the upstream activity of genes 
and  proteins,  as  well  as  being  modulated  by  factors  unrelated  to  the  genome  (e.g., 
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interaction  with  commensal  microorganisms  and  environmental  agents,  nutrition  and 
other  lifestyle-related  aspects),  metabolite  levels  closely  express  cellular  function, 
constituting  a  sensitive  probe  for  homeostasis  and  its  regulation  [5].  For  example, 
pharmacokinetics, related to drug safety, is an important aspect in pre-clinical trials [6–
9]. It includes drug clearance, how drugs are metabolized in the body in phase I and II:  
biotransformations to increase the reactivity (phase I) and hydrophilicity for excretion 
(phase II),  which can also sometimes increase their toxicity.  These phase II reactions 
include oxidation, hydrolysis, reduction or conjugation [10]. In vivo metabolite studies of 
organs  [11] or tissue-biopsies  [12] or biofluids  [13], provide information on complete 
living  systems  at  the  individual  level,  i.e.  they  provide  a  global  outcome  of  all  the 
influencing factors. The information from different studies is often combined and refined 
through  statistical  methods  to  extract  correlated  data  of  the  metabolism  of  a  living 
system.  This  combined  approach  is  often  called  metabonomics:  understanding  the 
metabolic  responses  of  living  systems  to  pathophysiological  stimuli  or  genetic 
modification via multivariate statistical analysis [14]. In practice, the terms metabolomics 
and  metabonomics  are  often  used  interchangeably,  and  the  analytical  and  modeling 
procedures  are  the  same.  Thus,  metabonomics  or  metabolomics  can  be  seen  as  the 
fulcrum of top-down systems biology (see Figure 1), rather than the study of single-gene 
effects, which is a bottom-up approach [15]. For instance, the phenotype is then viewed 
through the metabolite profile. 
Publications on metabolomics have seen a tremendous increase in the past lustrums. 
Between 2000 and 2010, metabonomics and metabolomics publications increased four- 
and sevenfold, respectively, to a total of 1288 and 3057 [17]. These publications cover 
various areas, e.g., drug toxicology [8,18], cancer [5,19], inborn errors [20], food analysis 
[21], interactions [22–24] and parasitic infections [25]. The goal of all these studies is to 
detect all metabolites; however, this is currently not technologically feasible  [26]. This 
due  to  three  factors:  (a)  the  complete  size  of  the  human  metabolome  is  yet  to  be 
determined; HMDB version 3.5 (2013) has 41,516 metabolite entries; this includes both 
water-soluble  and lipid-soluble  metabolites;  however,  in  this  set  the  number  of  lipid 
species is overwhelmingly large; the number of possible lipid species is >105 [19], due to 
the structural and chemical diversity of lipids, i.e.  there are different types of polar head 
groups,  various  fatty-acid  acyl  chain-lengths  and  different  degrees  and  positions  of 
(un-)saturation; (b) the wide range of chemical species, which includes low molecular 
weight polar volatiles, such as ethanol, but also high molecular weight polar glucosides, 
non-polar lipids and inorganic species; (c) the range of metabolite concentrations  (pM–
mM). These large variations in the nature and concentration of analytes are challenges to 
all  the  analytical  technologies  employed in metabolomics  strategies.  Thus,  to  acquire 
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good coverage of detected metabolites a combination of sample preparation and various 
analytical platform is recommended [18–20]. One good example of such a joint approach 
is  the  Husermet  project  (Human  Serum  Metabolome  in  Health  and  Disease, 
www.husermet.org),  where  gas  chromatography–mass  spectrometry  (GC–MS),  liquid 
chromatography–mass  spectrometry  (LC–MS),  NMR  spectroscopy,  and  Fourier 
transform-infrared (FT-IR) have all been applied [31]. Another example is the TI-Pharma 
project in the Netherlands on human cerebral spinal fluid (human CSF) where coverage, 
albeit still incomplete, of both proteome and metabolome was achieved by GC-MS, LC-
MS,  and NMR  [32].  Apart  from the  above  an  obvious  need exists  for  technological 
advances.
Figure 1 Schematic representation of the “top-down” relationship between the components of a  
systems  biology  approach.  Metabolomics  is  part  of  the  continuum  of  systems  biology  and  
represents a read of gene function and the physiological landscape. Pathological events can be  
measured by changes in the genome, transcriptome, proteome, and metabolome. Integration of  
these systems biology components can be viewed as host-specific rather than tissue- or site-
specific. Bioinformatics is a key element in data management and analysis of collected data sets  
arising from these 4 -omics. M2 is a metabolite originating from M1. (Figure adapted from [16])
In terms of data, system biology and (single- and multi-) platform(s) analytics generate 
huge amount of data. Sophisticated data analysis and data fusion techniques are required 
to extract and combine relevant information and knowledge about the complex biological 
system. Data analysis using chemometrics (multivariate statistical tool) is mainly used in 
metabolomics to enable the detection and identification of endogenous and exogenous 
metabolites responsible for mediating the phenotypic  expression of altered metabolism 
resulting  from a biological  challenge  [33–36].  Inter-omic  integration  includes  several 
statistical issues that  may directly impact data merging and the  interpretability of the 
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results. For example, issues related to the data size of different analytical methods and/or 
‘omics’ applications play an important role (e.g., size of established blood metabolites is 
~4530 [37] and of proteins ~10,546 [38]), but one also needs to consider noise related to 
analytical instruments (e.g., western blot vs. NMR) and biological samples (e.g., tissue, 
biofluids), as well as sample timing (e.g., urine can be sampled at several time points, 
while biopsies only once). A summary of the key points related to the different inter-
platform,  inter-sample  and  inter-omics  integration  strategies  has  been  published  by 
Richards et al. [36].
SAMPLING AND SAMPLE PREPARATION OF BIOFLUIDS
Sample collection and storage
Human  variation  (gender,  ethnicity,  diet,  lifestyle)  make  it  very  difficult  to 
differentiate  healthy  and  diseased  individuals.  To  enable  grouping  according  to 
phenotype, advanced data classification methods are usually used  [39]. However,  this 
requires correct data. It is then crucial to limit any side effects due to sample collection, 
preparation and storage, but also variations due to the human constitution. Biofluids can 
be  sampled either  non-invasively (e.g.,  urine,  tears,  saliva)  or  invasively (e.g.,  blood 
serum/plasma, cerebrospinal fluid, amiotic fluid, expressed prostatic fluid). The latter is 
inconvenient  to  individuals  and  can  be  a  source  of  metabolite  contamination.  For 
example, practice of blood venipuncture may influence the blood metabolome due to fear 
of  needles  or  anxiety,  which  can  be  detected  by  an  increase  in  catecholamine’s 
concentration  [40].  Some measures  can be taken with regard to  diet  and lifestyle  by 
asking patients  to  fast  and collecting biofluids  in the  morning (after a  night of  rest). 
Hence, proper experimental design is essential for preventing corruption of samples.  
Next to inter- and intra-human variation, are the sample collection and preparation per 
se  elements  that  are  vital  for  metabolites  studies  because  degradation,  oxidation  and 
volatility of molecules, and continuous enzyme activity (e.g., in blood plasma)  [41,42] 
and microbial contamination (e.g., in urine)  [43] may influence the metabolome. Thus 
sample analysis tends to be done as fast as possible after collection. Amiotic fluid, blood 
and CSF are centrifuged after collection to get rid of cells (e.g., red blood cells and white 
blood  cells).  Due  to  continuous  cell  activity  several  metabolites  concentrations  can 
otherwise  be  affected  [42,44].  Usually  blood  is  fractionated  to  serum or  plasma  for 
metabolomics. Blood plasma is blood without blood cells, while blood serum is blood 
plasma without the blood clotting proteins (fibrinogens and clotting factors). The fraction 
obtained  depends  on  the  collecting  tubes  employed  that  are  either  coated  with  clot 
activators  or  anticoagulants  for  serum  or  plasma,  respectively.  An  overview  of  the 
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different coating agents and of how their use affects discovery of biomarkers in blood 
plasma or serum has been reviewed by Gillio-Meina et al. [42].
Serum clotting process, prior to centrifugation, varies between samples on the basis of 
intrinsic  clotting  factor  levels  and  clinical  exposure  to  anticoagulants.  Too  long 
incubation  time  may  result  in  cell  lysis,  thereby  altering  analyte  composition  [45]. 
Metabolites  lactate  and  glucose  concentration  decrease  and  increase,  respectively  in 
blood cells [46]. Higher molecular weight species, like lipoproteins (LDL, VLDL), were 
more sensitive to preparation protocols than metabolites. The latter is due to enzymatic 
activity [41]. Serum can alternatively be collected in tubes containing a gel separator. The 
separator has a density between that of the cells and solution components, so that they 
separate  the  components  by  flowing  to  a  position  between  the  layers  during 
centrifugation  [47].  Following  centrifugation,  the  gels  stop  flowing  and  remain  as  a 
barrier between the layers, thus decreasing the incidence of hemolysis, increasing sample 
stability, and facilitating primary tube sampling and storage. However, gels have been 
shown  to  absorb  various  drugs  and  their  metabolites  [48].  The  diverse  tubes 
manufacturers each have their own patented clotting agents, gels and protocol manuals, 
which raises the question of variation due to inter laboratory serum preparation [49].
The advantage of fractionating to obtain blood plasma is that centrifugation can be 
done just after blood collection, compared to serum fractionation that needs a clotting 
period  of  ≤  30 minutes  on  ice.  Also,  the  protein content  is  retained.  Three  different 
anticoagulants can be used for plasma: citrate, ethylenediaminetetraacetic acid (EDTA) 
and heparin. Citrate is not an anticoagulant used in metabolomics studies because it is 
one  of  the  endogenous  metabolites  found  in  blood  plasma.  The  compound  EDTA 
complexes to metal ions and is preferred for proteomics studies because the activity of 
many proteases requires metals, and thus prevent further enzymatic reactions. In NMR-
based metabolomics, EDTA-metal-ion complexes give signals that usually overlap with 
metabolites resonances. For these reasons heparinated plasma is preferred. Heparin acts 
by  binding  and  enhancing  the  activity  of  antithrombin  III,  which  prevents  clotting. 
However, it also binds a significant number of other proteins (e.g., annexins) [50]. Other 
pre-analytical aspects, such as centrifugation (speed, time, and temperature), storage time 
and temperature, and exposure to freeze–thaw cycles, have been described step-by-step 
for  amiotic  fluid  [51],  blood  [52] and  CSF  [44].  For  example,  if  not  analyzed 
immediately samples are kept at cold temperature, 4 °C, or are stored after snap freezing 
at 77 K in liquid nitrogen to quench any metabolome composition change and -stored at 
-80 °C (sometimes after lyophilization).  Protocols  for  cells  and tissue preparation are 
discussed by Alvarez-Sanchez t al. [53].
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Homeostasis  maintains  blood  pH,  ionic  strength  and  concentration.  In  contrast, 
excretory  biofluids, like urine, are less regulated. Lauridsen et al.  [43] investigated the 
effects of preparation using buffers and storage temperature, as well as the effects of the 
presence of preservatives, on 1D 1H NMR spectral profiles of human urine assessed by 
principal  component  analysis  (PCA).  They  showed  that  the  chemical  shift  of  the 
metabolites  citrate  and  creatinine  depend  on  the  concentration  of  both  urine  and 
phosphate  buffer.  Concentrated  urine  needed  buffer  of  1  M,  while  0.3  M buffer  is 
recommended in routine  work.  Lyophilization and reconstitution in  D2O-based buffer 
altered the sample, either by loss of volatile metabolites or incomplete re-dissolution of 
abundant metabolites  or disappearance of creatinine CH2 signal due to deuteration. If 
urine is stored at ≤ -25 °C, no preservatives are needed. But for temporary storage at 4 °C 
or working in unsterile environment, 0.1% sodium azide is adequate. 
Metabolite extraction and Metal ions detection
Metabolite extraction is used in many of the different metabolomics strategies (Table 
1) and aims to: 
1. Efficiently release metabolites from the sample.
2. Remove interfering compounds that may complicate the analysis (e.g.,  salts and 
proteins).
3. Make the extract compatible with the analytical technique.
4. Concentrate trace metabolites before analysis [53].
Metabolite  extraction  not  only  depends  on  the  metabolic  strategy  but  also  on  the 
analytical technique. The strategies for NMR spectroscopy are presented below. 
The use of metal chelating agents, e.g., EDTA, can be of great use either to study 
metal ions or reducing ionic strength dependent frequency shifts. Indeed, Tomlins et al. 
[54] studied the biochemical process in the seminal fluid using EDTA. The seminal fluid 
is a mixture of secretions from seminal vesicles and prostate (and to a lesser extent, other 
Wolffian ducts, testes, and epididymi [55]). After mixing the secretions and following the 
reaction over time and using EDTA at different time points,  the authors followed the 
integrals of ethylene proton singlets upon addition of calcium, magnesium and zinc. They 
observed the  “double”  transfer  of  zinc  between low molecular  weight  organics  (e.g., 
citrate) and high molecular weight compounds. They also noticed the narrowing of citrate 
1H NMR signals, as citrate is known to be involved in the complexation of metal ions. In 
urine studies, addition of EDTA (2.5 μmol for 300 μl urine) minimizes frequency shifts 
and  narrows  peak-widths  by  reducing  the  interaction  of  divalent  metal  ions  such  as 
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calcium and  magnesium with  numerous  metabolites  (e.g.,  alanine,  citrate,  creatinine, 
formate) [56]. Comparing PCA score plots of the spectra without and with EDTA showed 
the improvement in the spectral alignment. The authors also discussed the trade-off using 
high buffer  concentration (more dielectric  [57] and more conductive  [58]) and buffer 
volume  required  for  optimal  urine  spectral  quality.  Though  increasing  the  buffer 
concentration improves peak alignment, it also leads to poorer quality spectra, i.e. lower 
signal to noise. The same applies for increased urine dilution. 
Table 1 The range of different strategies employed in metabolomic experiments
Metabolite target analysis 
Metabolic profiling 
Metabolic fingerprinting 
Quantitative determination of one or a few metabolites related to a specific metabolic 
pathway after extensive sample preparation and separation from the sample matrix and 
employing chromatographic separation and sensitive detection.
Quantitative analysis of set of metabolites in a selected biochemical pathway or a 
specific class of compounds. This includes target analysis, the analysis of a very limited 
number of metabolites, e.g. single analytes as precursors or products of biochemical 
reactions.
Global, rapid and high-throughput analysis of crude samples or sample extracts for 
sample classification or screening of samples. Minimal sample preparation. Ultimate goal 
to identify discriminating metabolites.
Metabolic footprinting 
Global measurement of metabolites in the extra-cellular growth medium, as a reflection 
of metabolite excretion or uptake by cells.
Usually samples are diluted in deuterated solvent/buffer to obtain a magnetic field lock 
signal for the spectrometer and to reach a sufficient measurable volume [59]. The effect 
of dilution on blood plasma was observed to relatively increase NMR resonance intensity 
and  cause  resonance  position  shifts  of  several  metabolites  (e.g.,  histidine,  citrate, 
tyrosine) [60,61]. These phenomena are due to the release of metabolites binding to blood 
plasma proteins.  Protein bound metabolites  are usually isolated by using liquid-liquid 
extraction  (using  acetone,  methanol/chloroform  and  acetonitrile  at  acidic  and 
physiological pH) or protein precipitation (perchloric acid precipitation) or solid-phase 
extraction  chromatography  (SPEC)  or  ultrafiltration.  The  efficiency  of  selective 
extraction  procedures  for  blood  plasma  and  serum  were  assessed  for  NMR  studies 
[62,63].  The  outcome  was  that  there  is  no  best  method.  Ultrafiltration  is  the  'safest  
method'  in  terms of  avoiding unwanted side-reactions with biofluid metabolites,  very 
reproducible, relatively quick to perform and does not introduce unwanted solvent peaks. 
Moreover,  the  pellet  left  on  the  filter  can  be  used  for  further  extraction  (e.g.,  lipid 
extraction). Ultrafiltration is now the method adopted by the team behind the Human 
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Metabolome Project [64].
NMR spectrometers can also be coupled to a chromatographic device by means of a 
flow-probe (hyphenation setup) [29,65,66]. This technique is used on biofluids with low 
protein content (e.g.,  urine) or biofluids that are deproteinized. The advantage of this 
setup is to increase concentration of metabolites and separate them in classes.
ANALYTICAL TECHNOLOGIES
Table 2 Comparison between NMR and MS
MS NMR
Sensitivity +++ -
Reproducibility (within lab) + +++
Reproducibility (across labs) - +++
+ +++
Sample preparation - +++
MW used as a molecular tag ++ +
Use of Chromatography +++ +
Targeted molecules +++ +
- +++
Identification of unknown ++ -
Structural information - ++
Identify binding to proteins - +++
Quantitation
Untargetted molecules
Collecting  metabolome  data  relies  on  techniques  which  provide  direct  and  fast 
analysis, without the need for anything other than minimal sample preparation and wide 
dynamic  range  [67].  Mass  spectrometry  (MS)  [68] and  nuclear  magnetic  resonance 
(NMR) spectroscopy  [69] are commonly employed analytical methods. Both analytical 
techniques have pros and cons (see Table 2). For instance, the main advantage of MS is  
its high sensitivity (fM compare to μM for NMR). NMR is non-destructive, quantitative, 
robust  and with  good reproducibility.  The reproducibility  has  been tested for  1D 1H 
NMR metabolomics in two studies considering the influence of different NMR probes, 
different  magnetic  field  strengths,  and  different  operators  who  were  asked  to  adjust 
several acquisition and processing parameters without any protocol (e.g., RF power for 
water presaturation) [70,71]. The studies used binning and principal component analysis 
(PCA) to compare the data. Both studies demonstrated that with well defined protocols it 
is possible to obtain similar multivariate classification among independent laboratories. 
The resolution of 1D 1H NMR is limited by its spectral width, ~15 ppm, resulting in 
crowded spectra for urine for instance even at 950 MHz (22.3 Tesla)  [15]. Pure shift 
NMR, 1H-1H and 1H-13C 2D-NMR (e.g., J-resolved, COSY, HSQC) help to increase 
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spectral resolution and thus enable better metabolite identification [72–74]. For instance, 
J-resolved [75], the simplest of the plethora of 2D NMR experiments, can be applied to 
separate homonuclear J-couplings and chemical shifts, thus reducing the complexity of 
spectra (see Figure 3). The main disadvantage of J-resolved NMR is that the cross-peaks 
in  the  spectra  cannot  be  recorded with  in-phase  line-shapes,  but  instead  with  phase-
twisted line-shapes which leads to unwanted broad lines. This can only partly be resolved 
by filtering [76]. 2D NMR TOCSY, on the other hand, displays the desired in-phase line 
shapes. However,  2D 1H-1H TOCSY has not been much applied in metabolomics as 
compared to structural  biology, although it  could provide extensive information on J-
coupling networks within a metabolite and be recorded with similar sensitivity as 1D 1H 
NMR spectra. Moreover, the information is spread out in two dimensions, which reduces 
resonance overlap.  Heteronuclear  2D-NMR, e.g.,  1H-13C HSQC, may also help  two 
reduce resonance overlap thanks to the correlation of 1H with 13C and spreading of 
resonances over two dimensions in in-phase cross-peaks [77]. These heteronuclear NMR 
methods have been used only to very small extent. This is in part due to the low (~ 1%) 
natural abundance of 13C spins. This reduces the signal in 2D HSQC to ~1% of 1H 
NMR, other circumstances being equal. In pure shift NMR, the aim is to record 1D NMR 
spectra (or 2D NMR) without homonuclear (or heteronuclear) J-couplings. This holds 
great  promise  in  reducing resonance  overlap  because  the  1H homonuclear  couplings 
spread a resonance over 20 to 50 Hz. This leads to a resolution enhancement of 20 to 50  
in  the  pure  shift  spectra,  assuming  a  usual  line-width  of  1  Hz  for  the  pure-shift 
resonances. Various pure-shifts  methods have been proposed over the years,  but they 
suffer  low sensitivity,  instability  and line-shapes problems.  Only recently has it  been 
shown  possible  to  record  such  1D  1H  NMR  spectra  with  good  line  shapes  [78]. 
Subsequently,  it  was shown that  pure-shift  NMR spectra  can be recorded with much 
improved sensitivity and quantitatively. This opens the way for its use in metabolomics, 
because the sensitivity appears good enough to record spectra with reasonable signal-to-
noise for concentration to ~5 to 10 µM. The additional aspect of a factor of 20 to 50 in 
resolution  enhancement  reduces  enormously  the  resonance  overlap  seen  in  present 
metabolite NMR spectra. Nevertheless, it is early days and pure-shift NMR has not yet 
been (much) applied in metabolomics.
Macromolecules,  e.g.,  in  blood  plasma,  generate  broad  signals  due  to  short  T2 
relaxation,  which  overlap  with  narrow signals  of  small  molecules  and  the  measured 
spectra  are  difficult  to  process  (e.g.,  distorted  baseline).  Using  relaxation  edited 
techniques macromolecules signals can be filtered  [79]. For blood plasma samples, the 
T1-, T1ρ-, and T2-based editing methods are all efficient, though T2-filters are the most 
commonly used (see Figure 2). To measure macromolecular signals T1-based editing and 
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diffusion editing are often used [80,81]. Solvent signals, usually from water, need to be 
suppressed  as  they  obscure  lower  signals  from  analytes  that  are  105-106  times  less 
concentrated. Solvent signals are usually suppressed using presaturation, WATERGATE, 
excitation sculpting or WET [82]. Suppressing the solvent usually causes suppression of 
analyte signals close to or under its resonance(s). By combining both water suppression 
and relaxation editing (water suppression pulse(s) before the relaxation pulses), analyte 
signals can be reestablished (RECUR-NMR) [83]. This is possible because magnetization 
transfer takes place via scalar or dipolar coupling during a TOCSY- or ROESY-based 
coherence transfer sequence, respectively (e.g., spin lock sequences MLEV-17) [83,84]. 
These methods ensure in-phase magnetization transfer, which make them without much 
modification readily applicable for the measurement of the transverse relaxation time 
(T2),  inter-nuclear  ROEs,  and  ROE  buildup  rates,  which  are  all  important  for 
investigating molecular structure and dynamics [83].
Figure 2 Blood plasma spectra recorded at 600 MHz. Difference between non-edited (top) and  
T2-edited (bottom) spectra.
NMR and MS can analyze  crude  samples,  but  MS is  often  coupled  to  separation 
techniques, e.g., to liquid chromatography (LC). Crude sample, for MS, introduces issues 
such as variability of ionization in complex mixtures (variation in chemical species) and 
ion  suppression  effects.  Furthermore,  one  LC run  cannot  cover  the  diverse  range  of 
analyte  polarities  present  in  most  biological  samples  [85].  Nevertheless,  the  LC-MS 
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combination is a good tool for targeted  analysis. Since no technology combines all the 
desired characteristics for metabolite analysis,  it  is  advantageous to  combine different 
analytical platforms to overcome their respective limits in  metabolite coverage and to 
identify important biomolecules, e.g., to find new biomarkers of disease or toxicity. A 
good example is the work accomplished on the blood serum metabolome by Psychogios 
et al. [64] (see Figure 4). They used 5 platforms and identified 3564 compounds. Another 
example is the combination of 4 platforms on CSF proteomics and metabolomics data 
[86,87].
Figure 3 J-resolved spectrum of human blood plasma at 600 MHz. Above is the 1D projection of  
the couplings.
Nevertheless, “The whole is more than the sum of its parts” (Aristotle ca. 350 BC). 
The quote exemplifies another characteristic of biofluids, their diversity in interactions 
and dynamics.  For  instance,  binding  interactions  of  metal-ions  with  small  molecules 
(metabolites, drugs, etc.) and biomacromolecules (proteins) are often seen together with 
binding interactions of these small molecules with biomacromolecules. These interactions 
lead to exchange processes, and thereby to changes in available concentrations. These 
interactions may also lead to micellar compartmentalization of metabolites and enzyme-
mediated biotransformations [88]. In the coming chapters of this thesis we present results 
of the study of interactions of metabolites with the most known protein, namely serum 
albumin (SA) using NMR spectroscopy.
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Figure 4 Venn diagram showing the overlap of serum metabolites detected by global NMR, GC–
MS,  LC/GC-FID,  LC-ESI-MS/MS  and  MS/MS  methods  compare  the  detectable  serum  
metabolome.  The  numbers  in  bracket  represent  the  unique  metabolite  detected  using  the  
respective  platforms.  Abbreviation:  NMR,  nuclear  magnetic  resonance;  TLC,  thin  layer  
chromatography;  GC,  gas  chromatography;  LC,  liquid  chromatography;  ESI,  electronspray  
ionization; DFI, direct flow infusion; MS, mass spectrometry; FID, flame ionization detector.  
Adapted from Psychogios et al. [64].
SERUM ALBUMIN
Albumin is the most studied protein, with a total number of publications of 185636 
between 1980 and 2010 and 11242 in 2012 (using albumin as search word [17]). It is a 
conserved protein within the vertebrate: human, house mouse, cattle, zebra fish, African 
clawed frog, etc.  [89]. Albumin comes from milk, urine, serum and a variety of other 
sources. Serum albumin (SA) is the most abundant protein in human blood plasma, about 
60% of the total protein content (30-50 g/L) [90]. The life-time of human serum albumin 
(HSA) is about 28-36 days. It circulates from blood across the capillary wall into the 
interstitial compartments, including cerebrospinal fluid, and returns to blood through the 
lymphatic system. An HSA molecule makes about 15000 passes through the circulation 
system incurring some damages that affect its ligand binding and anti-oxidant properties 
[91].
HSA is lost into the intestinal tract (1g per day) and some milligrams via the kidney 
tubule (from the 70 kg that passes each day) [92]. It may undergo several modifications, 
like glycation [93], acetylation of Lys [94], Cys34 nitrosylation [95]. In particular, HSA 
becomes non-enzymatically glycated by reducing sugars. The level of glycated HSA in 
normal humans is about 10%. However, this proportion typically increases to 20–30% in 
hyperglycemic  patients  [96].  HSA glycation  in  patients  affected  by  diabetes  mellitus 
results  in  lower  binding  capacity  of  Cu(II),  Fe(III)  and  L-tryptophan  [97–99]. 
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Nitrosylation of Cys34 can be fatal. Indeed, Cys34 acts as a physiological anti-oxidant, 
participating in radical scavenging (e.g., 82% of NO in blood, ~7 μM), and as a binding 
site  for  a  wide  variety  of  endogenous  ligands,  drugs  (i.e.,  ethacrynic  acid, 
organomercurials) and metal ions (e.g., Cu and Fe) [100]. Free Cu(I) and Fe(II) ions can 
react  with H2O2 leading to the formation of the deleterious hydroxyl radical  via the 
Fenton reaction [97].  The binding of Cu(I) and Fe(II)  to HSA usually promotes their 
oxidation to Cu(II) and Fe(III),  thus limiting their ability to participate in this Fenton 
reaction. 
Figure 5 Three-dimentional heart-shaped structure of HSA complexed with thyroxine (T4) and  
myristate in FA binding sites. HSA sub-domains are labelled IA to IIIB and colored black for As  
and gray for Bs. Myristate is rendered as sphere, thyroxine as sticks and HSA as ribbon. Atomic  
coordinates were taken from the PDB entry 1HK4 [105] and drawn in PYMOL [106].
HSA has a heart-shaped structure [101] made from a single polypeptide chain (68% α-
helix) of 585 amino acids residues, with a molecular weight of 66 kDa [102]. It contains 
three homologous domains usually indicated as I (1–195), II (196–383) and III  (384–
585), each having 2 subdomains (A and B) (see Figure 5). Between pH 4.3 and 8.0, HSA 
displays  the  N  form  (heart-shaped)  and  at  pH  greater  than  8.0  the  basic  form  (B) 
characterized by the loss of α-helix [103]. HSA genetic variants (83 were known in 2012) 
are observed in humans. They become evident mostly through bisalbiminemia, which 
occurs with a frequency of 0.0003-0.0010 in the average population. In bisalbiminemia 
wild type HSA and the variant are expressed at a ratio of 1:1. Most of the variations 
result  in  a  change  in  net  charge  of  ~  -15  with  respect  to  that  in  normal  HSA  at 
physiological pH [104].
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HSAs  transport  and  depot  99%  of  the  non-esterified  fatty  acids  (FAs).  Several 
different FAs with chains of  different lengths and which are either saturated or  non-
saturated have been found to  bind to HSA [107–109], and several crystals structures of 
FA-HSA complexes have been obtained [110]. The association equilibrium constant for 
FA  binding  to  HSA  increases  with  FA  chain  length.  The  FAs  C8  and  C10  bind 
preferentially to HSA subdomain IIIA, C12 binds to sites in subdomains IIIA and IIIB, 
whereas  C14  binds  in  subdomains  IB  and  IIIB  [111].  Nevertheless,  7  common  FA 
binding sites are known (see Figure 5) [110,112]. On FA binding the long inter-domain 
helices connecting domain I  with II and domain II with III are tilted by  16°, giving a 
rotation to domain I with respect to domain III  [113]. HSA also facilitates FA removal 
from donor cells  [114].  This  happens through domain III  that  is  involved in protein-
receptor  interaction  for  the  cellular  uptake.  This  interaction  protects  HSA  from 
intracellular proteases thus enabling it to return to the circulation [115]. 
FA binding sites also provide accommodation of several endogenous and exogenous 
ligands, including a wide variety of drugs. The FA1 cavity binds heme-Fe(III) (the main 
LDL and HDL oxidative agent) and bilirubin; FA3-FA4 constitute Sudlow's site II (drug 
site II) that binds ibuprofen; FA5 binds propofol; FA6 and FA2 are ibuprofen secondary 
and tertiary sites,  respectively;  FA7 constitute Sudlow's site  I  (drug site I)  that  binds 
warfarin. Thyroxine (T4) has 4 binding sites on HSA which overlap with FA7, FA3-FA4 
and  FA5.  In  the  presence  of  FAs,  all  the  T4  sites  are  occupied.  This  causes 
conformational changes, which create a fifth  T4 binding site,  a cleft  located between 
domains I and III (see Figure 5) [112].
The  extraordinary  ligand  binding  properties  of  HSA  reflect  its  multi-domain 
organization, which provides for multiple binding sites that adjust upon binding at other 
sites (allosteric effects). A good example of allosteric effects is the decrease in affinity of 
heme–Fe(III) bound in FA1 by about one order of magnitude upon FA7 ligand binding 
(e.g., warfarin) and vice versa [100,113,116]. HSA is known to carry almost every small 
molecule, thus it is a potential contender for being a molecular cargo/or nano-vehicle for 
clinical, biophysical, and industrial purposes [100,113]. Under physiological conditions, 
HSA binds not only endogenous and exogenous low molecular weight compounds but 
also  peptides  and proteins  [117].  Some bacteria,  like  Finegoldia  magna,  have  higher 
growth  speed  and  virulence  when  bound  to  HSA.  It  is  thought  that  HSA  provides 
nutrients to these bacteria  [118].  Finally, HSA binds a variety of metal ions as Al(III), 
Au(I/II),  Ca(II),  Cu(II),  Hg(II),  Mg(II),  Mn(II),  Ni(II)  and Zn(II),  [92,119,120].  HSA 
improves plasma solubility and half-life of ligands,  and also reduces their  free active 
concentration.  Moreover,  HSA  expresses  enzymatic  properties:  it  is  an  esterase  of 
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aspirin,  it  shows RNA hydrolysis,  it  is  an enolase of dihydrotestosterone, and a lipid 
peroxidase, etc. [121–124].
Clinical and medical laboratories frequently test the HSA level in circulation as it is an 
indicator  of  health.  Other  than its  binding and transport  capability,  HSA is  the  main 
protein  responsible  for  maintaining  osmotic  pressure  in  blood plasma and  interstitial 
space (oncotic pressure).  It  also acts  as  a  scavenger of  reactive nitrogen and oxygen 
species  [125].  HSA  injection  is  widely  used  clinically  to  treat  hypoalbuminemia 
occurring  after  serious  burn  injuries,  hemorrhagic  shock,  hypoproteinemia,  fetal 
erythroblastosis, and ascites caused by cirrhosis of the liver. For example, the inflamed 
joints of patients suffering from rheumatoid arthritis have highly active synovial cells and 
HSA  uptake  is  very  high.  This  further  develops  into  hypoalbuminemia,  the  lack  of 
albumin [126]. Hypoalbuminemia is also observed in cancer as tumors trap and degrade 
plasma proteins for nutrients for proliferation [127]. This accumulation in tumor is being 
used in  radio-therapy.  Radio-labeled HSA-single  chain  antibody fusion  proteins  have 
been used for localization of CEA-positive tumors in mice with single-photon emission 
computed  tomography  [128].  HSA  dialysis  is  widely  accepted  as  a  liver-support 
technique for  patients with liver failure. Albumin dialysis with the molecular adsorbent 
recirculation system (MARS)  or single pass albumin dialysis  (SPAD) uses HSA as a 
supplement  of  the  dialysate  fluid,  where  it  acts  as  a  trap  for  toxic  substances  (e.g.,  
bilirubin) [129].
Human serum albumin influences the pharmaco-kinetics and pharmaco-dynamics of 
drugs. For instance, binding of drugs to plasma proteins, in particular HSA, results in 
increased solubility for lipophilic drugs. This allows them to reach their site of action. 
However,  since  the  HSA-bound  drug  cannot  readily  leave  the  capillaries,  only  the 
unbound  drug  can  be  distributed  into  tissues.  Therefore,  HSA binding  can  improve 
pharmacological activity but also have toxic effects. Thus, depending on the drug and 
target, the high affinity of drugs for plasma proteins, i.e. HSA, may be either beneficial or 
a drawback for efficacy. If a drug is highly bound to HSA and has a high extraction ratio 
from the liver, which involves active transport mechanisms to concentrate the drug in the 
hepatic cells, then plasma proteins may act as delivery systems. Conversely, similar to 
hepatic uptake, if a drug has a high renal extraction ratio due to active tubular secretion, 
than HSA binding will promote drug elimination by transporting the drug to the kidney.
Finally, the possibility to synthesize recombinant HSA [130] and the knowledge of its 
structure has made it possible to produce fusion proteins in order to extend half-life of 
small  proteins  in  blood.  Recently,  recombinant-HSA-nanotubes  (rHSA-NT)  were 
produced to captured biotin-labeled nano-particles; these HSA-based Nts were shown to 
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retain enzymatic activities [131].
For further reading, large data bases of chemical and physical properties, and clinical 
use of albumin can be found on Albumin.org and pptaglobal.org.
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NMR SPECTROSCOPY
Based on appearance alone it  is  not possible to distinguish a glucose solution and 
fructose solution,  since both are  colorless liquids.  However,  the glucose and fructose 
molecules are structurally and chemically different and the Nuclear Magnetic Resonance 
(NMR)  phenomenon  can  provide  information  on  atomic  details  to  distinguish  them. 
NMR was experimentally detected in bulk matter in 1945 by Bloch et al. and Purcell et 
al. independently [132,133]. Since then NMR has developed into an important analytical 
tool thanks to the introduction of NMR frequency lock signal, Fourier Transform NMR 
(FT-NMR) and chemical shift among others [134]. NMR is nowadays accessible (e.g., 
portable  magnet)  and  interdisciplinary  covering  chemistry,  physics,  biology  and 
medicine. For example, cancer research of prostate uses anatomic structures (using NMR 
Imaging,  also  known  as  MRI)  and  analytical  measurement  of  metabolites  (NMR 
spectroscopy)  for  diagnostics  [135].  In  the  coming  sections  we  will  give  a  short 
introduction to NMR spectroscopy. Then we will discuss the use of chemical shift for 
structure determination, dynamics and susceptibility to the bulk environment. This is in 
large part based on the following reference materials, [136–140].
BASIC PRINCIPLES
Atoms are made of a nucleus surrounded by and at least one electron. The nuclei's 
neutrons and protons are themselves  made up of sub-particles. These sub-particles have 
orbital and spin motions which combine together to give a quantized nuclear spin angular 
momentum of the nucleus. This nuclear angular momentum I⃗  is a vector quantity with 
magnitude ∣⃗I∣ given by:
∣⃗I∣ = √( I⃗⋅⃗I ) =ℏ√ I (I +1) (1)
Here I the nuclear spin quantum number that can be 0, 1/2, 1, 3/2, ... and ħ equal h/2π 
with h being Plank's constant [141].
Nuclei with I > 0 possesses a magnetic dipole moment μ⃗ :
μ⃗ = γ I⃗ (2)
Here γ is the gyromagnetic ratio which is dependent on the nucleus isotope (see Table 3). 
In the presence of an external static magnetic field B0, the spin magnetic moment vector 
will be  distributed in  mI orientations (2I+1) and under quantum mechanics mI can only 
have values of +I, (I-1),..,-I, this is called the Zeeman interaction. For spins of I = ½, mI = 
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±½. With B0 being by convention along the z-axis and writing the z-components of I⃗
and μ⃗ as Iz and µz, respectively, and taking mI =mz, the two energy levels are given as:
E =−μ⃗⋅B0 =−γℏ I⃗ Z⋅B0 =−γ ℏmZ⋅B0 (3)
Table 3 Spin properties
Isotope Spin
½ 99.9885 4.83735357 26.7522128 100
½ 1.07 1.216613 6.728284 25.14502
½ 0.368 -0.49049746 -2.71261804 10.136767
½ 100 4.553333 25.18148 94.094011
½ 100 1.95999 10.8394 40.480742
1 1/2 100 2.8629811 7.0808493 26.4519
2 1/2 4.1 1.035556 1.676688 6.256803
Natural 
abundance (%)
Magnetic 
moment μ (μN)
Magnetic ratio, γ 
(10  rad s ¹ T ¹)⁷ ⁻ ⁻
Frequency 
ratio, Ξ (%)
1H
13C
15N
19F
31P
23Na
67Zn
Figure 6 Energy of nuclear spin (= ½) in a magnetic induction B0.
The two energy levels generated are mZ = +½ (state α) corresponding to a lowering of 
energy and mZ = -½ (state β) corresponding to an increase in energy. In classical terms, 
the state α correspond to alignment of the nuclear moment parallel to the field, and state β 
corresponding to alignment anti-parallel to the field (see Figure 6). The magnetic dipole 
now precess around the B0 field at the Larmor frequency ω0, which is proportional to the 
difference in energy level of the two sates (note that the usual sign convention is followed 
for the relation between ω0 and B0 [141]):
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ω0 =
Δ E
ℏ =−γ B0 (4)
BOLTZMANN DISTRIBUTION
The number of nuclei in the α states (Nα) and the β states (Nβ) in a sample follow the 
Boltzmann thermal distribution law between the two levels. The ratio between the two 
population is given by:
N α
N β
= exp ( Δ E
k B T
) = exp(
−γℏ B0
k B T
) (5)
Here kB is  Boltzmann's  constant and T the temperature.  The population of  the lower 
energy  level  is  larger  than  that  of  the  upper  energy  level,  i.e.  Nα >  Nβ.  Thus,  net 
macroscopic magnetization of the sample accumulates along B0. In the high temperature 
limit the macroscopic magnetization is given by the Curie Law:
M 0 =
N γ2 B0ℏ
2
2k B T
(6)
Here N is the number of spins per unit volume.
RADIO FREQUENCY PULSES
Figure 7 Pulse angle θ  and position of magnetization vector  M in the rotating frame after  
applying a B1 RF pulse in the x-direction.
Radio frequency (RF) energy can be used to induce transition of spins from lower 
energy  states  (α)  to  upper  energy  states  (β),  i.e.  absorption.  This  transition  between 
energy states arises when RF is applied on resonance, i.e. the frequency of RF  ωRF equals 
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the Larmor precession frequency of the spin magnetization ω0. Because different nuclei 
have different gyromagnetic ratios (γ), at constant B0 the frequency at resonance varies 
from nucleus to nucleus (Eq.4, Table 3). At resonance and with the RF pulse applied for a 
sufficient duration, Nα decreases and Nβ increases until they become equal. This is called 
saturation. After this saturating RF pulse is turn off the spin system exchanges energy 
with the  surrounding environment to reach the Boltzmann equilibrium. These restoring 
processes are known as relaxation.
The RF energy stems from an electromagnetic wave whose magnetic-field is usually 
named the B1 field.  The B1-field vector is  oriented perpendicular  to the B0 field and 
rotates around the B0-field with a frequency RF. This is illustrated in Figure 7, where the 
relevant vectors and components are all drawn in the so-called rotating frame. In this 
frame, the x and y axes rotate with a frequency  RF around the z-axis, i.e. around the 
direction of the Bo-field. In this rotating frame the magnetization M rotates around the z-
axis  with  a  frequency  equal  to  0-RF.  At  resonance,  i.e.  when  RF ≈  ω0,  the 
magnetization M stands still. Also the B1-field vector does not rotate in the rotating frame 
and points for instance in the direction of the x-axis depending on the chosen phase of the 
B1-field (see Figure 7).
Usually, not a long saturating RF pulse is given as described above but a much shorter 
one.  The  short  RF pulse  is  applied  at  or  near  resonance,  i.e.  RF at  or  near  ω0.  To 
understand the subsequent behavior of the magnetization M, we consider again Figure 7, 
the rotating frame. The magnetization vector  M is initially (equilibrium) aligned along 
the z-axis (Bo-field direction). The B1-field vector is taken to be oriented along the x-
axis.  In this  rotating frame and at  resonance (RF  = ω0)  the  magnetization vector  M 
experiences only the B1-field and rotates around B1 (x-axis) with a frequency B1 = B1. 
In this way, depending on the duration of the pulse, the M vector can be rotated over any 
angle. For instance, a 180° RF pulse rotates the magnetization from the +z-axis (along 
B0) to the –z-axis (opposite to B0), which is equivalent to inversion of the α-state and ß-
state spin populations. A 90° RF pulse flips the magnetization from the +z-axis (along B0) 
to the xy-plane. After the 90° pulse, the decaying magnetization, which rotates about the 
B0 field as a function of time,  is  detected on the xy-plane.  The signal is  called Free 
Induction Decay (FID).  Fourier  transformation  of  the  FID gives  the  NMR frequency 
spectrum. Each peak in the spectrum corresponds to the signal from a particular type of 
nuclear  spin  and  is  positioned  at  the  spin’s  Larmor  frequencies.  The  variation  in 
frequency in the spectrum of a certain type of nucleus (e.g., 1H) is called chemical shift 
and is discussed below.
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RELAXATION
The processes that restore magnetization equilibrium are spin-lattice (T1, longitudinal) 
and spin-spin (T2, transverse) relaxations, which are caused by time-dependent magnetic 
or electric fields at the  nucleus. The nucleus may experience time-dependent magnetic-
field perturbations caused by spins of other nuclei or unpaired electrons in paramagnetic 
species while the molecule to which it  belongs  rotates.  This relaxation mechanism is 
called dipolar relaxation. A nucleus is usually surrounded by electrons that form a shield. 
If the shape of this shield changes as the molecule rotates, the magnetic field experienced 
by the nucleus will also be affected. This effect is known as chemical shift anisotropy and 
it  also contributes to relaxation.  For a nucleus of spins I  > ½ an extra term must be 
considered, quadrupole coupling that involves the interactions between the spin states 
and the electric field gradient  (none uniform distribution of electron density around the 
nucleus).
T1  -relaxation  describes  the  relaxation  form the exited  state  back  to  the  thermal 
equilibrium along the z-axis:
M z( t ) = M 0(1−exp(
−t
T 1
)) (7)
Here,  Mz and  M0 are  the  magnetization  along  z-axis  and  the  net  equilibrium 
magnetization, respectively. The time constant, T1, determines the optimal value for the 
relaxation  delay,  i.e.  the  delay  between  two  accumulations  of  FIDs.  To  allow  the 
magnetization to return to equilibrium to a sufficient extent, usually a delay of 3-5 times 
T1 is used. The  T2-relaxation describes the dephasing of magnetization in the xy-plane, 
due to slight difference in phase between each individual spins:
M x (t ) = M 0 sin (ω0 t )exp(
−t
T 2
) (8)
M y (t) = M 0 cos(ω0t )exp (
−t
T 2
) (9)
Here, Mx and My are the magnetizations along x- and y-axis, respectively. The constant T2 
is inversely proportional to the peak width at half height.
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Chemical shift
The  term chemical  shift  (δ)  refers  to  a  relative  difference  in  resonance  frequency 
between nuclei  of the same atomic isotope at  different chemical sites  or for  samples 
under different physical conditions (for the exact definition see below section B5.3, Eq. 
31). This variation is due to the fact that the nuclei that do not experience the actually 
applied  magnetic  field  B0,  but  an  effective  field  Beff.  The  actual  or  effective  field 
experienced by the nucleus, Beff, is then given by:
Beff = B0(1−σ) (10)
Here, σ is here the shielding constant (negative sign).
In the simple situation of an isolated atom with a nucleus surrounded by for instance 
one electron in a 1s1 orbital (e.g.,  1H spin-1/2) and in the presence of B0, the spherical 
electron  distribution  precesses  about  B0.  This  produces  a  local  magnetic  field  that  is 
proportional to B0, but opposes the applied field (see Figure 8). The chemical shielding σ 
is then given this local shielding contribution σloc. In an isolated molecule, a nucleus will 
in addition be affected by local magnetic fields from electrons surrounding neighboring 
nuclei  within the molecule.  For instance, the B0-induced circulation of delocalized π-
electrons  in  benzene  lead  to  local  magnetic  fields  that  cause  large  shielding  or 
deshielding effects on neighboring nuclei depending on, whether these are positioned in 
the ring plane or above and below. This effect is known as the ring-current effect, σ rc. 
Also,  the  delocalized  π-electrons  in  double  or  triple  bonds  lead  to  shielding  or 
deshielding via this same mechanism and are usually included under the notion of ring-
current effects or indicated as magnetic anisotropy effects, σma [142,143]. In addition, the 
(partial) charges in the molecule may polarize a bond and thereby change the electron 
shielding of  a nucleus  [142,143]. This  leads to an additional shielding term, σch.  For 
atoms with p and d orbitals, paramagnetic circulation due to an unpaired electron needs to 
be  considered  and  may  be  the  main  component  of  deshielding,  σpar.  In  an  isolated 
molecule, the extent of the shielding σ is the sum of the shielding effects stemming from 
these various sources and is influenced by all structural features as bond angles and bond 
lengths as well as the confirmation of the molecule [144].
σm o l e cu l e = σl oc+σ r c+σma+σ ch+σ pa r (11)
Here, σmolecule is the term for nucleus in the isolated molecule
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Figure 8 Induce diamagnetism.
Apart  from  the  (de)shielding  that  a  nucleus  experiences  in  an  isolated  molecule, 
intermolecular interactions are to be considered in liquid phase or solution [123,124]:
σo b s = σmo l e c u l e+σme d i u m (12)
σm e d i u m = σW+σE+σC+σBMS (13)
Here, σobs is the observed shielding, σmolecule is the shielding term for the nucleus in the 
isolated molecule,  and σmedium is  the shielding arising from the medium. Usually,  the 
shielding due to σmolecule is larger than σmedium (e.g., for 1H: σmolecule ~15ppm and σmedium 
~3ppm).
The contribution σmedium is composed of 5 components.  The term σW is the shielding 
due to van der Waals dispersion forces between solvent and solute. Thus, the σW for a 
nucleus is affected only by molecules in the immediate vicinity of the molecule of which 
the nucleus is a part. The magnitude of σW depends on the mutual orientation of solute 
and solvent molecules, and will thus depend on the way in which molecules collide with 
one  another.  The  presence  of  any  factor  which  favors  one  orientation  of  solute  and 
solvent molecules will affect the value of σW. The term σE arises in polar or polarizable 
solvent  under  the  influence  of  the  permanent  dipole  moment  of  the  solute,  which 
modifies in turn the electron distribution of the immersed molecule (phenomenon known 
as reaction field) to an extent depending upon its polarizability. A corresponding term σch 
is also found within a molecule where it is caused by bond polarization due the charge 
distribution (see above). The term σC is a very general term which encompasses the many 
chemical-type interactions that may occur between solvent and solute molecules (e.g., 
hydrogen-bonding). The last term  σBMS is the shielding arising from bulk diamagnetic 
susceptibility  of  the  medium  and  is  treated  in  the  next  section  ‘Bulk  Magnetic 
Susceptibility’.  It  is  only  visible  when external  chemical  shift  referencing is  used as 
discussed in the last section ‘Chemical shift referencing’.
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Bulk magnetic susceptibility
To calculate the last term σBMS requires some sophisticated derivations of the magnetic 
flux  B at  the  position  of  nuclear  spin.  Levitt  has  discussed  in  Concept  in  Magnetic 
Resonance with great conceptual clarity the complexities involved with calculation of the 
magnetic flux B in a medium (sample) in the presence of an external field B0 [145]. Note 
that B is the crucial term to consider as the Larmor precession frequency of nuclear spins 
is proportional to B. Note further that B is sometimes called the magnetic induction field, 
while H is the magnetic field. We will now follow Levitt’s treatment in large lines in the 
next  paragraphs  to  explain  the  notions  of  macroscopic  and  local  microscopic 
contributions and the notion of the Lorentz sphere to calculate these contributions. We 
also consider the detailed derivations given by Durrant et al. [146] and applied by Kuchel 
et al. [147] as well as the derivations and discussions by Chu et al. [148].
In a medium the magnetic flux B is given by:
B = μH = μ0(H +M ) = B0+ μ0 M (14)
Here, µ and µ0 are the magnetic permeability’s of the medium and vacuum, respectively, 
and M is the magnetization. Note that M is proportional to the magnetic field H, with the 
volume magnetic susceptibility κ as proportionality constant:
M = κH (15)
B = μ0 H (1+κ) = B0(1+κ) (16)
We can further state that
M = κ
1+κ
⋅B
μ0
= κ
B0
μ0
(17)
Usually κ is a tensor, but for isotropic materials (e.g., liquids) a constant can be used. 
When the magnetic susceptibility is negative (κ < 0) the material is called diamagnetic 
and when it is positive (κ > 0) the material is called paramagnetic.
1. Diamagnetism is caused by the change in the orbital motion of electrons when a 
magnetic field is applied. This leads to a very weak magnetization and is present 
in every material and, therefore, is a fundamental property of all matter. Purely 
diamagnetic substances consist of atoms with filled electron shells, which have no 
net  magnetic  moment.  When  subjected  to  a  magnetic  field,  the  induced 
magnetization  opposes  the  applied  field  (Lenz’s  law;  Eq.20).  Therefore, 
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diamagnetic materials have negative susceptibility. The diamagnetic susceptibility 
is independent of temperature. 
2. Paramagnetism - For this type of magnetism, some of the atoms or ions in the 
material have a net magnetic moment due to unpaired electrons in partially filled 
orbitals.  Both  the  electron  spin  and  the  orbital  angular  momentum  give 
contributions to the magnetization. However, the individual magnetic moments do 
not  magnetically  interact  (disordered),  so  the  magnetization  is  zero  when  no 
magnetizing field is present. In the presence of a field, there is partial alignment of 
the  magnetic  moments,  resulting  in  a  positive  net  magnetization  and  positive 
susceptibility. In general, the susceptibility is inversely proportional to temperature 
(Curie law, Eq.18).
σ pa r a ma g net i c =
CB0
T
(18)
Here, C is the Curie constant and T is the temperature in Kelvin.
The magnetization of the sample is in general inhomogeneous and is described by a 
vector  field  M(r).  Here  r  defines  the  position  of  a  small  volume element  within  the 
sample, so that M(r)  gives the direction and magnitude of the magnetization density in 
the  sample  at  that  point.  It  must  directly  be  emphasized  that  a  description  of  the 
magnetization as a “smooth” vector field cannot be true on a fine  distance scale.  For 
example, the nuclear spins are magnetic dipole sources of negligible spatial extent. The 
actual magnetization in the sample is therefore “grainy” when viewed on a molecular 
distance scale. Care must be taken when interpreting the results of “smooth” macroscopic 
calculations. Normally the results cannot be assumed to apply all the way down to the 
molecular  level.  We  first  consider  the  macroscopic  approach  and  then  handle  the 
microscopic or molecular level.
Consider a sample with some spatial distribution of magnetization M(r), immersed in a 
uniform applied magnetic field.  In the absence of  sample,  the external magnetic flux 
density is taken to have magnitude B0 and to be directed along the z-axis: B(no sample) = 
B0 ez.  This  B  field  is  in  general  distorted  by  the  magnetization  of  the  sample.  The 
distorted flux field B(r) can be calculated by solving Maxwell’s equations (see Appendix 
A). However, the problem is difficult, and simple results are available only for special 
cases, a few of which we consider now.
Spherical sample with uniform magnetization.
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Binside sphere = B0 e z+
2μ0 M
3
= B0 e z+
2μ0 M z e z
3
(19)
Infinite cylindrical sample parallel to B0 with uniform magnetization.
Binsidecylinder = B0 ez+μ0 M = B0 e z+μ0 M z e z (20)
Tilted plane or cylinder.
Btilted planes = B0 e z+μ0 M sin
2θ = B0 ez+μ0 M z e z sin
2θ (21)
Here,  is the angle between the normal of the plane and ez.
In summary, one thus obtains for the magnetic flux the following relation.
B = e z(B0+μ0 M z D) = e z(B0+κ B0 D) (22)
D is  related to  the  shape factor  (see  Durrant  et  al.[146])  and is  discussed later  in 
conjunction with chemical shift (Eq.33 and 34).
In the above, the magnetization field M(r) was treated as continuous. The results for 
the macroscopic flux density B are therefore averages over a distance scale much larger 
than a molecule.  However, the nuclear spins sense the tiny details of the magnetic flux 
density. Care is needed when adapting macroscopic results for the magnetic flux density 
to the local microscopic distance scale appropriate to the individual nuclear spins. This is 
a long-standing problem in electromagnetic physics.  The proper  approach is  however 
well established and based on the concept of the Lorentz sphere. The basic idea is to let 
the macroscopic approach handle the long-range interactions. Interactions at short range 
are dealt with explicitly, using either classical or quantum physics, as appropriate. 
The  approach  taken  is  as  follows.  The  sample  is  divided  into  a  “local  region,” 
containing only a small number of dipoles, and a “long-range region,” which is treated as 
an approximate continuum. The magnetic flux density at a point r in the sample, Bloc, is 
estimated as:
BΔ l o c = BΔ ne a r+BΔ far (23)
Bnear is  the contribution from the small number of “explicit  dipoles” within “local 
region”. Bfar is the contribution from the continuum region outside “local region”. For 
convenience, the near region is assumed to be spherical and called the Lorentz sphere.
The long-range contribution Bfar can be estimated by continuum magnetostatics, as 
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described in the previous section. We need the macroscopic flux density within a small 
circular  hole  inside  a  magnetized sample.  This  can be calculated  as  the  sum of  two 
contributions, one  from the entire sample  with the hole filled and one from a fictitious 
piece of continuously magnetized material, of the same size as the hole, but magnetized 
the opposite way. So the long-range contribution can be written as:
BΔ far = BΔm a c ro+BΔ ho l e (24)
Bmacro is  the  macroscopic magnetic  flux  density  at  the  point  r disregarding  the 
graininess of the magnetization over the sample without a hole; Bmacro = B(r) where B 
is the result of continuum magnetostatics. The term Bhole is the macroscopic magnetic 
flux density inside a spherical object with uniform magnetization equal to – M(r) (= Mz 
ez) in the absence of an applied field:
BΔ h o l e =−
2μ0 M (rΔ)
3
(25)
What about the local contribution Bnear? In a completely classical treatment, this can 
be calculated explicitly by summing the magnetic field contributed by the dipoles within 
the small sphere. In principle, this depends on the physical geometry, but in most cases 
the result is zero. For example, if all the dipoles are oriented parallel and evenly disposed 
on  spherical  shells,  the  magnetic  field  at  the  center  is  proportional  to  the  spherical 
average  of  the  function  3cos2-1,  which  is  zero.  In  a  liquid,  the  near  region can  be 
defined by the length scale of rapid molecular diffusion on an NMR time scale, in which 
case the nuclear dipolar fields are averaged out by the molecular motion. More generally, 
an  explicit quantum calculation of the small number of spins in the near region can be 
made. In most cases, we can take Bnear = 0, except at the very edges of the sample. The 
result is the following relationship between the macroscopic magnetic flux density and 
the local microscopic flux density at point r:
BΔ l oc = BΔ ne ar+BΔ far = BΔm a c r o+BΔ hol e = B(rΔ)−
2μ0 M (rΔ)
3
(26)
This applies to all points within an object of arbitrary shape, except at the extreme 
boundary, where a local spherical volume cannot be defined. We can now estimate the 
microscopic  magnetic  flux  densities  at  the  sites  of  the  magnetization  sources  inside 
objects of different shape.
Spherical sample with uniform magnetization.
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Bl oc(sphere ) = B0 e z+
2μ0 M z e z
3
−
2μ0 M (rΔ)
3
= B0 ez (27)
Infinite cylindrical sample parallel with uniform magnetization.
Bl o c( insidecylinder ) = B0 e z+μ0 M z ez−
2μ0 M (rΔ)
3
= B0 e z+
μ0 M z ez
3
(28)
Tilted plane or cylinder.
Bloc (tilted planes) = B0 e z+μ0 M zsin
2θez−
2μ0 M (rΔ)
3
= B0 e z+μ0 M z ez( sin² θ−
2
3
)
(29)
Here,  is the angle between the normal of the plane and ez.
In summary, one thus obtains for the magnetic flux the following relation.
Bl oc = ez B0(1+κ D−
2κ
3
) (30)
D is related to the so-called shape factor (Eq. 22, 33 and 34).
Table 4 Theoretical shape factors (adapted from [149])
Shape in a vertical magnetic field Shape factor (A)
Infinite vertical cylinder 0    
 1/3
Infinite horizontal cylinder  1/2
Sphere, infinite cylinder at the magic 
angle, or any shape cylindrically 
symmetrical about the magic angle
Infinite cylinder at angle θ to the field (1-cos² θ)/2
Given these expressions for the local magnetic flux density B, the next step is to derive 
the Larmor frequencies and/or the bulk magnetic susceptibility related shielding, σBMS. 
The Larmor frequency of the nuclei is proportional to the local magnetic flux density B at 
the nuclear sites and the shielding proportional to the relative change in B.  As  shown 
above, for a spherical sample Bloc equals Bo, but for other sample geometries, Bloc is not 
equal  to  Bo leading  to  a  change  in  Larmor  frequency  and thus  to  (de)shielding.  As 
evident  from  Eq.30,  two  main  contributions  arise,  stemming  from  Bnear and  Bfar 
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respectively and leading to two terms in the shielding (for the definition of shielding see 
Eq.10).
σBMS =−
(Bl o c−B0)
B 0
=
−
(BΔ far+BΔne ar−B0)
B0
=−
(BΔmac r o−B0)
B0
+(
BΔ ho l e
B0
) = σ B+σA
(31)
σBMS = σB+σ A = (−D+
1
3
)κ (32)
The frequency shift due to bulk magnetic susceptibility effects can then be described 
as a sum of two terms (see e.g. Yablonskiy et al. [150,151]): 
Δ f
f 0
=
Δ f 1
f 0
+
Δ f 2
f 0
=−Aκ+ 1
3
κ (33)
The chemical shift due to BMS effects  is then given by (see e.g. Yablonskiy et al. 
[150,151], Harris et al. [149], Hoffman [152]:
δχ =−Aκ+
1
3
κ (34)
The first term arises from the presence of the media’s external boundary. A depends on 
the specific shape of the media boundary and is called the shape factor.  A for different 
geometries is given in Table 4 and κ for several solvents used in biological studies is 
given in Table 5. SI units and conventions for susceptibility and shape factor have been 
used throughout this work. However, published tables of magnetic susceptibilities can be 
found in cgs units. To convert from cgs units to SI, the magnetic susceptibility must be 
multiplied by 4π and the shape factor must be divided by 4π. Note further, that the term 
(/3) in Eq.34 arises entirely from the medium within the Lorentz sphere and depends on 
the  magnetic  susceptibility.  The  term  -A is  the  shift  arising  from  the  macroscopic 
approach and depends on the magnetic susceptibility and the shape factor.
As  pointed  out  by  Luo  et al.  the  Lorentzian  sphere  approach  is  based  on  the 
assumption that for a homogeneous, isotropic solution the microscopic local field acting 
on a spin can be evaluated as if this spin were moving inside a ‘hollow’ sphere embedded 
in the magnetized media, while the media outside the Lorentz sphere can be modeled as a 
homogeneous and isotropic continuum [153]. With these assumptions, the frequency shift 
or thus shielding effect in the presence of external static field B0 is described by Eq.32. It 
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should be noted, however, that in biological tissues exhibiting anisotropic structure (i.e., 
white matter in the brain), the simple Lorentzian sphere approximation is no longer valid 
and a more general approach should be used [150,151]. In MRI literature there are present 
discussions  about  the  interpretation  of  MRI  image  data  in  terms  of  the  two  contributions 
macroscopic  shape  term  (-Aκ)  and  Lorentz  term  ((1/3)κ)  in  Eq.34.  This  originates  from 
anisotropic structure of biological  tissue (e.g.,  human brain).  There appear  to be two trends. 
Harris  et  al.  and  Yablonskiy  et  al.  [149,150]  keep  κ  as  a  scalar  term  and  derive  that  the 
anisotropic local structure leads to an angle dependence in the Lorentz term. Others, i.e. Duyn et 
al.  [154] and Li et al.  [155] incorporate the effects of anisotropic structure in an asymmetric κ 
tensor. Either approach or method leads to expressions that appear to explain the experimental 
observations. However, recently Duyn (in 2013) discussed these issues concerning the origins of 
the  angle  dependence  of  MRI data  obtained from anisotropically  structured  biomaterial  and 
concluded that both approaches apply and that they should be combined [156].
Table 5 Magnetic susceptibilities, relative permittivity and electric dipole moment of a selection  
of  substances  that  are  useful  in  biologic  systems  (adapted  from  [147,157–159]).  NA:  not  
available.
Compound Name
Acetone 5.78 1.0(0°C)
Benzene 7.68 2.28 [0]
Carbon tetrachloride 8.68 2.2 [0]
8.55 55
8.82 78.3(25°C)
Ethanol 7.23 5.3 [1.69]
Ethylene glycol 8.77 37
D-Glucose 10.92(25°C) NA
Glycerol 9.79 42.5(25°C)
9.04 80.4 [1.85]
11.4 3(21.7°C)
Methanol 6.66 33.6 [1.7]
8.31(60°C) NA
8.31(18°C) 2.5
8.31(62°C) 2.3(71.1°C)
Toluene 7.76 2.35
κ(-10  × SI Units; ⁶
Dimensionless)
(20°C)
Relative Permittivity & 
[Electric Dipole moment]
(20°C)
Dimethyl sulfoxide
D2O
H2O
Mannitol
Myristic acid
Oleic acid
Palmitic acid
Calculation of the shape factor for a typical NMR configuration, cylinder sample.
The geometry of the sample often deviates from ideal geometry. For instance, an NMR 
sample is not exactly an infinite cylinder. Hoffman has calculated via numerical methods 
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the shape factor for a typical NMR tube assembly  [152]. As pointed out by Hoffman, 
previous attempts to  measure shape  factors empirically  are  likely flawed because the 
spectrum required re-shimming, thereby modifying the average effective magnetic field, 
whenever  the  tube  configuration  was  changed.  Therefore,  the  shape  factor  must  be 
determined by calculation. It is then interesting to describe the approach and outcomes.
The chemical shift, δ, can be determined for a sample in a tube with negligibly thin 
walls  (Eq.35,  where  δ0 is  the  observed shift,  δ is  the  BMS shift,  A is  the  effective 
average shape factor of the sample and  is the unit-less volume magnetic susceptibility 
of the sample).
δ = δ0+δχ = δ0+(
1
3
− Ā)κ (35)
The effective shape factor is a combination of spatial contribution of the shape factor 
and the coil sensitivity:
Ā =∫AIdv
∫ Idv
(36)
Here, I is the coil sensitivity for the volume element and v the volume. The shape factor  
at a point is an integral over the bounding surface of the depth (in the direction of the 
field) below the point multiplied by the cosine of the angle subtended by the field to the 
normal to the surface divided by the cube of the distance from the point. It is expressed 
mathematically as follows (Figure 9, Eq.37):
A( x ' ) = 1
4
π∫cos(β) [ x '−x
0]⋅̄z
∣x '− x0∣3
ds (37)
Here, A(x') is the shape factor at point x', β is the angle between the normal to the surface 
element and the field,  z is the unit vector normal to the surface element, and ds is the 
surface element). 
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Figure 9 Calculation of shape factor by integrating over surface elements (Eq.50, where x' is the  
point for which the shape factor is being , calculated, x0 is the location of the surface element, ds  
is the surface element,  z is the unit vector normal to the surface element and β is the z angle  
between the applied magnetic field and the normal to the surface element). 
For example, for x' at the center of a sphere of radius r, and using spherical coordinates 
(Figure 10), where ds = rsinθ dθ rdφ, one obtains Eq.38: 
A(0,0,0 ) =− 14π∫0
2π
∫
0
π
cosθ−rcosθ
r 3
r sinθd θ rd ϕ ,
A(0,0,0) = 1
4π∫0
2 π
∫
0
π
cos2θ r sinθd θd ϕ ,
A(0,0,0) =− 14π∫0
2π
[ cos
3θ
3 ]
π
0 d ϕ ,
A(0,0,0) = 1
4π∫0
2π 2
3
d ϕ ,
A(0,0,0) = 1
3
.
(38)
In the case of a sphere, the integration lends itself to an analytical solution. However, 
more  complex  shapes  usually  require  numerical  integration.  Hoffman  described  the 
equations  for  cylinders  parallel,  perpendicular  and at  magic  angle  with respect to  B0 
[152]. The author also calculated the error when considering the bottom of the NMR 
tubes, the meniscus and probe profile. It was found that  that the shape factor is ~0.007 
(tube 20 mm below center of receiver coil and liquid 40 mm above bottom tube) instead 
of  0  that  one  would  obtain  for  an  infinite  cylinder  oriented  parallel  to  the  B0 field. 
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Therefore,  the  deviation  from  ideality  in  δNMRtube equals  ((δNMRtube -  δinfinite 
cylinder)/δinfinite cylinder) = 0.007/0.3333 = 2.1 %. 
Figure 10 Spherical coordinates: Cartesian (x, y, z) and polar (r, θ, φ). 
Frequency shift referencing
The  shielding  constants  are  not  directly  measurable.  A reference  is  required  and 
measured  in  the  same  instrument  to  minimize  hardware  discrepancy.  As  mentioned 
earlier, NMR signals are given in frequency terms:
νob s =
γ
2π
B0(1−σo b s) (39)
where νobs is the observed resonance in Hertz (Hz) for a given nucleus. The chemical shift  
is defined as:
δs am p l e(X ) =
νs a m pl e( X )−ν r e f e r e nce (X )
νr e f er e nce (X )
(40)
where X is a specific nuclear isotope. δ is given in part per million (ppm) as σ is usually 
of  the  order  of  10 .  There  are  three  ways  of  frequency  shift  referencing:  internal,⁻⁶  
substitution and external methods. 
Internal  referencing  is  the  most  favored  method  in  isotropic  liquids.  Sample  and 
reference compounds are molecularly dispersed in a homogeneous liquid contained in a 
single sample tube  (usually cylindrical) at infinite dilution. The solvent contribution to 
σobs (encompassing σM) is then reduce to σE+σC. For proton NMR σC is generally > σE, and 
the latter is neglected. The inconvenience of this technique reside in the eventuality of 
reference not being isotropic and not sufficiently volatile to be disposed of easily for 
recovery of the pure sample, or intermolecular interaction of the reference with solvent or 
solutes. The latter is observed for blood plasma proteins that binds usual frequency shift  
reference molecules [160]. The reference signal can also come from the solute molecule 
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[140].
The  substitution  method  implies  that  one  measures  the  reference  frequency  by 
substituting the sample for a reference sample in the NMR probe [149,161]. If either the 
sample or the reference is  measured without a field lock , and if the magnetic field has 
adequate  stability  for  the  measurement,  then  B0(sample) ~  B0(reference).  However,  it  is 
recommended not to re-shimmed between the two measurements, due to the unknown z0 
component  that  often  accompanies  higher-order  field  gradient  shims  [152]. If  both 
sample and reference use the same field lock substance, then Eq.40 is directly applicable. 
Otherwise, the use of two field lock substances will require a correction for the frequency 
difference.  Here  we  can  ask  which  inert  reference  solvent  is  adequate?  The  solvent 
should possess a dielectric constant as near as unity as possible, because as mentioned 
earlier  polar  solutes  are  submitted  to  an  electric  field  shift  which  increases  with  the 
polarizability of the medium. The usual recommendation is the use of tetramethylsilane 
(TMS) in  dilute  solution  in  CDCl3.  However,  excitation  of  vibrational  and rotational 
modes with increased temperature may alter the intramolecular shielding of TMS, and 
changes in solvent effects may also influence the intermolecular shielding of TMS. A 
correction of -5×10  ppm/K for the temperature coefficient of the chemical shift of TMS⁻⁴  
is required between -20 and 80°C [162]. 
The use of an external reference involve its separation by a glass wall from the sample, 
thus  avoiding  any possible  interactions.  This  come at  the  an  expense  of  requiring  a 
correction for the difference in magnetic susceptibility between reference and sample and 
includes a term for shape of the containers and their orientation with respect to B0 (Table 
4). For solution state NMR the two main setup are: (a) a pair of coaxial cylindrical tubes 
or (b) a capillary-sphere assembly in a cylindrical tube. The  mathematical solution to 
obtain the chemical shift of the solute is given by:
δ = δo bs+δBMS = δo bs+(
1
3
−Α)(κ s am p l e−κr e f er e n ce) (41)
Here the δ and δobs are the true frequency shift (chemical shift) and the one determined 
by Eq.41, respectively. δBMS is the chemical shift induced by bulk magnetic susceptibility 
(BMS) and is described above. A is shape factor A for the interface of contact of the 
containers  for  cylindrical  and  spherical  capillaries  0  and  1/3,  respectively.  κsample and 
κreference are the bulk magnetic susceptibility (BMS) of respective solution containing the 
sample and the reference. It is clear from the Eq.41 that the use of of a spherical capillary 
is an advantage as δ = δobs. Unfortunately these capillaries are imperfect spheres with 
shape factor that deviate from 1/3  [147]. The setup with coaxial cylindrical tubes for 
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referencing is therefore capable of better accuracy.
The  last  above  example  of  external  referencing  requires  knowledge  of  BMS  to 
determine the true δ. The BMS induced δBMS is a very interesting phenomenon that has 
captivated a lot of attention in MRI and MRS studies [151]. For instance, solution state 
NMR of heterogeneous samples can generate complex spectra.  However,  with proper 
knowledge of the physical principles that lead to the shifts in the resonances stremming 
form inside or outside cellular compartments very valuable conclusions can be drawn 
with regard to cellular function.  Consider for  instance,  lipid bodies in muscle tissues 
[163]: intracellular lipid and extracellular lipid have  similar chemical composition, yet 
they give  1H NMR peaks at  different  frequencies.  It  is  now known that  the  separate 
frequencies are simply the consequence of a combination of the differences in magnetic 
susceptibility across the cellular compartments and the respective shapes of the micro-
compartments occupied by the lipids. The large difference in the magnetic susceptibility 
between the inside and outside of the cells creates large spatial magnetic field variations 
in and around the cells. This gives rise to a distribution of Larmor frequencies. 
To estimate κsolution one often uses the Wiedemann’s additivity law, which state that the 
overall  magnetic  susceptibility  of  a  mixture  is  the  weighted  sum  of  the  magnetic 
susceptibilities  of  the  constituents,  weighted  according  to  their  relative  volumes  of 
occupation of the mixture: 
κso l u t io n =
∑
i=1
n
V iκi
∑
i=1
n
V i
(42)
Here Vi is the volume of the solution occupied by substance i. Though the equation is 
rather  straightforward  it  unfortunately  does  not  account  for  the  effect  of  molecular 
interactions. For instance, the conformation and by that also the size, of a macromolecule 
like albumin changes through the binding of fatty acids. 
APPENDIX
Maxwell equations to derive macroscopic magnetic field.
In general,  the spatial  variation of the magnetic field can be found using Maxwell 
equations:
∇⋅D =ρvo l u me (43)
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∇⋅B = 0 (44)
∇×E =−∂ B
∂ t (45)
∇×H = ∂D
∂ t
+ J (46)
Here, Eq.15 is Gauss' law, Eq.16 is Gauss' magnetism law, Eq.17 is Farady's law and 
Eq.18 is Ampere's law.  is the divergence operator, x is the curl operator, ρvolume is the 
electric charge density, E is the electric field, H is the magnetic field, D is the electric flux 
density (D=εE,  ε= permittivity of the medium), B is the magnetic flux density (B=aH, 
a=permeability of the medium), J is the electric current density (J=ς E, ς=conductivity of 
the medium), and t is time.
For a macroscopically stationary state or magnetostatics (e.g., NMR tube in a static 
magnet),  δD/δt is  0  and  J  is  0,  i.e. there  is  no  electric  current  and  no  charge.  This 
simplifies these equations to: 
∇×H = 0 (47)
∇⋅B = 0 (48)
It can then be shown (see e.g. Durrant et al. (extra ref) and/or Kuchel et al.) that H=-
Φ , where  Φ is a scalar field and thus that B=-μΦ   and thus .(μΦ)=0. In uniform 
material,  where  μ is  constant  throughout,  this  equation reduces to Laplace’s equation 
.Φ=0. The solution of the Laplace equation for a given boundary/body depends on the 
specification of the behavior at infinity and at the surface of the body.
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ABSTRACT
Purpose: Accurate metabolite and protein quantification in blood plasma and other 
body  fluids  from one  single  NMR measurement,  allowing  for  improved  quantitative 
metabolic profiling and better assessment of metabolite-protein interactions.
Method: The total protein concentration is derived from the common chemical-shift 
changes - caused by protein-induced bulk magnetic susceptibility (BMS) – measured on 
well-accessible and exchange-free metabolite resonances. These BMS shifts are simply 
obtained by external referencing with respect to TSP in a coaxial insert.
Results: Based on blood-plasma data from 5 volunteers, the estimated accuracy of the 
BMS method is ≤ 5 % with respect and comparable to the 3.8 % error of the standard  
colorimetric,  Biuret,  method.  Valine,  alanine,  glucose,  leucine  and  lactate  display  no 
exchange-induced shift changes. Their well-accessible signals act as reliable probes for 
pure  protein-induced  BMS.  The  slopes  and  intercepts  of  their  chemical-shift  change 
versus protein concentration were derived from metabolite mixtures with (fatted) human 
and bovine albumin acting as blood-plasma mimics.
Discussion and conclusion: The BMS method, demonstrated on blood plasma, can 
also be employed on other  samples  containing  sufficient  protein (> 10 g/L).  Also,  it  
allows  measurement  of  the  presence  and  sign  of  exchange-induced  chemical-shift 
changes. 
Keywords: Bulk magnetic susceptibility, Blood plasma, Protein quantification, NMR, 
Metabolomics.
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INTRODUCTION
Metabolomics  is  the  study  of  the  full  complement  of  small  biomolecules  or 
metabolites in a whole biological system, like in human body fluids  [1–5]. Metabolites 
report  on  various  aspects  of  biological  (mal)-function,  e.g.,  on  gene  expression  [6], 
enzymatic  function  [7],  etc.  Thus,  metabolomics  holds  great  promise  for  (disease) 
diagnostics and various recent examples of its use in clinical diagnosis and biomarker 
discovery have been published [8–18]. Mass Spectrometry and NMR form the two main 
analytical platforms employed. MS is usually more sensitive, but requires sample specific 
preparations to detect certain metabolites or classes of metabolites. NMR does not require 
much sample preparation, is non-destructive, quantitative, and non-specific and therefore 
well suited for non-targeted quantitative metabolic profiling. Metabolomics is a relatively 
young field and although various appropriate NMR and MS methods and protocols are 
available, they do have limitations, e.g., with regard to the limited number of metabolites 
detected and quantified  [1,2]. We focus here on another aspect, namely that of protein 
content in metabolite samples. 
At  present  the  protein  and  metabolite  content  cannot  be  determined  on  the  same 
sample at the same time. Protein content can be measured separately, but this requires 
additional sample and preparation and is thus more prone to error. Moreover, the standard 
colorimetric methods have their own drawbacks [19–21]. The relevance of simultaneous 
knowledge of protein and metabolite content in quantitative metabolic profiling is well 
illustrated  by  the  example  of  metabolite-protein  interactions.  These  interactions  are 
especially prominent  in  blood plasma due to  its  high protein content  (~ 70 g/L) and 
important,  because  plasma  proteins  act  as  transporter  of  nutrients,  endogenous 
metabolites and drug molecules  [22,23]. These interactions affect the NMR metabolic 
profile  [24–26] and  are  influenced  by  competition  with  lipids  and/or  fatty  acids  for 
binding sites  [25,26]; also pH, salt concentration, and genetic variation of proteins, as 
well  as  their  degree  of  expression  play  a  role.  Only  recently,  methods  have  been 
presented  that  allow  for  broad-spectrum  monitoring  of  metabolite-macromolecules 
interactions in NMR metabolite profiling of biofluids  [24–26]. To make full use of this 
information, combined knowledge of protein and metabolite concentrations in biofluids is 
highly desirable [25]. As a final example, the protein content of biological samples is in 
itself or in combination with metabolic content a biomarker of various disease states, e.g., 
of infection,  of proteinuria,  etc.  Again combined and ideally simultaneous knowledge 
and/or  measurement  of  protein  and  metabolite  concentrations  of  body  fluid  samples 
would be of major importance. 
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Here, we propose a simple extension of present NMR metabolic profiling methods. It 
allows  for  accurate  and  robust  measurement  of  the  total  protein  and  metabolite 
concentrations on the same sample and at the same time. The sample may be from blood 
plasma or other sources. The proposed method makes use of bulk magnetic susceptibility 
(BMS)  [27–30]. It  simply requires external chemical-shift referencing, by for instance 
TSP in a coaxial insert in the sample tube, instead of the common internal chemical-shift 
referencing with respect to for instance α-glucose. The external referencing leads to a 
chemical shift change between sample and insert proportional to the difference in BMS 
[27–30].
BMS  effects  have  been  observed  in  whole-cell  NMR/MRS  where  differences  in 
magnetic susceptibility inside and outside a cell lead to different frequency shifts of the 
resonance of the same compound [31–33]. BMS effects are also often seen in MRI due to 
magnetic susceptibility differences in in-vivo material leading for instance to remarkable 
phase  contrast  in  high-field  MRI  of  human  brain  [27,34,35].  To  better  define  the 
underlying biophysics recent studies have shown the dependence of water 1H resonance 
frequency  on  protein  concentration  using  bovine  serum  albumin  (BSA)  samples 
[27,36,37]. The water 1H resonance frequency shift was found to be caused by (i) protein-
induced BMS, and (ii) exchange of the water proton between free- and protein-associated 
water. The protein-induced BMS is linear in the protein concentration and found to be ~ 
-0.16 Hz/ (g/L) for the BSA. In blood plasma, the total protein content is ~ 70 g/L (see  
e.g., [23,25]). One then expects and finds [25] a frequency shift in blood plasma of ~ 10 
Hz due to protein-induced BMS, which should be measurable on the narrow metabolite 
resonances in NMR metabolite spectra.
To demonstrate and validate that accurate metabolite and total protein quantification of 
blood  plasma  can  indeed  be  achieved  from  one  single  NMR  measurement  via  the 
proposed BMS method, we specifically investigate the following aspects. (a) In a blood-
plasma-like environment we assess the size of the chemical-shift change by BMS as a 
function of protein concentration for different proteins and establish which metabolite 
resonances  are  best  suited  to  probe  this  change.  (b)  We  validate  the  method  by 
determining the total protein concentration by protein-induced BMS in blood plasma of 
five volunteers and compared it  to the total protein concentration derived by standard 
colorimetric methods. 
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THEORY
When external referencing is employed, the chemical shift δobs of a spin (e.g., in a 
metabolite) immersed in a homogeneous medium can be written as (e.g., [27–30]),
δob s = δ f +F b Δδe xc h+∆δχ (1)
Here, δf is the chemical shift of the free metabolite, FbΔδexch arises in case of fast- and 
intermediate-exchange binding,  and  Δδχ is  the  chemical  shift  change caused by bulk 
magnetic susceptibility (BMS), a term absent in case of internal referencing. In FbΔδexch, 
Fb is  the  fraction  of  bound  ligand  and  Δδexch stands  for  the  difference  between  the 
chemical shift of the ligand in its bound state, δb, and its free state, δf (Δδexch =δb – δf) 
[38]. The BMS term, Δδχ, is the sum of two terms [27–30] (here in cgs units), 
∆δ χ=(F s ha pe+
4π
3
)   Δ χ     (2)
The  first,  Fshape,  is  called  the  shape  factor  and  arises  from  the  media’s  external 
boundary. For an infinite cylinder whose axis is oriented at an angle θ with respect to the 
magnetic  field  B0,  Fshape equals  –2πsin2θ [28,30].  Because  we  consider  external 
referencing here with inner and outer coaxial tubes parallel to the B0 field, the angle θ is 
zero. The shape factor then nulls, when the infinite cylinder assumption may be applied, 
leaving in equation 2 only the second term (4π/3)Δχ . However, for typical NMR sample 
tubes  and  using  the  geometry  and  receiver  coil  configuration  of  a  superconducting 
magnet Hoffman [29] found that small deviations from zero may occur, e.g., for a 5 mm 
wide NMR tube with 20 mm above and below the center of the receiver coil a deviation 
of ~2% from the theoretical value of 4π/3 is found. The second term, (4π/3)Δχ, describes 
the  frequency  shift  caused  by  neighboring  molecules  in  the  sample  volume  [27,30]. 
Equation  2  is  expressed  in  cgs  units,  which  fits  with  units  commonly  employed  in 
published tables of magnetic susceptibilities (see e.g., Harris et al. [28]). To convert from 
cgs to SI, magnetic susceptibilities must be multiplied by 4π and the first and second term 
in equation 2 divided by 4π. The term Δχ is the difference of χsample and χref, the volume 
bulk magnetic susceptibilities of the sample and reference insert, respectively,
Δ χ = (χ sample−χref ) = ζ protein(χ protein−χwater)+(χwater−χD2O )+C (3)
The right-hand-side
53
THEORY
χ sample = χwater+ζ protein(χ protein−χwater)+∑
i
ζmetai (χmetai−χwater)
+∑
j
ζion j(χion j−χwater)
(4)
χ ref = χD2O+ζTSP(χTSP−χD2O ) (5)
Here, ζj is the volume fraction of the relevant solution-component j and χj its volume 
magnetic susceptibility. The magnetic susceptibilities of protein, water and D2O form the 
leading terms in equation 3, their literature values in cgs units are,  χprotein ≈ -0.801 ppm 
[30,39], χwater = -0.719 ppm [32] and χD2O = -0.702 ppm [32]. Although different, χj’s of 
different molecular species are of the same order of magnitude [32]. In contrast, volume 
fractions of macromolecules and ions/metabolites may differ by orders of magnitude (e.g. 
the molecular volume of HSA is over 300 times that of an amino acid). Consequently, the 
contribution of TSP, ions and metabolites to  Δχ is (usually negligibly) small. They are 
collected  in  term  C  in  equation  3. The  chemical  shift  of  metabolite  i  in  sample  y 
calibrated with respect to external TSP is then,
δobs
i , y = δ f
i , y+F bΔδexch
+(F shape+
4 π
3
)[ζ protein(χ protein−χwater)+(χwater−χD2O)+C ]
(6)
For  non-interacting  metabolites  or  metabolites  whose  interactions  do  not  lead  to 
exchange-induced shift changes FbΔδexch equals zero and δobs is proportional to ζprotein,
δobs
i , y=δ0f
i , y+    ζ proteinS ' prot
i , y = δo f
i , y+    cg ( gL ) 600
ρ ( gL )
S ' prot
i , y
=   δ 0f
i , y+cg ( gL )S proti , y ( H zL/ g )  
(7)
where the intercept δ0f
i , y  equals,
δ0f
i , y = δ f
i , y+(F shape+
4π
3
)((χwater−χD2O)+C ) (8)
and the slope equals,
S ´ prot
i , y = (F shape+
4π
3
)(χ protein−χwater) (9)
We call these BMS intercept and slope. They can be determined from measurement of 
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δobs versus  ζprotein.  As  described  in  subsequent  sections  (Results,  Discussion  etc.)  the 
intercepts and slopes were here determined from three different blood-plasma mimics 
(y=fBSA, HSA, fHSA).
Conversely, when the BMS intercept and slope are known from a mimic and assumed 
not to change, the total protein concentration in an unknown sample (e.g., in a blood 
plasma  sample  X,  y=BLPX)  can  be  derived  from  the  δobs
i , BLPX  of  an  exchange-free 
metabolite,
ζ protein=( δobs
i ,BLPX−δ0f
i , fBSA/HSA/ fHSA)/   S ' prot
i , fBSA /HSA / fHSA (10)
Whether this assumption, that given similar solvent conditions and experimental set-up 
(same external reference compound and insert), slope and intercept do not change, indeed 
holds needs to be verified, described in Results and Discussion.
Alternatively,  one  can  simply  measure  δobs of  the  exchange-free  metabolites  with 
external referencing for the original blood plasma sample δobs,1 and for a once-diluted 
sample δobs,2 in the same buffer and compute ζprotein from the difference δobs,1 - δobs,2, 
ζ protein=2∗( δobs ,1−δobs ,2) /S ' prot
i , fBSA /HSA / fHSA   (11)
The intercept cancels out, because the slope and intercept terms in equation 7 are not 
likely to change when similar solvent conditions and experimental set-up (same external 
reference compound and insert) are used. The BMS slope depends on χ terms from only 
the sample. The outcome equation 11 is thus independent of reference signal, so that also 
another reference solvent may be used.
Still  another  alternative  would  be  to  measure  δobs with  and  without  external 
referencing. However, this approach is likely to be more prone to errors, because one 
needs to know or derive various terms,  some of which are of somewhat uncertain size, 
e.g., F and C. 
We finally consider metabolites that interact with the protein fraction such that  FbΔδ 
<> 0. For weak interactions and common protein concentrations the bound fraction Fb is 
roughly  proportional  to  the  protein  concentration  (see  e.g.,  [25]);  Fb approaches 
saturation only at protein concentrations that are very high relative to the dissociation 
constant. Consequently, the slope of δobs-vs.-ζprotein equals for such interacting metabolites 
((δprotein - δwater) (F+(4π/3)) + (FbΔδexch/ ζprotein)) and is larger or smaller than the slope for 
non-interacting metabolites, (δprotein - δwater) (F+(4π/3)), depending on the sign of Δδexch. 
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Hence, proper measurement of δobs with external referencing may identify exchange and 
provide  the  sign  of  Δδexch,  which  is  otherwise  not  easily  ascertained,  as  it  generally 
requires rather complex T2 and T1ρ relaxation experiments [40].
MATERIALS AND METHODS
Materials
All  chemical  products  were  purchased at  Sigma-Aldrich,  including  a)  pure  human 
serum  albumin  (HSA/A3782),  which  is  essentially globulin  and  fatty  acid  free 
(~0.005%),  and b)  fatted  HSA (fHSA/A8763),  which  is  essentially globulin  free  but 
contains  fatty  acids.  Sigma-Aldrich  employs  the  purification  protocols  of  Saifer  and 
Goldman [41](41), who describe the common fatty acid composition of fatted albumin 
(fHSA), as consisting mostly of C18:x (x = 0,1,2, and 3) and to a lesser extent shorter-
length fatty acids. To remove globulins from fHSA Sigma-Aldrich uses caprylate, a small 
fatty acid also known as octanoic acid (C8:0). It is then important to note the following. 
1)  HSA preferably  binds  long-chain  fatty  acids  (>  C14:x;  see  e.g.,  Ashbrook  et  al.  
[42,43]); they are not easily replaced by less hydrophobic short-chain fatty acids such as 
caprylate. 2) The potential presence of some caprylate (C8:0) on HSA or fHSA did not 
block binding of metatolites to fHSA as evident from our results [25].
Preparation of blood-plasma mimics
Four  types  of  blood-plasma  mimics  were  created:  (a)  a  mimic  with  endogenous 
metabolites at normal plasma concentrations (Table S1; data from HMDB, normal adults 
>  18  years  old,  [2,25]),  (b)  a  mimic  with  endogenous  metabolites  at  normal  plasma 
concentrations and fatted bovine albumin (fBSA), 0 to 100 g/L (0 to ~1.5 mM) , (c) a 
mimic with endogenous metabolites at normal plasma concentrations and human albumin 
(HSA), 0 to 100 g/L (0 to ~1.5 mM) , and (d) a mimic with endogenous metabolites at 
normal plasma concentrations and fatted human albumin (fHSA), 0 to 100 g/L (0 to ~1.5 
mM) .
The mixture of metabolites in the mimics was chosen to represent normal plasma as 
much as possible, as published before  [24,25,44]. The metabolite concentrations in the 
mimics  follow  normal  blood-plasma  values.  In  total  17  metabolites  were  chosen:  l-
arginine, l-asparagine, l-aspartate,  l-alanine, acetate,  citrate,  creatinine, D-+-glucose, l-
glutamine, l-histidine, l-lactate, l-leucine, l-lysine, l-phenylalanine, pyruvate, l-threonine 
and l-valine. They represent essentially the ~20 metabolites commonly found by NMR in 
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blood plasma, concentration ~10 µM or higher [45–49]. Nevertheless, in a general sense 
this  group of  metabolites  is  small  compared to the total  number of ~200 metabolites 
presently potentially identifiable by NMR in plasma [1–3].
For each selected metabolite a stock solution was prepared by dissolution in a 7.0 mM 
phosphate-buffered saline (PBS stock) of pH 7.4 (~0.8% NaCl, ionic strength of buffer 
154 mM) to a metabolite concentration as given in Table S1; the stock solutions were 
stored at -20 °C. Stock solutions of fBSA, HSA, and fHSA were also prepared in the 
same PBS buffer to reach a final concentration of about 100 g/L and were filtered using 
Millex® GP 0.22 μm. The concentrations of non-fatted and fatted albumin in PBS were 
measured with a Cary300 spectrophotometer; we used as before  [25] an absorbance of 
6.5 for 1% solution of protein at 280 nm for BSA and an absorbance of 5.3 for 1% 
solution of protein at 280 nm for HSA. The PBS-buffered protein-stock solutions were 
stored at 4 °C if not immediately used. In addition, a stock solution of the mixture of 
selected metabolites was made at 20 times their normal concentration in blood plasma 
and stored  at  -20  °C.  From these  stock  solutions  of  the  mixtures,  the  four  types  of 
different blood-plasma mimics as mentioned above were made. 
Preparation of blood-plasma mimics for pH test
Only the blood-plasma mimic without protein, i.e. the metabolites mixture, was used 
to test the effect of pH on the chemical shift of the metabolites. The pH was set at 6.5,  
7.0, 7.5, 8.0 and 8.5 using highly concentrated NaOH and HCl solution. For each pH four 
samples  were  prepared  from  the  stock  solutions  for  error  estimation.  Samples  were 
degassed for 30 minutes to remove any air bubbles.
Preparation of blood-plasma mimics for protein titration
The albumin-metabolite mixtures were prepared by adding stock metabolites mixture 
(concentration 20 x normal) to the albumin stock solution to a final  concentration of 
albumin of  0-100 g/L and metabolite  concentrations  corresponding to  those found in 
normal blood plasma as above. The ultimate albumin-metabolite mixture was dissolved 
in 7.0 mM phosphate buffered saline (PBS; pH 7.4; ~0.8% NaCl, ionic strength of buffer 
154 mM). The pH of all samples was adjusted to 7.4 ± 0.5 using highly concentrated  
NaOH and HCl. Samples were degassed for 30 minutes to remove any air bubbles.
Preparation of blood plasma; measurement of HSA and total protein concentration
Heparinated blood plasma of five healthy volunteers was obtained and employed for 
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three  measurements.  a)  The  HSA  concentration  was  measured  using  the  standard 
Bromocresol-purple test performed by the Laboratory of Clinical Chemistry, University 
Medical  Center  Nijmegen  Chemical  laboratory  (UMCN).  b)  The  total  protein 
concentration was measured using the standard Biuret test performed by UMCN. c) NMR 
measurements were performed as follows. The samples were prepared at dilution factor 
equal to 1 and to 2. The samples were diluted in 2 mL eppendorf tubes using PBS, thus 
keeping ionic strength constant at 154 mM (NaCl concentration of ≈0.8%). The pH of all 
samples was adjusted to 7.4 ± 0.5 using highly concentrated NaOH and HCL. The pH 
measurement  were  done  using  pH  meter  PHM220  from  Radiometer  Copenhagen 
equipped with Inlab micro probe from Mettler Toledo.
NMR measurements
The  1D  1H  NMR  spectra  were  all  recorded  at  298  K  using  the  following  pulse 
sequences. a) RD-30°-acquisition, with relaxation delay (RD) and acquisition of 6 and 
3.9 s, respectively. b) Presat-1D-noesy with pulse-field gradients (RD-90°-gpz1-90°-tm-
gpz2-90°-acquisition), with RD, tm and acquisition of 4, 0.1 and 3.9 s, respectively. gpz1 
and gpz2 are pulse-field gradients (shape: smoothed square) of 1 ms duration. The pulse-
field  gradients  in  the  first  and  second  block  were  50% and  -10% of  the  maximum 
gradient strength, respectively. c) RD-90°-ES-(τ-180°-τ)n-acquisition. The sequence starts 
with a relaxation delay (RD). Subsequently, a 1H 90°-excitation pulse is applied followed 
by water suppression by means of an excitation sculpting sequence (ES) [25,50,51]. The 
ES sequence consists of two subsequent pulse sequence blocks that each consists of a 
water selective (sinc-shaped) 180° inversion pulse of 2 ms followed by a non-selective 
180° pulse. These two 180° pulses are bracketed by two equal sign pulse-field gradients 
(shape:  square  with  top)  of  1  ms duration.  The  pulse-field  gradients  in  the  first  and 
second block are 31% and 11% of the maximum gradient strength, respectively. Prior to 
acquisition a T2-filter is used to remove macromolecular NMR signals. The T2-filter is 
composed  of  a  CPMG-sequence  [52] with  τ=830  µs  and  n=128.  Acquisition  and 
relaxation delays were equal to 3 s and 3.5 s, respectively. 
The  samples  of  500  μL were  put  in  5  mm  NMR  tubes.  For  the  chemical-shift 
calibration and lock signal 2 mm coaxial tubes containing D2O and 0.55 mM TSP were 
used. Measurements were carried out on a Bruker Avance III spectrometer operating at 
600 MHz equipped with a cryoprobe (Triple Resonance:  1H,  13C,  15N; z gradient; and 
high sensitivity 1H detection and 13C detection). 
The 1D 1H-NMR spectra were analyzed using Bruker Topspin 3.0 and ACD lab 12.0. 
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Processing involved chemical shift calibration to coaxial TSP at 0.0 ppm.
RESULTS
Blood plasma
Table  1  Blood   plasma   samples   from   five   healthy   volunteers.   The   HSA   and   total   protein  
concentrations are shown as determined by standard colorimetric methods. Also shown are the  
chemical shifts in Hz of lactate and glucose signals at 1.31 ppm and 5.21 ppm, respectively, for  
two dilution factors. The change in chemical shift upon dilution is caused by protein-induced  
BMS because external TSP referencing is used.
Volunteer
F 42 74 780.79 3124.585 785.415 3129.205
FRE 41 70 780.79 3124.715 784.9 3128.825
L 46 78 779.64 3123.425 785.16 3129.075
M 45 75 780.405 3124.585 785.675 3129.595
S 40 69 778.995 3123.945 785.285 3129.205
Dilution factor = 1 Dilution factor = 2
Chemical shift wrt coaxial TSP (Hz) error~1Hzb
HSA(g/L) 
error<3.8%a
Protein(g/L) 
error<3%a
Lactate @ 
1.31 ppm
α-glucose @ 
5.21 ppm
Lactate @ 
1.31 ppm
α-glucose @ 
5.21 ppm
aThe error given is determined by the vendor of the colorimetric test and to be reported in the  
clinical assays of blood plasma. bThe chemical shift is externally calibrated with respect to TSP  
in the coaxial insert. The error in the chemical shift due to usage of different coaxial inserts was  
estimated to be ~1 Hz and 0.3 Hz when using the same insert.
Blood-plasma samples were  obtained from five healthy volunteers (methods).  Two 
colorimetric  concentration  determinations  were  performed  on  the  volunteers’ blood 
plasma: a) Bromocresol-purple for HSA and b) Biuret test for the total protein (Table 1). 
The volunteers showed normal HSA and total protein concentrations of ~42 g/L and ~73 
g/L, respectively. The 1H NMR metabolite spectra were externally calibrated with respect 
to TSP in the coaxial insert, so that chemical-shift changes caused by protein-induced 
BMS could be observed. The NMR spectra were measured for blood plasma samples at 
dilution  factors  1  and  2.  Upon  dilution  by  a  factor  2,  the  chemical  shift  for  most 
metabolites  changed,  like  those  for  lactate  and  glucose  shown in  Table1,  by  ~5  Hz 
(exceptions  are  pyruvate  and  histidine,  which  gave  larger  changes,  probably  due  to 
exchange contributions;  a  full  list  is  given in  supplementary  material,  Table  S2).  We 
conclude that indeed considerable and thus well-measurable chemical shift changes occur 
for  most  metabolites  in  blood  plasma.  These  changes  are  likely  caused  by  protein-
induced BMS, because of the overall equal magnitude of the chemical shift changes for 
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the different (mostly non-interacting) metabolites, but this will be established in full in 
the next sections.
Figure 1  Excerpts from the 1H NMR spectra of blood plasma and of the three blood-plasma  
mimics with either added fBSA, HSA and fHSA at albumin concentration of 20 g/L. Signals  
assignment: TSP (1), Leucine (2), Valine (3), Lipids (LDL+VLDL) (4), Lactate (5,14), Alanine  
(6), Acetate (7), Glycoprotein+Lipids (8), Glutamine (9,11), Pyruvate (10), ), Creatinine (12,13),  
Glucose (15), Tyrosine (16), Histidine (17), Phenylalanine (18), Formate (19). Valine was used  
here as (internal) chemical shift reference and peak height standard. 
Assessment which metabolite NMR signals from blood-plasma mimics and blood 
plasma can best be used as chemical shift probes for protein-induced 
BMS
From the 3 blood-plasma mimics - containing fatted BSA, HSA and fatted HSA as 
well as a mixture of ~20 metabolites - the chemical shift of the metabolites signals was 
measured as function of albumin concentration (0 - ~100 g/l) using external chemical 
shift  referencing (methods).  At  high albumin concentration some metabolites  become 
NMR-invisible, e.g., citrate, histidine, phenylalanine and pyruvate. In contrast, signals of 
leucine (0.95 ppm), valine (1.03 ppm), lactate (1.31 ppm), alanine (1.45 ppm), acetate 
(1.91 ppm) and α-glucose (5.21 ppm) remain  NMR-visible  in  all  samples  and in  all 
volunteer blood plasma samples. Of these, valine (1.03 ppm), alanine (1.45 ppm) and α-
glucose (5.21 ppm) are particularly relevant as they were previously determined not to be 
affected by interaction with albumin  [25,26]. Other signals were not used because they 
have  too  complex  multiplets,  e.g.,  glutamine  multiplets,  or  may  overlap  with  other 
resonances. Figure 1 shows the 1H NMR spectra of blood plasma and the 3 blood-plasma 
mimics with fatted/non-fatted albumin added at an intermediate concentration of 20 g/L. 
It illustrates the spectral quality and shows which metabolites are best visible as well as 
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the degree of overlap.
We also considered the effect of pH on metabolite chemical shifts and highlight here 
the most salient observations (see for an overview Table S3). Between pH 6.5 and 8.5 the 
signals of lactate (1.31 ppm and 4.11 ppm), pyruvate (2.36 ppm), β-glucose (4.62 ppm), 
and α-glucose (5.21 ppm) are not at all pH sensitive within a standard deviation of 0.3Hz. 
Other  important  metabolite  signals  for  BMS measurements,  like  those from the non-
binding  metabolites  valine  and  alanine,  display  from pH 6.5  to  8.0  relatively  small 
changes (<1.2 Hz). Although these changes are small, it is recommended to stabilize pH 
by buffering (PBS, methods).
Establishing the size of the chemical-shift change by protein-induced BMS in 
metabolite NMR signals as a function of protein concentration in blood-
plasma mimics
The  chemical-shift  changes  of  resonances  from  non-interacting  metabolites  are 
expected to be linearly proportional to the concentration of fatted or non-fatted albumin 
according to equation 7 and the slopes for the different metabolite signals are expected to 
be  equal.  Interacting metabolites,  when not-saturated,  will  also give linear  regression 
lines, but the slopes are then larger or smaller (see theory section). 
Table  2  Slopes  and   intercepts   of   the   fitted   linear   regression   line  δobs-vs-ζproteina  for   various  
metabolites in three blood-plasma mimics measured at 600 MHz. 
-0.170 -0.161 -0.157 -0.152 -0.200 NA NA NA -0.238 -0.152 -0.135 -0.113
570 619 790 881 1145 NA NA NA 2461 3135 4230 4667
-0.122 -0.109 -0.109 -0.103 -0.123 NA NA -0.150 -0.147 -0.103 NA NA
570 618 790 881 1145 NA NA 2428 2463 3135 NA NA
-0.147 -0.137 -0.133 -0.132 -1.234 -0.166 -0.165 -0.166 0.095 -0.131 -0.105 -0.072
569 618 790 880 1149 1417 1522 2428 2610 3134 4232 4673
Leucine 
@ 0.95c
Valine   
 @ 1.03
Lactate 
 @ 1.31
Alanine 
 @ 1.45
Acetate 
@ 1.91
Pyruvate 
@ 2.36
Citrate  
 @ 2.54
Creatinin
e @ 4.05
Lactate 
@ 4.64
Glucose 
@ 5.21
Histidin
e @ 7.06
Histidin
e @ 7.79
Slopeb Mimic 
fatted BSAInterceptb
Slope Mimic 
HSAIntercept
Slope Mimic 
fatted HSAIntercept
aThe  protein   volume-fraction   ζprotein  is   converted  here   to   cg  (g/L)   (see   equation  7)   and   the  
chemical shift δobs is converted from ppm to Hz (see equation 7) so that, the slopeb is expressed 
in (Hz/(g/L)) and the interceptb  in Hz.  cChemical shift of the considered metabolite resonance;  
chemical shifts of doublets, e.g., valine, lactate, alanine, glucose, are averaged.
We indeed find (Table 2) that the slopes of δobs versus ζprotein of the metabolites valine, 
lactate, alanine, and  α-glucose are quite similar within each of the 3 albumin mimics, 
with average values of (fBSA = -0.156(4) Hz/(g/L), HSA = -0.106(3) Hz/(g/L), fHSA = 
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-0.133(3) Hz/(g/L). These metabolites do not interact with HSA/BSA except for lactate 
[25,26]. Lactate binds in the slow-exchange regime (signal intensity changes), but does 
not show exchange broadening or shift  changes (binding fast  exchange regime)  [25]. 
Leucine  gives  slope  values  very  close  to  the  average  values  of  non-interacting 
metabolites. As lactate, leucine interacts with HSA in the slow-exchange regime but does 
not show shift changes (fast exchange) [25]. Steeper slopes are seen in the fHSA mimic 
for albumin-interacting metabolites, like acetate, pyruvate, creatinine, whereas histidine 
shows a less steep slope (also in  fBSA).  Histidine shows the largest  slope deviation. 
Consistently (see also discussion), it was previously seen to give the largest shift changes 
due to fast-exchange interaction with HSA [25].
Total protein concentration in blood plasma from chemical-shift changes caused 
by protein-induced BMS 
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Figure 2 Chemical shift of α-glucose calibrated with respect to external TSP from blood-plasma  
mimics and from volunteers blood plasma versus protein concentration.
We investigate in this section whether the plasma protein concentration can reliably be 
determined  from  protein-induced  BMS  chemical  shift  changes  of  blood  plasma 
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metabolites. First, we compare in Figure 2, the ‘raw measured’ data from blood plasma 
and blood-plasma mimics. Figure 2 shows the chemical-shift of the doublet resonance at 
~5.21 ppm of the non-interacting metabolite  α-glucose  [25,26,49,53] as a function of 
albumin concentration for the three mimics using external TSP calibration.  The BMS 
slopes for the fBSA and fHSA mimics are relatively close while that of HSA is clearly 
less  steep.  We  then  added  the  corresponding  datapoints  using  again  external  TSP 
calibration from the five blood plasma samples at two dilutions; that is we added the 
chemical  shifts  of  the  α-glucose  resonance  (at  ~5.21  ppm)  versus  the  colorimetric 
determined total protein concentration (black filled circles and crosses) and versus the 
standard colorimetric determined albumin concentration (grey filled circles and crosses) 
at the two dilutions. The blood-plasma datapoints versus the total protein concentration 
(black filled circles and black crosses) overlap fully with the datapoints from the fBSA 
and fHSA mimics, whereas the data points versus the HSA concentration do not overlap. 
This demonstrates that the BMS chemical-shift changes of the non-interacting metabolite 
α-glucose in blood plasma correspond to the total protein concentration and not the HSA 
concentration.  Similar  results  are  obtained  for  the  other  non-interacting  metabolites. 
Conversely,  these  results  indicate  that  it  is  possible  to  calculate  the  total  protein 
concentration from these protein-induced-BMS chemical-shift changes of non-interacting 
metabolites. We next consider this aspect.
Table 4 Calculated total protein concentration using averaged BMS shifts from combinations of  
metabolite signals. NB stands for signals from the non-binding metabolites, valine, alanine and  
glucose; NB+Le are signals from NB metabolites and leucine; NB+La stands for the signals  
from NB and lactate (1.31 ppm); NB+Le+La stands for signals from NB metabolites plus leucine  
and lactate (1.31 ppm).   a  see Table 3.  #Total protein concentration from standard colometric  
measurement (see methods).
HSA
NB NB+Le NB+La NB+Le+La NB NB+Le NB+La NB+Le+La NB NB+Le NB+La NB+Le+La
F 74 69 69 67 68 98 97 95 95 74 74 72 73
FRE 70 68 68 66 67 96 95 94 94 72 73 71 72
L 78 76 76 74 75 109 107 106 105 82 83 81 82
M 75 68 69 67 67 97 96 95 95 73 73 73 73
S 69 72 72 72 72 103 102 103 102 78 78 79 79
5 5 7 7 37 36 35 34 5 5 5 5
Colorimetry 
measurement 
(g/L)#
Estimate of total protein concentration (g/L) using BMS slope and intercept of :
fBSA fHSA
Average 
difference (%)a
The total protein concentration in blood-plasma can be calculated using equation 10 
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from  the  chemical  shift  of  an  ‘exchange-free’  (internal  chemical  shift  reference) 
metabolite  [25].  We also  need  the  BMS ‘slope’ and  ‘intercept’ of  the  corresponding 
metabolite derived in a plasma mimic; their values are assumed not to change going from 
mimic  to  real  blood  plasma.  The  results  are  given  in  Table  3  and  compared  to  the 
standard colorimetric test  values.  Best  estimates of  the total-protein concentration are 
obtained for the ‘exchange-free’ metabolites  -  leucine,  valine,  alanine,  and α-glucose. 
Further,  employing the  BMS slopes and intercepts  from the fBSA and fHSA mimics 
gives  for  these  ‘exchange-free’  metabolites  considerably  better  estimates,  ≤  6  % 
difference, than the slopes and intercepts from the HSA mimic.
To further reduce the error in the BMS concentration estimates, we also calculated the 
total  concentration  averaged  over  four  combinations  of  easily  accessible  metabolites 
(Table 4).  For all combinations, the total protein concentration is best estimated from 
fBSA or fHSA, with a slight overestimation for fHSA and a slight underestimation for 
fBSA. Including, the lactate signal at 1.31 ppm to the average increases the difference to 
7 % for fBSA and 6 % for fHSA-NB+Le+La. The groups NB and NB+Le perform best, ≤ 
5 % difference, in fBSA and fHSA.
We also considered the approach of once diluting the sample and calculating the total 
protein concentration from the difference in chemical shifts  (equation 11).  The mean 
absolute difference for the best sets (NB and NB+Le) is ≤ 9% using slopes from fHSA 
mimics (Table S4), which is somewhat larger than for BMS method 1 (Table 4) due to the 
additional dilution, but still quite acceptable. Note that upon dilution some (interacting) 
metabolites may get released (e.g., lactate), so that their signals remain relatively high, 
Sdil2 > 0.5 Sdil1 [25].
DISCUSSION AND CONCLUSIONS
The chemical  shift  change  caused  by  protein-induced  bulk  magnetic  susceptibility 
(BMS)  was  demonstrated  here  as  a  simple  and  accurate  means  to  estimate  the  total 
protein concentration in blood plasma from its  metabolite  NMR spectrum. The BMS 
method requires external chemical shift referencing, for instance by a TSP/D2O-mixture 
in a coaxial insert in the sample tube and subsequent measurement of the chemical shift 
of a number of metabolites that are well-accessible in the metabolite NMR spectra and 
not  affected by chemical exchange.  These  metabolites  are  leucine (0.95 ppm),  valine 
(1.03 ppm), lactate (1.31 ppm), alanine (1.45 ppm) and α-glucose (5.21 ppm). The error 
in the BMS method is estimated to be ≤ 5 %, which is comparable to the ~4 % error of 
the standard colometric method used in the clinic; the BMS error is estimated as the mean 
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absolute difference in concentration as measured by the standard colorimetric and BMS 
methods.  Assuming  an  error  of  0.3  Hz  in  the  chemical-shift  determination,  one  can 
estimate that a meaningful (> 3σ) concentration determination can be performed at and 
above ~10 g/L. Further attesting to the quality of the data is the fact that χprotein ‘s derived 
from the three different blood-plasma mimics show small error (~ 0.5%) and are very 
close  to  literature  values  (~0.8%),  <χprotein,  fBSA/fHSA>  (ppm  ml/g):  -7.304±0.033  / 
-7.416±0.038 vs. <χprotein, lit>: -7.367 (ppm ml/g) [39] (further detyails in supplementary 
material). 
An important  strength  of  the  proposed BMS method is  that  it  provides  additional 
information, namely protein concentration, in NMR metabolomics or lipidomics studies 
in  a  straightforward manner  and under exactly  the  same sample  conditions  as  where 
metabolites  and/or  lipid  NMR spectra  are  measured.  We  further  note  that  automatic 
recording of NMR spectra of multiple samples, which includes automatic referencing, is 
possible  with  the  external  TSP referencing.  This  could  be  combined  with  automatic 
detection of the mentioned well-accessible metabolites and in this way provide a quick 
way to determine the total protein  concentration in blood plasma; see for instance the 
method proposed for the automatic detection of α-glucose in serum  [53]. Finally,  the 
proposed BMS method can easily be implemented to  measure protein concentration in 
samples used for structural biology studies. 
For  metabolites  interacting  in  the  fast-exchange  regime  FbΔδexc does  not  equal  0 
(theory).  Thus,  they display chemical-shift  changes  beyond those caused by (protein-
induced) BMS. The  deviations from the mean slope of δobs versus cg may be used to 
identify metabolites with fast-exchange interactions. The sign of the deviations may be 
employed to determine the sign of Δδexc = δb –δc (see theory). A nice example is formed 
by  Histidine.  It  shows  a  BMS slope  of  -0.105  Hz/(g/L)  in  the  fHSA  mimic,  which 
deviates considerably from the protein-induced BMS slope, -0.133(3) Hz/(g/L). Hence, 
(FbΔδexc/cg) equals +0.028 Hz/(g/L) which is larger than zero and thus Δδexc>0.
Another  relevant  question  is:  can  metabolite  quantification  from  their  resonance 
integrals still be carried out correctly in the context of the BMS method and thus in the 
context of external chemical-shift referencing. This metabolite quantification requires an 
internal  or  external  compound  whose  concentration  is  known  and  whose  resonance 
integral/height can act as internal or external calibrator for estimating the concentration of 
other  compounds  from their  resonance  integrals/heights.  It  is  often  very  difficult  for 
solutions of biological macromolecules to find a proper internal calibration compound 
namely one that does not interact with the macromolecules  [54]. We and others found 
66
Chapter 2 - Protein-induced Bulk Magnetic Susceptibility
that in  blood plasma valine or glucose do not interact given normal concentrations and 
can  thus  act  as  internal  calibration  compounds  [25,26,49].  Nevertheless,  an  external 
reference  compound  solves  the  (potential)  interaction  problem  in  a  general  way. 
However, one then needs to account for potential differences in 90° pulse lengths due to 
different solvent environments in coaxial insert and sample tube. The underlying concept 
of PULCON [54] shows how to do this. Here, this correction factor is simply the ratio of 
90° pulse lengths for TSP and main sample compounds,  θ90m/θ90TSP.  The NMR-derived 
concentration (Cm, NMR) of metabolite m is then,
Cm , NMR = CTSP
( I m/nm )
( I TSP /nTSP )
θ 90
m
θ 90
TSP (12)
Here, CTSP is the concentration of external TSP, Im and ITSP are the integrals of the 
resonance of  metabolite  m and TSP,  respectively;  nm and nTSP are  the  corresponding 
numbers of protons, contributing to the resonance [25]. In practice, this correction factor 
was found negligible (see also [25]).
In conclusion, thanks to the external referencing quantitative metabolic profiling and 
total protein quantification of blood plasma and other body fluids can be simultaneously 
achieved from one NMR experiment on one sample that in principle does not require any 
additions.  This  improves  the  quantitative  metabolic  profiling  and  adds  total  protein 
content as a biomarker to the output. 
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SUPPLEMENTARY MATERIALS
Table S1 Overview of metabolites and their concentration in the blood plasma mimics used.
Number Metabolite
1 82
2 48
3 22
4 citrate 88
5 L-alanine 333
6 66
7 D-+-glucose 4520
8 612
9 86
10 lactate 1510
11 159
12 L-lysine 190
13 Acetate 30
14 L-phenylalanine 61
15 pyruvate 63
16 150
17 231
Normal human (µM)#
L-arginine
L-asparagine
L-aspartate
creatinine
L-glutamine
L-histidine
L-leucine
threonine
valine
#The data are from the HMDB (see main text) and for normal adults who are over 18 years old.
Table S2 Chemical  shift  difference (Hz)  of  metabolites  NMR resonances  in  5 blood plasma  
samples due to protein-induced BMS (see main text, Table 1) upon twice dilution (Hz). The NMR  
spectra are measured at 600 MHz.
Lactate Alanine Acetate Citrate Glucose Histidine1 Histidine2
0.95 1.03 1.31 1.45 1.91 2.36 2.54 4.05 5.21 7.06 7.79
F -5.7 -4.9 -4.6 -4.8 -4.9 -5.9 -4.9 -7.5 -4.6 -2.8 0.3
FRE -4.9 -4.4 -4.1 -4.1 -4.4 -5.7 -4.4 -6.2 -4.1 -5.1 -7.2
L -6.7 -6.0 -5.5 -5.9 -5.9 -8.2 -5.6 -8.2 -5.6 -9.5 -14.9
M -5.6 -5.3 -5.3 -5.0 -5.1 1.5 -5.1 -6.9 -5.0 -5.6 -7.5
S -5.9 -5.5 -6.3 -5.4 -5.4 -6.9 -5.4 -7.2 -5.3 -5.9 -7.2
Leucine Valine Pyruvate Creatinine
δ(ppm)
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Table S3a Chemical shift of metabolite signals between pH 6.5 - 8.5 at 600 MHz
aChemical shift δ in ppm at pH 6.5. bChemical shift δ in Hz at the different pH values (columns  
3, 5, 7, 9, and 11); average over four samples that were prepared and measured, n=4. cStandard 
deviation σ in Hz at the different pH values over the four prepared and measured samples (n=4).
pH
6.5 7 7.5 8 8.5
Metabolite
0.96 575.5 0.5 575.6 0.2 575.6 0.3 575.2 0.1 574.5 0.1
Valine1 1.03 620.3 0.5 620.3 0.2 620.3 0.3 619.5 0.2 617.6 0.3
Valine2 1.04 627.3 0.4 627.3 0.2 627.3 0.3 626.5 0.3 624.7 0.3
Lactate1 1.32 792.6 0.5 792.6 0.2 792.8 0.3 792.6 0.2 792.5 0.3
Lactate2 1.33 799.4 0.4 799.7 0.4 799.7 0.3 799.5 0.2 799.5 0.3
Alanine1 1.47 882.4 0.5 882.4 0.2 882.3 0.4 881.2 0.3 878.3 0.5
Alanine2 1.48 889.6 0.5 889.7 0.3 889.6 0.4 888.5 0.2 885.7 0.5
Acetate 1.92 1151.3 0.8 1150.6 0.3 1150.4 0.4 1150.0 0.2 1150.0 0.3
2.37 1421.8 0.5 1422.0 0.3 1422.1 0.4 1421.9 0.2 1421.9 0.3
2.41 1445.6 0.4 1445.5 0.2 1444.9 0.6 1442.3 0.4 1435.3 1.2
Citrate 2.57 1554.9 10.1 1547.1 1.5 1541.5 1.9 1538.7 0.3 1537.9 0.4
Lysine 3.03 1816.4 0.3 1816.2 0.2 1816.2 0.4 1815.3 0.2 1813.2 0.4
Creatinine1 3.04 1825.1 0.6 1824.4 0.2 1824.2 0.3 1824.0 0.1 1824.1 0.2
Threonine1 3.58 2150.1 0.5 2149.0 0.3 2145.9 1.9 2136.4 1.4 2136.4 1.4
Creatinine2 4.06 2435.1 1.0 2433.4 0.2 2432.9 0.4 2432.4 0.2 2432.3 0.1
Lactate3 4.11 2464.0 0.4 2463.9 0.2 2464.0 0.3 2463.8 0.1 2463.8 0.2
Lactate4 4.12 2470.9 0.4 2470.8 0.2 2470.9 0.4 2470.7 0.2 2470.7 0.2
Threonine2 4.25 2549.0 0.5 2548.3 0.3 2546.3 1.3 2540.2 0.9 2522.1 2.8
4.64 2782.1 0.4 2782.3 0.2 2782.3 0.4 2782.1 0.2 2782.2 0.2
5.24 3140.8 0.4 3140.8 0.2 3141.0 0.3 3140.8 0.1 3140.9 0.2
Histidine1 7.11 4272.9 8.4 4246.1 2.4 4232.1 3.9 4223.3 0.5 4215.8 1.1
Phenylalanine1 7.34 4399.1 0.4 4398.8 0.3 4399.1 0.9 4398.2 0.7 4395.9 0.4
Phenylalanine2 7.38 4424.8 0.4 4424.6 0.2 4424.4 0.3 4423.3 0.1 4420.2 0.5
Phenylalanine3 7.43 4456.1 0.5 4456.1 0.2 4456.1 0.4 4455.1 0.2 4452.9 0.4
Histidine2 7.91 4772.2 21.7 4701.7 7.7 4665.3 9.4 4645.4 0.9 4636.6 0.6
aδ bδ cσ δ σ δ σ δ σ δ σ
Leucine
Pyruvate
Glutamine
ß-glucose
α-glucose
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Table S3b Chemical shift of metabolite signals between pH 6.5 - 8.5 at 600 MHz. The chemical  
shift  difference in  Hz with respect  to its  value at pH 7.5 is  shown as well  as the maximum  
change, chemical shift at pH 6.5 versus pH 8.5.
aChemical shift δ in ppm at pH 6.5. bChemical shift difference Δδ in Hz with respect to value at  
pH 7.5 at the different pH values (columns 3, 4, 5, 6, and 7); data were taken from Table S3a and  
thus  average  is  over  four  samples  that  were  prepared and measured,  n=4.  cChemical  shift  
difference Δδ in Hz between  pH values 8.5 and 6.5 (Δδ = -(δpH6.5 – δpH8.5)); data from Table S3a 
and thus average over four datasets, n=4.  dThe metabolites with essentially no chemical shift  
change are highlighted in grey. The metabolites used for BMS are given in bold. 
pH
6.5 7 7.5 8 8.5
Metabolite
0.96 0.1 0.0 0.0 0.4 1.2 1.1
Valine1 1.03 0.0 0.0 0.0 0.8 2.7 2.6
Valine2 1.04 0.0 0.0 0.0 0.7 2.6 2.6
1.32 0.2 0.2 0.0 0.2 0.3 0.1
Lactate2 1.33 0.3 0.0 0.0 0.2 0.2 -0.1
Alanine1 1.47 -0.1 -0.1 0.0 1.1 3.9 4.1
Alanine2 1.48 0.0 -0.1 0.0 1.1 3.9 3.9
Acetate 1.92 -0.9 -0.2 0.0 0.4 0.5 1.3
2.37 0.3 0.1 0.0 0.2 0.2 -0.1
2.41 -0.7 -0.6 0.0 2.6 9.6 10.3
Citrate 2.57 -13.4 -5.6 0.0 2.8 3.5 16.9
Lysine 3.03 -0.1 0.0 0.0 1.0 3.0 3.2
Creatinine1 3.04 -1.0 -0.2 0.0 0.2 0.1 1.1
Threonine1 3.58 -4.2 -3.0 0.0 9.5 9.5 13.7
Creatinine2 4.06 -2.2 -0.5 0.0 0.5 0.6 2.8
Lactate3 4.11 0.0 0.1 0.0 0.2 0.2 0.2
Lactate4 4.12 0.0 0.1 0.0 0.2 0.2 0.2
Threonine2 4.25 -2.7 -2.0 0.0 6.1 24.3 27.0
4.64 0.2 0.1 0.0 0.3 0.1 -0.1
5.24 0.3 0.2 0.0 0.2 0.1 -0.2
Histidine1 7.11 -40.8 -14.0 0.0 8.8 16.3 57.0
Phenylalanine1 7.34 0.0 0.3 0.0 0.9 3.2 3.2
Phenylalanine2 7.38 -0.4 -0.2 0.0 1.1 4.2 4.5
phenylalanine3 7.43 0.0 0.0 0.0 1.0 3.2 3.2
Histidine2 7.91 -107.0 -36.4 0.0 19.8 28.7 135.7
aδ bΔδ Δδ Δδ Δδ Δδ cΔδ
Leucined
Lactate1d
Pyruvate
Glutamine
ß-glucose
α-glucose
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Comparison with literature values of the protein gram magnetic susceptibility χg, protein of three 
albumins obtained from blood-plasma mimics.
The  protein  gram  magnetic  susceptibility  χg,protein derived  from  the  chemical  shift 
change  of  metabolites  in  the  three  blood-plasma  mimics  is  compared  with  literature 
values. We consider the metabolites which are not or not much affected by exchange 
(Valine, Alanine, Glucose, Leucine, and Lactate). To calculate χg we employ equation 1, 
which follows from equation 8 with the  relevant unit conversions. The slope  is taken 
from Table 2. For the density (ρ) of albumin we use the value provided from the vendor 
(Sigma-Aldrich),  ρalbumin =  1364  (g/L),  which  is  similar  for  the  3  different  albumin 
sources. The shape factor Fshape was taken zero (see theory) and χwater equals -0.719 ppm 
(see theory).
χ g = [S proti , y ( H zg /L )(  ρ( gL )600 ( Hz ) (F shape+ 4π3 ) )+ χwater ] 4˙πρalbumin (1)
The χg,protein values are given in Table S5. They are determined with high accuracy 
(stdev ≤ 0.5%). Further, they are also close to the “common χg value” of proteins: -7.376 
ppm mL/g [1]. This is expected because albumin is a globular protein like the ones on 
which “common χg value” is based. Nevertheless, the χg values for the three different 
mimics do display some variation, i.e. |χgHSA| < |χgfHSA| ≤ |χgfBSA|.
Table S5 Gram susceptibility χg of three albumins in ppm mL/g obtained from the three blood-
plasma mimics.
Glucose
0.95 1.03 1.31 1.45 5.21
-7474 -7429 -7409 -7384 -7384 -7416 38
-7234 -7168 -7169 -7139 -7139 -7170 39
-7359 -7309 -7289 -7284 -7279 -7304 33
Leucine Valine Lactate Alanine Mean Stdevδ(ppm)
Mimic fatted BSA
Mimic HSA
Mimic fatted HSA
The explanation for these relatively small differences in  χg, protein may in part be the 
following. The  χg,  protein of a mixture and thus of a protein volume may be calculated 
using Wiedemann’s law [2],  which states  that the overall magnetic susceptibility of a 
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mixture is the weighted sum of the magnetic susceptibilities of the constituents, weighted 
according to their relative volumes of occupation of the mixture. Because χg of fatty acids 
is more negative than of proteins one expects the fHSA and fBSA mimics to have a more 
negative χg than the HSA mimic. 
We now consider the total protein concentration in blood plasma estimated from the 
chemical shift change caused by protein-induced BMS. From Table 4 it is evident that the 
total protein concentration is estimated accurately within  ≤ 5% of the standard Biuret 
measurement using the slopes (and intercepts) from fatted albumin mimics (fBSA and 
fHSA mimics). Mimics with fatty-acids-free HSA performed worst with regard to protein 
estimation and leads to overestimation. The underlying cause for these relatively small 
differences  in  total  protein  concentration  estimates  appears  thus  related  to  the  small 
differences in volume magnetic susceptibility discussed above, which follows the same 
trend |χgHSA| < |χgfHSA| ≤ |χgfBSA|. 
References
[1]  M. Cerdonio, S. Morante, D. Torresani, S. Vitale, A. DeYoung, R.W. Noble, 
Reexamination of the evidence for paramagnetism in oxy- and carbonmonoxyhemoglobins, 
Proc. Natl. Acad. Sci. 82 (1985) 102–103.
[2]  P.W. Kuchel, B.E. Chapman, W.A. Bubb, P.E. Hansen, C.J. Durrant, M.P. Hertzberg, 
Magnetic susceptibility: Solutions, emulsions, and cells, Concepts Magn. Reson. 18A 
(2003) 56–71.
78
79
CHAPTER 3
NMR Identification of Endogenous Metabolites interacting with Fatted  
and Non-Fatted Human Serum Albumin in Blood Plasma: Fatty Acids  
influence the HSA-Metabolite Interaction.
Marc Jupin, Paul Michiels, Frederic Girard, Manfred Spraul, Sybren Wijmenga
Journal of Magnetic Resonance 228 (2013) 81–94
ABSTRACT
Metabolites and their concentrations are direct reporters on body biochemistry. Thanks 
to technical developments metabolic profiling of body fluids, such as blood plasma, by 
for  instance  NMR  has  in  the  past  decade  become  increasingly  accurate  enabling 
successful clinical diagnostics. Human Serum Albumin (HSA) is the main plasma protein 
(~60% of all plasma protein) and responsible for the transport of endogenous (e.g. fatty 
acids) and exogenous metabolites, which it achieves thanks to its multiple binding sites 
and its flexibility. HSA has been extensively studied with regard to its binding of drugs 
(exogenous  metabolites),  but  only  to  a  lesser  extent  with  regard  to  its  binding  of 
endogenous (non-fatty  acid)  metabolites.  To obtain correct  NMR measured metabolic 
profiles of blood plasma and/or potentially extract information on HSA and fatty acids 
content,  it  is  necessary  to  characterize  these  endogenous  metabolite/plasma  protein 
interactions. Here, we investigate these metabolite-HSA interactions in blood plasma and 
blood  plasma  mimics.  The  latter  contain  the  roughly  twenty  metabolites  routinely 
detected by NMR (also most abundant) in normal relative concentrations with fatted or 
non-fatted HSA added or not. First, we find that chemical shift changes are small and 
seen only for a few of the metabolites. In contrast, a significant number of the metabolites 
display reduced resonance integrals and reduced free concentrations in the presence of 
HSA or  fatted  HSA.  For  slow-exchange  (or  strong)  interactions,  NMR  resonance 
integrals report the free metabolite concentration, while for fast exchange (weak binding) 
the chemical shift reports on the binding. Hence, these metabolites bind strongly to HSA 
and/or  fatted  HSA,  but  to  a  limited  degree  because  for  most  metabolites  their 
concentration  is  smaller  than  the  HSA concentration.  Most  interestingly,  fatty  acids 
decrease  the  HSA-metabolite  binding  quite  significantly  for  most  of  the  interacting 
metabolites.  We further  find  that  competition  between the  metabolites  for  binding is 
absent for most of these metabolites. These mappings in plasma mimics may thus open 
new  opportunities  for  improved  metabolic  profiling  of  blood  plasma.  For  instance, 
correct metabolite concentrations can be determined for the non-interacting metabolites 
and/or  concentration  corrections  made  for  interacting  metabolites.  Secondly,  the 
interacting  metabolites  could  be  used  to  act  as  reporters  on  HSA and  fatty  acid 
concentration in plasma, and thus potentially act as biomarker in diagnostic studies of 
trauma or cardiovascular diseases. Finally, we find in the blood plasma mimics that after 
ultrafiltration,  commonly  used  to  remove  the  protein  from  plasma,  the  measured 
concentration equals the total metabolite concentration, except for the strongest binding 
metabolite citrate.
Keywords: Metabolites; Metabolomics; NMR; Albumin; Fatty acids; Blood plasma; 
Interactions.
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INTRODUCTION
Blood is one of the main transporting biofluids in humans and contains molecules of 
various  size  and  mobility:  proteins,  lipids,  lipoproteins,  cholesterols,  metabolites  and 
ions, and their concentrations range from nM to mM. Blood plasma is blood without 
blood  cells,  while  blood  serum  is  blood  plasma  without  the  blood  clotting  proteins 
(fibrinogens). Endogenous metabolites are defined as low molecular weight chemicals, 
which are reactants, intermediates or products of enzyme mediated biochemical reactions 
[1]. Endogenous metabolites are in a unique position as they are the building blocks for 
all other biochemical species and structures including proteins, genes and cell walls. Such 
metabolites  as  well  as  drug metabolites  are  exchanged and transported  by  the  blood 
system throughout the body. Hence, the whole body biochemistry can be analyzed by 
studying endogenous blood metabolites and their presence and concentration reflects the 
health  and/or  disease  states,  and can  show how the  body  reacts  to  stimuli  from the 
environment.  The number of  endogenous metabolites  is  estimated around 6000 [1,2], 
which is much smaller than the number of genes or transcriptions products, proteins. The 
metabolome is therefore sometimes considered as an ideal ‘filtered’ reporter on the state 
of  the  biosystem  [1].  For  the  last  decade,  qualitative  and  quantitative  studies  of 
metabolites, known as metabolomics, have provided metabolite profiles that may be used 
as blood plasma biomarkers in clinical diagnostics [3,4]. 
Metabolomics is defined as the study of the quantitative complement of metabolites in 
a biological system and changes in metabolite concentrations or fluxes related to genetic 
or  environmental  perturbations  [1].  Metabolomics  studies  are  typically  holistic  (non-
targetted)  in  nature  although  targeted  studies  are  also  encompassed  in  the  term 
metabolomics.. The metabolomics field has developed tremendously from its start in the 
early  2000’s  with  ca  1400  publications  in  2011  and  a  doubling  time  of  ca  3  years. 
Metabolomics studies on blood serum or blood plasma in turn constitute one third of the 
total.  The  recently  determined  human  metabolome,  that  has  been  made  accessible 
through web interaction, is expected to further enhance the role of metabolomics studies 
of blood serum or plasma [2,5,6]. NMR and MS (GC-MS, LC-MS, TLC-MS) form the 
main analytical techniques in metabolomics [1,2,7]. NMR contributes about one-third of 
the publications. 
Each of these analytical techniques has its pro’s and con’s. The strength of NMR lies 
in  the  fact  that  it  is  a  non-invasive  quantitative  analytical  method  with  highest 
reproducibility and transferability and well suited for non-targeted profiling. It does not 
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require chemical reactions or extensive manipulations before measurement. MS detection 
often does require chemical modification prior to measurement and can be subject to ion 
suppression  in  co-elution  and  as  a  consequence  may  be  less  suited  for  non-targeted 
detection. In addition, quantification is often more difficult. However, MS methods can 
be  considerably  more  sensitive  than  NMR,  although  when  quantification  is  required 
similar amounts are needed. From the HMDB [2,5,6] it can be surmised that for serum 
~200  water-soluble  metabolites  can  in  principle  be  detected  in  routine  1H 1D NMR 
applications  (detection  limit  ~5  to  10  µM).  However,  due  to  resonance  overlap  the 
practical number turns out to be 30 to 50 metabolites that are detected by routine 1H 1D 
NMR  in  plasma  [2]  or  cerebral  spinal  fluid  [6,8].  GC-MS  can  detect  50  to  100 
metabolites when quantification is performed; the sets of metabolites detected by GC-
MS/LC-MS and NMR partly overlap and are complementary [2,6,8]. TLC-MS turns out 
to be quite sensitive and can detect a large number of metabolites [2]. For diagnostic 
purposes, not only detection but also quantification is of great importance. Thanks to its 
ability to quantify, NMR is well suited for and may provide opportunities in targeted as 
well as non-targeted quantitative metabolic profiling of blood plasma/serum.
Blood  plasma  is  a  heterogeneous  mixture  that  produces  complex  NMR  spectra 
crowded  with  1H  NMR  signals  originating  from  a  large  number  of  overlapping 
resonances due to a wide range of molecules with different line shapes, the line shapes 
depending themselves on the molecular weights and mobility.  For example, relatively 
large plasma proteins and lipoproteins relax faster than small size metabolites leading to 
broad resonances; due to their abundance these broad resonances will nevertheless partly 
overwhelm the much sharper metabolite resonances in the NMR spectra [9]. To solve this 
overlap problem relaxation filters [9] are used that remove the broad signals so that more 
or  less  clean  small  metabolites  signals  can  be  recorded.  Nevertheless,  even  in  these 
cleaned NMR plasma metabolite spectra, the substantial number of different metabolites 
still leads to complex spectra with considerable resonance overlap. Apart from spectral 
complexity and overlap, this heterogeneous mixture also displays high possibilities of 
metabolite-protein and other types of interactions (e.g. enzyme mediated or metal ions 
complexation)[10,11],  which  are  likely  to  affect  the  NMR  metabolite  spectra.  The 
interactions can, for instance result in different amounts of free metabolites depending on 
the interaction strength and presence of other molecules. When the interaction is strong 
enough,  both  bound  and  free  metabolite  signals  are  visible  in  the  NMR  spectrum. 
However, the bound-state resonance is likely broadened to the extent that it is invisible. 
Consequently,  the  metabolite  resonance is  only observed in  its  free  state.  The  signal 
intensity thus corresponds to that of the free fraction and the chemical shift and relaxation 
82
Chapter 3 - Metabolites Interacting with Fatted and Non-Fatted Human Serum Albumin
parameters are then essentially that of the free metabolite. These NMR parameters open 
the opportunity to identify the type of metabolite interaction as well as characterize it. 
The  interactions  of  metabolites  with  the  blood  plasma  protein  matrix  via  NMR 
analysis  have  been  reported  on  previously.  (a)  In  one  study,  tryptophan,  tyrosine, 
phenylalanine and histidine were added to plasma [12]. The NMR spectra displayed poor 
recovery of their expected resonance signal intensities. Only, upon acidifying the blood 
plasma these  metabolites  were  released leading to  higher  resonance intensities  in  the 
NMR spectra  [12].  (b)  By adding salt  (ammonium chloride)  to  plasma,  lactate,  3-D-
hydroxybutyrate, and aceto-acetate are liberated [13]. (c) When lactate is added to the 
pure  high  molecular  weight  blood plasma fraction,  the  intensity  of  the  lactate  NMR 
signal is attenuated and also somewhat broadened [13]. In this last example, the authors 
thus  showed  lactate  binding  to  the  protein  matrix  of  blood  plasma.  They  also 
demonstrated that  lactate binds to the plasma proteins α1-antitrypsine and transferrin. 
Furthermore, they found an increase of up to 200% in the intensity of lactate upon adding 
agents such as SDS, NaCl, HClO4, and NH4Cl or by raising the temperature to 50°C. 
They concluded that the NMR signal of lactate may reflect only a small part of the real  
lactate concentration. Thus interactions of metabolites with the protein matrix can lead to 
metabolite profiling results that may be misinterpreted and thus to wrong conclusions on 
the metabolic system. 
In an effort to reduce or even remove the influence of these metabolite-plasma protein 
interactions on the NMR analysis of metabolites different preparation methods for blood 
plasma  have  been  attempted  [10,14].  Moreover,  catalytically  active  proteins  may  be 
present; it is therefore desirable to inactivate or remove such proteins, in particular when 
NMR2 spectra are to be recorded over longer periods of time [10]. These methods all aim 
to release bound metabolites from the plasma protein matrix and to subsequently remove 
the  plasma proteins.  They employ acidification  to  extract  the  metabolites  or  achieve 
metabolite  extraction  via  addition  of  acetone,  methanol/chloroform,  or  acetonitrile 
[10,14]. Daykin et al. [14] showed that none of these precipitation methods is optimal as 
each gives different results and none releases all metabolites completely. Tiziani et al. 
[10] further showed that most of these extraction or deproteinization methods not only 
release metabolites but also deplete some metabolites. Overall, the best results appear to 
be obtained by acetonitrile precipitation at physiological pH, because it allows detection 
of more metabolites and at higher concentrations than observed for the other precipitation 
methods.  Moreover,  acetonitrile  precipitation  is  being  rapid  and  simple  [14].  Ultra 
filtration  was  shown  to  provide  an  excellent  alternative  method  for  deproteination, 
because  it  appears  superior  in  retaining  high  metabolite  concentrations  and  to  offer 
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excellent reproducibility [10,14]. In the recently published Human Serum Metabolome 
Database [2] the method of ultra-filtration was used to remove proteins. Finally, it should 
be noted that additional ultra-filtration steps (or precipitation steps) may be employed on 
the  filtrate  to  recover  still  bound metabolites.  All  these  studies  show that  due to  the 
deproteination procedure plasma/serum metabolites  of interest  can potentially be lost. 
This will affect the metabolite profile. 
The need for reliable quantification in metabolomic profiling of blood plasma/serum 
led us to further investigate the interaction of metabolites with the plasma protein matrix. 
We focus on the main plasma protein, human serum albumin (HSA). HSA is a protein of 
about 585 amino acids [15,16,17,18] which is produced in the liver [19], and makes up 
about 60% of all  plasma proteins and has a concentration of  35-50 mg/mL (with 40 
mg/mL being ca. 0.6mM). Its main function is to transport endogenous and exogenous 
metabolites[20], which it achieves thanks to its multiple binding sites and its flexibility. 
Also, HSA has enzymatic properties, for example it can perform esterase reactions [17].  
HSA has been extensively studied with regard to its binding of drugs and to a lesser  
extent to its binding of endogenous molecules, i.e. metabolites. Several aspects of the 
drug-HSA interaction have been studied, drugs binding sites and their respective affinities 
have been established and drug-drug interaction and/or competition for binding sites on 
HSA have  been  investigated  to  reveal  drug  secondary  effects  [15,16,20,21,22,23]. 
Concerning  endogenous  molecules,  HSA transports  mainly  non-esterified  fatty  acid 
anions [19,24,25,26,27,28] (FAs) from fat storage, adipose tissue, to consuming tissues, 
like the heart. Saifer and Goldman [24] showed that FAs transported by HSA are similar 
to the free FAs in blood plasma; the FAs found are saturated and non-saturated and have a 
chain length ranging from 12 to 20 carbons. Recent crystallographic studies [25,26] on 
FAs C10, C12, C14, C16, C18, C18:1 and C20:4 showed that they have seven common 
binding sites distributed across HSA. Binding of these FAs to their fatty acid binding 
sites leads to conformational changes on HSA at drug site 1. This observation explains 
why FA binding affects drug binding to HSA. In addition, FA binding also involves direct 
competition for drug site 2. 
FA binding to HSA has both cooperative and antagonistic effects on the binding of 
endogenous and exogenous molecules to HSA [16,29]. For example, the drug warfarin 
shows, at FA-HSA mole ratios of 3 for long-chain fatty acids (e.g. oleate and palmitate), 
an increase in binding, whereas at mole ratios greater than 5, a decrease in binding is 
observed [16]. In another case study, the effect of myristate (C14)-HSA binding on the 
interaction  of  endogenous  molecule  Mn(III)heme  with  HSA was  investigated  [29]. 
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Interestingly, one observes competition for binding as well as antagonistic effects, i.e. one 
observes myristate-induced conformational changes that affect other Mn(II)heme binding 
sites on HSA [29]. Furthermore, upon addition of palmitate (or laurate) to HSA (mole 
ratio 3:1), the endogenous molecules, progesterone and testosterone, and bilirubin, show 
an increase in binding [16].  These findings bring up the question, how extensively do 
fatty acids affect the binding of endogenous molecules (i.e. metabolites) with HSA in 
blood plasma. 
The importance of establishing metabolite-macromolecule interactions was stressed in 
the  recent  study  by  Daykin  et  al.  [11],  who  showed  how metabolite-macromolecule 
interactions can be detected in an untargeted manner in plasma by means of Diffusion-
Ordered  Spectroscopy  (DOSY)  in  a  method  called  i-metabolomics.  In  the  study,  a 
standard mixture was prepared, representative of human blood plasma, consisting of HSA 
and 20 metabolites commonly observed by NMR; in addition, ibuprofen was added to a 
number of these standard samples; further, bovine serum albumin (BSA) samples with 
ibuprofen added were prepared and finally a blood plasma was employed. This study 
revealed  that  for  instance  acetone,  acetate  and  citrate  appear  bind  to  HSA.  More 
extensive mapping of the metabolite interaction with HSA or with the plasma protein 
matrix is highly desirable. Moreover, FAs have been shown to influence the interaction of 
drug  molecules  and  some  specific  endogenous  metabolites;  it  can  therefore  not  be 
excluded  that  the  interaction  of  one  endogenous  metabolite  affects  that  of  another 
metabolite.  This  suggests  a  complex  network  of  interactions,  which  has  not  been 
characterized.  In  NMR  metabolic  profiling  the  correct  estimation  of  metabolite 
concentrations is highly relevant as this relates to functioning of metabolic pathways. In 
complex  biofluids  like  blood  plasma  the  strong  interactions  of  metabolites  with  the 
protein matrix may lead to wrong information if not properly understood. Thus, there is a 
need to characterize the metabolites’ interactions with proteins.
In  the  present  study,  we  identify  which  of  the  endogenous  metabolites,  that  are 
commonly observed in blood plasma NMR metabolomics studies [2,30,31] interact with 
HSA and  with  fatted  HSA (fHSA)  and  characterize  the  interaction  in  a  controlled 
environment.  For  this,  three  blood  plasma  mimics  were  prepared.  In  one,  only  the 
selected metabolite mixture was present with metabolite in concentrations as commonly 
seen in plasma [2]. In the other two, the selected metabolites mixtures were mixed with 
either HSA or fHSA to a HSA/fHSA concentration such as that commonly observed in 
blood plasma. In this way, the metabolite HSA interaction can be studied and the impact 
of fatty acids on the HSA binding of metabolites established. Also, the influence of any of 
the other metabolites on the HSA/fHSA binding in investigated. Further, we investigate 
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the extent to which removal of HSA or fHSA from the plasma mimics by ultra-filtration 
affects  the  NMR  measured  metabolite  concentrations.  In  addition,  we  consider  for 
comparison these interactions in a few blood plasma samples.
MATERIALS AND METHODS
Materials
All chemical products were purchased at Sigma-Aldrich. Two types of Human Serum 
Albumin (HSA) stock were purchased: (a) Pure human serum albumin (HSA), i.e. HSA 
is essentially globulin free and essentially fatty acid free (~0.005%), product no. A 3782; 
(b)  fatted  HSA (fHSA),  i.e.  is  essentially  globulin  free  but  does  contain  fatty  acids, 
product  no.  A 8763.  Sigma-Aldrich  employs  the  purification  protocols  of  Saifer  and 
Goldman [24],  who describe  the  common fatty  acid  composition  of  fHSA,  which  is 
mostly C18:x (where x = 0,1,2 and 3), but also shorter length fatty acids may be present 
to a lesser extent. To remove globulins caprylate was used by Sigma-Aldrich; caprylate is 
a small fatty acid also known as octanoic acid (C8:0). It is important to note the following 
two points with regard to fHSA. 1) HSA preferably binds long-chain fatty acids (> C14:x; 
see e.g. Ashbrook et al. [32,33]); they are not easily replaced by the less hydrophobic 
short-chain fatty acids (such as caprylate). 2) We further the potential presence of some 
caprylate (C8:0) did not prevent binding of citrate and pyruvate to fHSA as one can see 
from our results (Tables 1 &2); in other words it did not block binding.
Preparation of blood plasma mimics 
Three  types  of  blood  plasma  mimics  were  created  in  triplicate:  (a)  a  mimic  with 
endogenous metabolites at normal plasma concentrations (Table S1; data from HMDB, 
for  normal  adult  patients  >  18  years  old  [2,6,34,35]),  (b)  a  mimic  with  endogenous 
metabolites at normal plasma concentrations and human serum albumin (HSA) added to 
a normal plasma concentration, namely of 50 mg/mL (~0.75 mM) and (c) a mimic with 
endogenous metabolites at normal plasma concentrations and fHSA added to a normal 
plasma concentration of 50 mg/mL.
The mixture of metabolites present in the three mimics was chosen such that the mimic 
represents  the  situation  in  normal  plasma  as  much  as  possible.  To  achieve  this,  the 
metabolites were selected based on the following criteria. 1) The ultimate mixture should 
contain  the  full  spectrum  of  highly  concentrated  metabolites  to  relatively  low 
concentrated metabolites with the latter limited by whether they can still be measured in 
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the 1D 1H NMR spectra. 2) They should have resonances that are clearly visible and non-
overlapping in the 1D 1H NMR spectrum. 3) The set should include as much as possible 
those metabolites, which have previously been characterized as to their binding properties 
with respect to the plasma protein matrix, i.e. they should be known to either bind or not 
bind [12,13,14]. In total 17 metabolites were thus chosen from a set of previously and 
commonly  identified  in  1D  1H  NMR  blood  plasma  analysis  [30,31]:  l-arginine,  l-
asparagine, l-aspartate, l-alanine, acetate, citrate, creatinine, D-+-glucose, l-glutamine, l-
histidine, l-lactate, l-leucine, l-lysine, l-phenylalanine, pyruvate, l-threonine and l-valine. 
The  concentrations  of  metabolites  in  the  mimic  follow  the  measured  normal 
concentrations in blood plasma (data from HMDB, for normal adult patients > 18 years 
old  [2,34]).  We further  note  that  in  the  recently  published Serum HMDB [2],  NMR 
spectra were recorded of serum samples of healthy individuals and of patients with a 
heart transplant and per sample ~32 metabolites were identified of which 21-25 were 
seen in every sample. The set of metabolites in our plasma mimics largely corresponds to 
these ~20 compounds. Thus, the mimics contain essentially all metabolites commonly 
found by NMR in plasma with a concentration of ca. 10 µM or higher. Furthermore, other 
researchers, who studied for instance albumin removal and/or qualitatively metabolite-
albumin interactions, have employed and studied similar numbers of metabolites [11,36]. 
Nevertheless, in a general sense this group of metabolites is small compared to the total 
number of metabolites potentially identifiable by NMR in plasma [2].
The mimics were prepared via the following protocol. For each selected metabolite a 
stock solution was prepared by dissolution in a 7.0 mM Phosphate buffer saline (PBS 
stock)  of  pH  7.4  (~0.8%  NaCl,  ionic  strength  of  buffer  154  mM)  to  a  metabolite 
concentration given in Table S1 (supplementary material); the stock solutions were stored 
at  -20 °C.  Stock solutions  of  human serum albumin (HSA) and fatted human serum 
albumin (fHSA) were each also prepared in the same PBS buffer. The concentrations of 
the human serum albumin and fatted human serum albumin in PBS were each measured 
with a Cary300 spectrophotometer and we used an absorbance of 5.3 for 1% solution of 
protein at 280 nm [37].  The buffered protein solutions were also stored at -20 °C. In 
addition, a stock solution mixture of the selected metabolites was made at 20 times their 
normal concentration in blood plasma (data from HMDB [2,34,35], Table S1) and also 
stored at -20 °C. From these stock solutions of the mixtures, HSA and fHSA, the three 
types of different blood plasma mimics as mentioned above were made. For each type, 
three such samples were prepared from these stock solutions to allow for error estimates. 
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Preparation of blood plasma mimics for ultra-filtration
For the ultra-filtration experiments also three types of plasma mimic mixtures were 
prepared following the protocol described above.  They were  prepared in triplicate as 
above and using the stock solutions of the metabolite mixtures of 20 times the normal 
concentration, HSA, and fHSA. They contain same mixture of metabolites as described 
above. 
Spiking of blood plasma mimics with selected metabolites
For the spiking experiments also the three types of plasma mimics were prepared from 
scratch following the described protocol, but with citrulline and 2-oxoglutarate replacing 
l-alanine  and  acetate.  Each  one  of  these  three  plasma  mimics  was  spiked  with  the 
following  metabolites:  citrate,  glutamine,  histidine,  lactate,  lysine,  phenylalanine, 
pyruvate,  and valine. For each metabolite,  4 different amounts were added creating 5 
separate samples (the first mixture plus the 4 further titrations). Table S2 gives a complete 
overview of the used concentrations. The highest final spiked metabolite concentration 
was equal to ~1.8 mM (ca. 3 times the HSA/fHSA concentration) for all  metabolites 
except lactate, for which a maximum concentration of 6 mM was used (ca. 6 times the 
HSA/fHSA concentration). 
Dilution series of the blood plasma mimics and blood plasma
For the dilution series the same three plasma mimic mixtures were employed as in the 
spiking experiments. The plasma mimics were diluted by factors of 1, 1.5, 2, 5, 8.33, 
16.67, 25, 50, 62.5, 71.43 and 100 using the phosphate buffer saline, PBS mentioned 
above,  thus  keeping  pH constant  at  7.4  and  ionic  strength  constant  at  154  mM.  In 
addition, heparinated blood plasma of three volunteers was obtained and their metabolite 
profiles were measured at different dilution factors; the samples were diluted in 2 mL 
eppendorf tubes up to hundred times in 7 or 8 dilution steps (with highest dilution factor 
100) using PBS, thus keeping ionic strength constant at 154 mM (NaCl concentration of 
≈0.8%) and the pH constant at ~7.4 (see supplementary materials, Table S3). The pH 
measurement  were  done  using  pH  meter  PHM220  from  Radiometer  Copenhagen 
equipped with Inlab micro probe from Mettler Toledo. 
Each mimic and blood plasma was measured twice or three times to ensure reliability 
and  repeatability.  For  all  three  mimic  samples  and  for  all  three  patients’  spectra 
calibration was done using α-H1-glucose signal at 5.23 ppm.
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Ultra-Filtration to remove plasma protein 
To remove plasma protein ultra-filtration was employed. For the ultra-filtration the 
approach was similar to that applied by Psychogios et al. [2] and Sheedy et al. [36]. Prior 
to  filtration  the  -3-kDa  cut-off  centrifugal  filtration  device  (Centricon® device  with 
Ultracel YM-3 membrane) was washed twelve times with water by centrifugation at 37 
°C for 60 minutes at 7500 g to remove residual glycerol on the membrane (the filtrate 
was checked in the NMR for absence/near absence of glycerol signal) and kept moist 
prior to use. The PBS buffered plasma mimic samples were then placed into the 3-kDa 
cut-off centrifugal filtration device and each centrifuged for ~120 minutes at 7500 g (at 4 
°C). After the ultra-filtration the filtrates were placed in NMR tubes for measurements. 
NMR: data recording and analysis
The 1D 1H NMR spectra were recorded on Bruker Avance III spectrometers operating 
at 500 MHz or 600 MHz equipped with cryoprobes (Triple Resonance:  1H,  13C,  15N; z 
gradient;  and  high  sensitivity  1H  detection)  and  using  5  mm  NMR  tubes.  In  some 
instances, that is for NMR experiments on blood plasma (dilution) and the spiking and 
dilution experiments on the plasma mimics an inner 2 mm coaxial tube purchased from 
Norell  was  inserted.  The  coaxial  tube  contained  0.4  mM  trimethylsilyl-2,  2,  3,  3-
tetradeuteropropionic acid (TSP, sodium salt) and 0.6 mM MnSO4 in D2O. The MnSO4 
was used to assure complete relaxation of TSP between each scan. The inner tube was 
employed  to  avoid  interaction  of  TSP with  plasma  proteins.  It  is  to  be  noted  that 
ultimately, the TSP from the inner tube was not used for concentration determination 
and/or chemical shift calibration because of magnetic susceptibility effects resulting from 
the  presence  of  protein.  The  5  mm NMR tube  contained  (when  the  inner  tube  was 
present) 450-500 µl of sample with no reference or calibration compound added. For all 
other experiments no inner tube was inserted and instead ~10 % D2O was added. Finally, 
to confirm/further establish the metabolite concentration in addition plasma mimics that 
contained  only  metabolite,  were  prepared  in  triplicate  as  described  in  the  section 
‘Preparation blood plasma mimics samples’ but with TSP added to a concentration of 130 
µM and ~10 % D2O and their 1D 1H NMR spectra recorded. All measurements were 
done at 298 K.
The  1D  1H  NMR  spectra  were  all  recorded  using  the  following  pulse  sequence 
“CPMGes1d”: RD - 90° - (τ -180°- τ)n  -ES- acquisition. It starts with a relaxation delay 
(RD).  Subsequently,  a  1H 90°  excitation  pulse  is  applied  followed  by  a  T2-filter  to 
remove  macromolecular  NMR signals.  The  T2-filter  is  composed  of  a  Carr-Purcell-
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Meiboom-Gill (CPMG) sequence [9,38] with τ set to 830 µs and n equal to 128. Prior to 
acquisition the water signal is suppressed by means of an excitation sculpting sequence 
(ES) [39,40]. The ES sequence consists of two subsequent pulse sequence blocks that 
each consists of a water selective (sinc-shaped) 180° inversion pulse of 2 ms followed by 
a non-selective 180° pulse. These two 180° pulses are bracketed by two equal sign pulse-
field gradients (shape: square with top) of 1 ms duration. The pulse-field gradients in the 
first and second block are 31% and 11 % of the maximum gradient strength, respectively. 
Acquisition and relaxation delay were 3 s and 3.5 s, respectively, for the dilution series 
and  5  s  and  10  s,  respectively,  for  the  direct  measurement  and  spiking.  The  longer 
relaxation delay (and acquisition) for the direct measurement and spiking experiment was 
taken to assure that the signal had returned to +z-axis and no signal quantification errors 
were made. Pulse calibrations were done for each sample to assure proper quantification. 
The 1D 1H NMR spectra were analyzed using Bruker Topspin 3.0 and/or Mestre NOVA. 
Metabolites were identified using the HMDB web software [2,41]. The dilution curves 
were fitted using home-written programs using Matlab (Math Works) R2010a.
In addition, 1D 1H NMR spectra were recorded with the pulse sequence “cppr1d”: prcp 
- 90° - acquisition [42];  in the pulse sequence the H2O solvent signal is suppressed by 
means  of  a  composite  pulse  presaturation  scheme  (prcp,  [42])  prior  to  the  1H  90° 
excitation  pulse.  Acquisition  and  relaxation  delays  were  as  mentioned  above  for  the 
dilution series, for the direct measurement and spiking. Note that for mimics with HSA 
and or fHSA the “cppr1d” sequence leads to NMR spectra in which the HSA and/or 
fHSA resonances are visible next or on top of the metabolite resonances. However, for 
the pure metabolite mixtures the “cppr1d” and “CPMGes1d” lead in terms of metabolite 
concentrations to the same result after correcting for the “ES” solvent suppression profile. 
The CPMG sequence suppresses the broad protein signals, but may also attenuate the 
metabolite signals when they have relatively short T2s. The effect of the CPMG on the 
metabolite signals was checked by comparing their integrals and resonances in 1D  1H 
NMR spectra obtained using “cppr1d” and “CPMGes1d” sequences (see Supplementary 
Material).
The NMR measured concentration of a metabolite was obtained as follows. The non-
overlapping resonances (or a cluster of partly overlapping resonances) were integrated. 
These  integrals  were  then  compared  to  the  integral  of  a  reference  resonance.  This 
reference integral  was either TSP (separate triplicate measurement with TSP added to 
metabolite only plasma mimic, see above and results) or one of the methyl resonances 
(doublet at 1.03ppm) of Valine (in the mixture, which does not interact with HSA and/or 
fHSA, see results). For the “CPMGes1d” sequence the integrals were corrected for the es 
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profile  and  for  some  metabolites  for  the  attenuation  due  to  the  CPMG  filter  (see 
Supplementary  Material).  Given the  known concentration  of  TSP (and/or  Valine)  the 
integrals  were  converted to  concentrations  accounting for  the  varying the  number  of 
protons involved (TSP 9; Valine methyl 3; metabolite resonance: x). 
Metabolites were identified using the HMDB web software [41,43]. In addition, for 
each of the metabolites in the PBS buffers a  1H  1D NMR spectrum was recorded and 
compared with the 1H 1D NMR spectra of the metabolite mixture (and/or metabolite 
mixture with HSA added or fHSA added). In this way, all metabolite resonances in the 
metabolite mixtures could be fully and reliably identified and overlapping resonances 
established. Based on this comparison non-overlapping or partly overlapping resonances 
were chosen for quantification.
Qualitative assessment of metabolite binding to protein matrix for various 
conditions and how it affects the NMR parameters; effect of dilution of the 
plasma mimic and/or plasma samples
In  metabolomics  studies  of  blood  plasma  by  NMR  only  free  metabolites  can  be 
measured and bound metabolites are not observable, thus limiting proper quantification 
of the latter for diagnostic purposes. Several techniques have been applied to solve this 
problem (see introduction). However, there is no clear picture as to which metabolites 
show binding to the protein matrix and which do not. We therefore designed an NMR 
experiment  for  systematic  delineation  of  the  metabolite-(lipo)protein  interactions  in 
plasma. It consists of a dilution series using PBS to keep the same pH of 7.4 and the ionic 
strength constant at 0.154 M, as in physiological conditions. The NMR resonances will 
be affected depending on relative concentrations of the metabolites and proteins in the 
plasma and strength of  the  interaction.  We consider  the  matrix  of  possible  outcomes 
below. 
We first consider the situation that the KD for binding of the metabolites to the protein 
matrix lies above 10-6M. These KD values correspond to relatively low affinities and lead 
to fast exchange [44,45]). In this context, the matrix of conditions as displayed in Figure 
1 applies. Horizontally, the situation is displayed that 1) the protein concentration [P] is 
larger than KD and 2) the protein concentration [P] is smaller than KD.  Vertically,  the 
situation is considered that (a), the metabolites concentrations [Met] are much lower than 
the protein concentrations, [Met] < [P] and in (b) the metabolite concentration [Met] is 
higher  than the protein concentration,  [Met]  > P.  The most  abundant  plasma protein, 
HSA, has a concentration of ~ 50 mg/mL (0.75 mM). We initially assume that for all 
relevant  situations  the  protein concentration is  larger  than KD prior  to  dilution.  After 
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dilution,  we assume that  the  protein concentration is  smaller  than KD.   When before 
dilution option 1a applies ([P] >> KD; [Met] << [P]), all metabolites are bound. Upon 
dilution, we reach option 2a ([P] << KD; [Met] << [P]), where all metabolites are free. 
When before dilution option 1b applies ([P] >> KD; [Met] >> [P]), some metabolites are 
bound and some free. Upon dilution, we reach option 2b ([P] << KD; [Met] << [P]) and 
all metabolites are free. When the protein concentration before dilution is smaller than KD 
(very weak binding), the metabolites will be free and stay free upon dilution.
[Protein] >> KD [Protein] << KD
option a
[Metabolite] << [Protein]
option b
[Metabolite] >> [Protein]
Before dilution 
Option 1
After dilution 
Option 2
All metabolites 
bound
All metabolites 
free
Some metabolites 
bound, some free
All metabolites 
free
Figure 1 The effect of dilution on our system is overviewed here for a metabolite which has one  
binding site on a protein (with KD between 10-6 and 10-3 M) and through dilution (up to 100  
times) the protein concentration get lower than the KD, thus lowering the binding probability  
between the metabolite and the protein.  Two options were taken into account: (a) the metabolite  
concentration is lower than the protein concentration, in this case we expect the metabolite to be  
bound and get completely release upon dilution; and (b) the metabolite concentration is higher  
than the protein concentration, in this case we expect the part of the metabolite fraction to be  
bound and part to be free, and having only free state upon dilution. 
We next consider the situation that the affinity is strong, i.e. the KD is below 10-6 M. 
The  exchange  is  then  usually  slow.  The  protein  concentration  is  then  for  the  most 
abundant protein (HSA) larger than KD and dilution is not likely to lead to a protein 
concentration which lies  below KD.   Consequently,  option 1 pertains before and after 
dilution.  This  implies  that  when option 1a applies  before  dilution all  metabolites  are 
bound and stay fully bound upon dilution (option 1a still holds). When before dilution 
option 1b applies, some metabolites are bound and some are free; upon dilution one stays 
within option 1b, but moves closer to KD, so that more metabolites are free. Finally, one 
should  realize  that  a  metabolite  may  display  both  slow  and  fast  exchange  binding 
simultaneously. 
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We next need to consider how the dilution affects the NMR spectrum. We consider 
here how the main NMR parameters,  resonance integral,  chemical shift  position,  and 
line-width are affected by dilution or other changes. (a) In the slow exchange regime 
(KD< 10-6 M), the resonance of the free metabolite is observed separate from that of the  
bound metabolite [44].  The latter resonance is broadened beyond detection, while the 
resonance of  the  free  metabolite  is  narrow and likely to  stay narrow and at  the  free 
chemical shift position upon dilution, i.e. when the exchange is slow enough. It should 
however be noted that when the slow exchange approaches the intermediate exchange 
limit the line width of the free metabolite resonance may become broadened. The integral 
of the free metabolite signal corresponds to the concentration of free metabolite. (b) In 
the  fast  exchange  regime,  the  signal  integral  corresponds  to  that  of  total  metabolite 
concentration, while the chemical shift is weighted average of the chemical shift in the 
free and bound state. The same applies for the line width. 
In the dilution series, a change in chemical shift position is easily detected and reports 
then essentially on the binding in the fast exchange regime (some broadening due to an 
approach  from  the  slow  exchange  regime  towards  intermediate  exchange  cannot  be 
excluded). In contrast, the change in the normalized integral of a resonance (normalized 
by the dilution factor) reports on the slow exchange binding. There are limitations to the 
dilution experiment. (a) NMR detection limit - NMR sensitivity is such that metabolite 
concentration down to ca. 1 µM can be detected and not further. Thus, KD values smaller 
than  1  µM cannot  be  directly  detected  from  chemical  shift  changes.   Anyhow,  one 
reaches then the slow-exchange regime. (b) NMR signal to noise - The higher the dilution 
factor the lower is the concentration of molecules, thus lowering their signal intensity and 
making integration of the peak less reliable.  To compensate for this we increased the 
number of scans up to 1024 for the highest dilution factors of the plasma mimics and 
blood plasma samples.
Binding of Ligand/Metabolite to Protein matrix, Hill equation
To describe the binding of a metabolite to the protein matrix,  we consider binding 
curves as expressed in the Hill equation [46] for the fractional saturation θ:
θ = ν
n
= [L ]
α
([L ]α+K D)
(1)
Here, ν is the fraction bound ligands (= [Lb]/PT), where [Lb] is concentration of bound 
ligand and PT the total protein concentration and n is number of binding sites per protein. 
Further, [L] is the concentration of free ligand and α is the Hill coefficient, which runs 
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from 1 to n, where 1 means no cooperativety and n full cooperativety. In the above, KD is 
the apparent dissociation constant [46,47]. When several molecules of ligand bind to a 
receptor, the value of the Hill coefficient is usually less than the number of binding sites. 
When [L] → 0, θ approaches 0 and when [L] → ∞, θ approaches 1. 
In  case  of  slow  exchange,  one  observes  in  the  NMR  spectrum  the  free  ligand 
resonance and its integral, If, is proportional to the free ligand concentration,
I f = S c L f (2)
Here,  Sc is  the  conversion  factor  for  resonance  integral  to  concentration.  The 
concentration  of  bound ligand Lb is  related  to  Lf via  the  Hill  equation  (equation  1). 
Consequently, a plot of Lb versus Lf   (or If) would then provide KD and n, number of 
binding sites. Note that KD is for the slow exchange regime usually much smaller than LT 
or Lf, i.e. the binding is saturated. Consequently, Lb approaches n [PT], the concentration 
of  binding  sites  of  P.  It  is  also  possible  to  plot  [Lf]  versus  [LT],  the  total  ligand 
concentration. Under these saturation conditions [Lf] = [LT] – [Lb] = [LT] –n[PT]. Hence, 
[Lf] increases proportional with [LT], when [LT] => n[PT] and when [LT] < n[PT], [Lf] 
approaches 0. That is, the plot of [Lf] versus [LT] displays a straight line parallel to the 
diagonal  (slope  1),  which  is  displaced  by  a  distance  n[PT].  In  brief,  because  of  the 
saturation, an increase in the total ligand concentration leads to an increase in the free 
ligand concentration in proportion to the total  ligand concentration.  Thus the integral 
increases in proportion to the total ligand concentration. In other words, deviation from 
this proportionality measures a change in the number of binding sites as function of the 
total ligand concentration. 
In case of fast exchange, the major NMR parameter to detect is the chemical shift. The 
chemical shift is then the weighted average of their values in the bound and free states,
δobs = F b∗δb+F f∗δ f = δ f +F bΔδ (3)
Here, δobs, δf, and δb are the observed, free, bound chemical shifts, respectively and Δδ 
is the difference bound and free chemical shift [44]. The terms Fb (= [Lb]/[LT]) and Ff 
(=[Lf]/[LT]) represent the fraction of bound and free ligand, respectively. The term Fb can 
be expressed in terms of the Hill equation (equation 1).
F b =
[Lb]
[LT ]
=
(n [PT ]/ [LT ])[L f ]
α
([L f ]
α+K D)
=
c [L f ]
α
[L f ]
α+K D
(4)
The fraction of free ligand is then given by,
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F f = (1−F b) = 1−
c [L ]α
[L]α+K D
(5)
We then obtain for the chemical shift,
δobs = δ f +F bΔδ = δ f +(
c [L f ]
α
[L f ]
α+K D
)Δδ (6)
For the dilution series c is constant with increasing dilution factor D (=[LT]/[LT]0), 
because c equals n[PT]/[LT]. On the other hand, [Lf] decreases with increasing dilution 
factor D ([LT]/[LT]0). At high values of D, δobs approaches then δf. For the fitting, equation 
6 was employed.
In the fitting of equation 6, the Hill coefficient α was set to 1, that is no cooperativety; 
this simplification was chosen because the dilution series do not start from a situation 
where all metabolites are bound thus we have no information about the first part of the 
sigmoidal curve from the Hill equation. Fittings were performed for those metabolites 
that showed clear chemical shift changes. Monte Carlo calculation was used to obtain the 
estimate distribution of KD, δf and δb due to the experimental error in the chemical shift; 
this error was estimated 0.5 Hz on each point. Fittings were performed for the chemical 
shifts of resonances in the three mimics, and the volunteers F, O and P. 
RESULTS
The  extent  of  the  binding  of  metabolites  to  HSA and  to  fHSA was  analyzed  by 
extracting their concentration and chemical shift changes from the NMR spectra of blood 
plasma mimics. The plasma mimics contained the most common metabolites in relative 
concentrations normally found in plasma as presented in the HMDB [6].  In addition, 
plasma mimics were prepared with the most abundant plasma protein (HSA or fHSA) 
added  at  normal  HSA concentrations.  These  mimics  were  prepared  to  establish  in  a 
quantitative  manner  the  effect  of  protein  on  the  NMR  measured  metabolite 
concentrations.  To  obtain  reliable  resonance  assignments,  1D  1H-NMR spectra  were 
recorded of all individual metabolites as well as JRES and 2D TOCSY of the plasma 
mimic (Supplementary Material).
To  establish  the  effect  of  these  proteins  on  the  NMR-measured  metabolite 
concentrations,  it  is  crucially  important  to  establish the analytical  error  in the  NMR-
derived concentrations  and in  the  chemical  shift  changes.  We therefore  discuss  these 
aspects prior to a description of the outcome of the experiments on the blood plasma 
mimics and blood plasma samples. 1D 1H NMR spectra of each sample were always 
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recorded with good signal-to-noise (as indicated in Materials and Methods)). 
The NMR-derived concentration (Cm, NMR) of a metabolite was obtained from its 1D 1H 
NMR spectrum by integration of its resonances (Im) and subsequent conversion of Im into 
metabolite concentration by comparison with the integral of a reference signal Iref,
Cm , NMR =
I m /nm
I ref /nref
∗Cm ,ref (7)
Here,  Cm,ref  is  the  concentration  of  the  metabolite  whose  resonance  was  used as 
reference signal, nm is the number of protons in the metabolite signal, and nref is the 
number of protons in the reference signal. As reference signal, we either employed the 
signal  from  the  130  µM  TSP  (see  Materials  and  Methods,  separate  triplicate 
measurement)  at  ~ 0 ppm,  which corresponds to  9 protons  and/or  the  Valine  methyl 
doublet at 1.03 ppm that corresponds to 3 protons (Valine concentration 150 µM). Valine 
was used, because it  shows no HSA binding (see below). The analytical error on the 
NMR-derived metabolite  concentrations  was estimated by preparing three metabolite-
only samples from the high concentrated metabolite mixture stock solution once with 
TSP as reference and once with Valine as reference and repeating the NMR measurement 
with “zgcppr” and the “zgCPMGes” sequence and deriving the standard deviation. The 
three metabolite-only samples used in the ultra-filtration were also included.
The 1D 1H NMR measurements were thus carried out in two ways A) presaturation of 
the H2O signal  (‘zgcppr’ sequence)  and B) by employing excitation sculpting (es) to 
suppress  the  H2O  signal  followed  by  a  CPMG  sequence  to  suppress  protein  signal 
(‘zgcpmges’ sequence). The ‘zgcpmges’ sequence needs to be employed when samples 
with  HSA or  fHSA added are  measured.  The  excitation  sculpting  reduces  the  signal 
around H2O resonance and leading to a smooth attenuation profile; the attenuation profile 
can be obtained by simulation or by direct comparison with the integrals obtained when 
using  the  ‘zgcppr’ sequence;  the  metabolite  integrals  were  corrected  for  this  smooth 
profile  by  comparison with  the  ‘zgcppr’ results.  In  addition,  due  to  variation  in  T2-
relaxation the  metabolite  signals  may be reduced by the  CPMG sequence in varying 
degrees. This reduction was also assessed by comparison with the ‘zgcppr’. 
From the various triple-repeated sample preparations and measurement of the NMR 
signal  of  metabolite-only  samples  using  the  two  NMR  approaches  (‘zgcppr’  and 
‘zgcpmges’ sequence) for the non-filtrated and ultimately ultra-filtrated metabolite-only 
mimics we found that the standard deviation increases from ~20 µM at low concentration 
(< ~ 300 µM) to ~ 500 µM at the highest concentrations (ß-glucose; 2880 µM) (Figure 
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S1, Table 2). We note that this error is essentially caused by integration errors as follows 
from the increase of the absolute standard deviation with increasing concentration. This 
trend in the absolute error corresponds to a relative standard deviation of ~12 % over the 
whole concentration range (Table 2). Comparison of the integrals of the two resonances 
of  valine  (reference  resonance  at  1.03  ppm;  3.61  ppm),  lactate  (1.34;  4.11  ppm), 
threonine (3.58; 4.58 ppm), creatinine (3.04; 3.05 ppm), and histidine (7.06; 7.79 ppm) 
shows that they have a relative error on average of ~10 %. The valine signal 1.03 ppm 
leads  to  a  concentration  of  158  µM,  while  the  integral  at  3.61  ppm  leads  to  a 
concentration of 194 µM, which corresponds to a deviation of 20 %. We finally note that 
the  chosen  metabolite  concentrations  indeed  approximately  follow  the  normal 
concentrations  in  the  HMDB  (Table  2).  For  some  metabolites  a  somewhat  higher 
concentration was taken, i.e. for acetate the concentration was 226 µM versus 30 µM in 
the HMDB and for threonine in the metabolite mimic the concentration was 230 µM 
versus  150  µM in  the  HMDB.  Given  the  average  analytical  error  of  ~10  % in  the 
metabolite concentration, we consider changes in metabolite concentrations - upon e.g. 
addition of HSA or fHSA – larger than 2 standard deviations, i.e. 20%, as significant. 
The chemical shift calibration was done using α-glucose H1 as a reference [30,31]; 
glucose is the most concentrated metabolite in blood plasma and plasma mimics, ~4500 
µM of which α-glucose corresponds to 1620 µM and ß-glucose to 2880 µM; the chemical 
shift was indeed found to be unaffected by HSA or other metabolites. The 1D 1H NMR 
spectra  were  recorded with  high  digital  resolution  so  that  the  analytical  error  in  the 
chemical shift is estimated to be small ~1 Hz or less. We finally note that calibration with 
respect to TSP in an inner tube showed that upon dilution the α-glucose resonance shifts  
somewhat due to changes in global  magnetic susceptibility  caused by changes in the 
(HSA; fHSA) protein concentration [48]. 
Slow-exchange regime and difference in binding on HSA and fatted HSA
We find from the 1D  1H NMR spectra of the mimics that of the 17 most abundant 
endogenous metabolites, the presence of HSA leads for a number of them to a strong 
decrease in their NMR signals. This is evident from Figure 1 where the NMR signals of 
histidine, phenylalanine, citrate, pyruvate, lactate, valine, and leucine are shown in the 
absence and presence of HSA, Figure 2c and Figure 2b, respectively. Valine (label 10) is 
found to show no change in its NMR signal, demonstrating insignificant or absence of 
binding to HSA. In contrast, the phenylalanine signal (2) completely or nearly completely 
disappears upon addition of HSA. The same holds true for citrate (4), pyruvate (6), and 
lactate (8). The histidine is reduced (1, 3), whereas leucine (11) is only mildly affected. 
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Interestingly, addition of fatty acid (i.e. in the presence of fHSA) has remarkably strong 
giving appearance of a triplet). The broad signal in d stems from fatty acids. The spectra are  
scaled relative to the valine doublet signal at 1.03ppm.
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For plasma or serum the proteins are commonly removed by means of ultra-filtration 
[2,36],  which  is  superior  to  protein  removal  methods  in  retaining  metabolite 
concentration  and shows excellent  reproducibility  (see  e.g.  [10]).  The effect  of  ultra-
filtration on the measured metabolite concentration is demonstrated in Figure 2d-f. We 
first  note  that  in  the  absence  of  protein  after  ultra-filtration  the  metabolite  signal 
intensities  (Figure  2f)  are  essentially  the  same  as  before  ultra-filtration  (Figure  2c), 
indicating that the ultra-filtration by itself does not remove metabolite from the mixture. 
More importantly, in the presence of HSA (Figure 2e) or fHSA (Figure 2d) the signals of 
nearly all considered metabolites are recovered (compare with Figure 2f). Note also that 
the signal heights in Figure 1d and 1e are essentially equal to that in the original pure 
metabolite mixture (Figure 2c), indicating again that no or little metabolite is lost upon 
filtration. The single exception is formed by citrate (4). Its signals do not recover in the 
presence of HSA (Figure 2e vs. Figure 2f) or only partly recover in the presence of fHSA 
(Figure 2d vs. Figure 2f). Finally, we note that fatty acids are released, at least in part, by 
the ultra-filtration as evident from the appearance of broad signals in the NMR spectrum 
of ultra-filtrated metabolite mimic with fHSA removed, Figure 2d.
To  quantify  and  obtain  an  overview of  the  effect  of  HSA and  fHSA on  the  free 
metabolite  concentrations  we  measured  the  metabolite  concentrations  by  NMR  (see 
Materials  and Methods)  and compared them in the  three  metabolite  mimics.  Table  1 
provides an overview of the effect of addition of HSA and/or fHSA on the concentration 
of the metabolites in these blood plasma mimics, and the effect of ultrafiltration. We first 
consider the non-filtrated data.
As can be seen in Table 1, the presence of HSA at its common plasma concentration 
(~0.6 mM) compared to when HSA is absent leads to a reduction in the free metabolite 
concentration below that of its total concentration for quite a number of the 17 common 
metabolites; only a small number is not or little affected, namely leucine, valine, alanine, 
glutamine, and glucose, taking 80 % as cut-off/significance level. Note that the composite 
signals  cannot  always  be  attributed  to  a  specific  metabolite.  Further,  note  that  the 
reference signal of valine at 1.03 ppm is also not affected. 
Table 1 Metabolite concentrations measured by NMR ([M]free) in the three types of plasma  
metabolite mimics used before and after ultra filtration showing the effect of metabolite binding  
to  HSA  and  to  fHSA:  the  not-filtrated  pure  metabolite  mixture  (Metmix_afil),  the  same  
metabolite mixture with HSA added (Metmix_afil+HSA) and the same metabolite mixture with  
fHSA added (Metmix_afil+fHSA) and the same three metabolite mixtures but now ultra filtrated  
(Metmix_ufil, Metmix_ufil+HSA, Metmix_ufil+fHSA). The absolute concentration measured in  
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Metmix_afil  is  given  and  compared  with  the  normal  values  [M]normHMDB in  the  Human  
Metabolome Data Base; for convenience the other concentrations are given relative to that of  
Metmix_afil.
Not filtrated Ultra filtrated
1.03 231 158 ± 0 100 100 100 100 100
3.61 231 194 ± 11 93 102 105 100 103
5.23 1620 1830 ± 82 82 86 103 99 98
2.45 612 630 ± 10 86 98 99 101 101
1.47 Alanine 333 435 ± 14 87 99 96 103 110
0.96 159 152 ± 2 83 98 99 98 102
3.04 66 83 ± 2 99 100 99 105
4.05 66 75 ± 8 61 79 98 101 99
1.9 Acetate* 30 226 ± 19 76 104 117
7.06 86 85 ± 14 51 103 98 95 98
7.79 86 83 ± 18 46 102 98 99 100
1.34 1510 1540 ± 39 42 90 97 102 109
4.11 Lactate 1510 1409 ± 74 46 92 94 103 104
2.37 63 30 ± 1 36 87 99 95 104
7.37 Phenylalanine 61 61 ± 8 16 80 99 95 100
2.55 Citrate 88 87 ± 15 7 34 82 76
3.58 150 233 ± 59 76 89 - 79 105
1.7 190 189 ± 11 43 107 93 105 -
3.98 70 102 ± 12 42 83 92 106 100
19
Chem.  shift 
(ppm)&1 Metabolite  Name
&2 [M]norm  
HMDB (μM)
[M]free(μM)  
(Metmix_afil)
Metabolite concentration [M]free in % of Metmix 
Metmix_afil 
+ HSA&2
Metmix_afil 
+ fHSA Metmix_ufil 
Metmix_ufil 
+ HSA
Metmix_ufil 
+ fHSA
Valine
Valine
α-glucose*&3
Glutamine
Leucine
Creatinine/lysine$ 81c
Creatinine*
147# 151#
Histidine
Histidine
Lactate/ threonine
Pyruvate*
18&4
Threonine
Arginine/leucine/ 
lysine
Asparagine/ histidine/ 
phenylalanine
Average std ([M]free 
< ~300 µM)
&1The chemical shift of the resonance multiplet in the NMR spectrum used to determine the peak  
integral and/or the peak intensity to derive concentrations. The absolute concentrations were  
determined relative to internal TSP and subsequently relative to the Valine resonance at 1.03  
ppm (see Materials and Methods). &2The metabolites are ordered from high to low according to  
the relative concentrations for Metmix_afil+HSA (%) to better appreciate the effect of binding to  
HSA; the composite signals are given at the bottom of the table; also threonine is given at the  
bottom because of uncertainty due to potential overlap with lactate; the metabolites in bold are  
the ones that  are not  or little bound to HSA, while  metabolites whose free concentration is  
strongly reduced by HSA binding are grey boxed, and those whose concentration is only mildly  
reduced are italic (see also text).  When multiple metabolite names are given at a particular  
resonance position the metabolite concentration in the HMDB in the next column is that of the  
first one mentioned. For the metabolites with a * behind their name the resonance volume was  
calculated from the peak height times peak width to reduce the effect of overlap from nearby  
resonances. $The creatinine/lysine peak at 3.04 ppm is from creatinine with some lysine multiplet  
overlap and the integral might to some degree be affected. &3Further note that the ß-glucose (at  
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4.64 ppm) resonance was close to the H2O resonance and thus strongly affected by the water  
suppression in the ‘zgcpmges’ pulse sequence; therefore, it was removed from consideration and  
only the α-glucose (at 5.23 ppm) was used.  &4Note that for citrate, in the presence of HSA, the  
ultra-filtration leads to reduced free concentration (bold number), but for fHSA ultra filtration  
leads to the correct concentration. #For acetate the measured concentration with fHSA appears  
for the resonance at 1.90 ppm consistently higher than the actual value; this may be due to  
partial overlap with signal from fatty acid.
Considering these composite signals, one observes that the composite lactate/threonine 
signal is essentially from lactate thanks to its much higher concentration. On the other 
hand,  the  composite  signals  arginine/leucine/lysine  is  likely  a  mixture  of  these 
metabolites.  The  composite  ‘creatinine/lysine’ at  3.04  ppm could  to  some  degree  be 
affected  by  lysine,  although  the  signal  appears  to  correspond  quite  well  with  the 
creatinine  concentration  (this  can  be  confirmed  also  by  comparison  with  the  second 
signal  of  creatinine  at  ~4  ppm).  Also  the  asparagine/histidine/phenylalanine  is  a 
composite  signal  whose  integrals  can  stem  from  all  of  the  metabolites.  The 
histidine/phenylalanine and arginine/lysine signals have been removed and considered as 
unreliable due to such overlap. Further, creatinine signal at 4.05 ppm is reduced in HSA 
to ~60%, whereas the composite creatinine signal at 3.04 ppm (‘creatinine/lysine’ signal) 
lies above 80%; however, this signal cannot be attributed to one single metabolite nor 
could it  be integrated reliably.  Consequently,  except for lactate the composite signals 
cannot reliably be attributed to a single metabolite.
Thus, in summary, for the non-filtrated data, the metabolites whose free concentration 
is  reduced only by a limited extent are histidine, creatinine and acetate (ordered from 
strongly to less  strongly affected metabolites).  The free concentration of  the  strongly 
HSA affected metabolites ordered from strongly to less strongly affected are as follows: 
citrate  <  phenylalanine  <  lactate  ~<  lysine  ~<  pyruvate.  The  signals  of  arginine, 
asparagine and aspartate overlap with other signals. Because, they have a relatively low 
normal concentration, it is not possible to attribute the lower relative concentration due to 
HSA binding to a single metabolite for them. Finally, it is to be noted that in the presence 
of HSA, citrate signals are nearly invisible in the NMR spectra (see also Figure 2). This 
directly indicates a stronger HSA binding affinity for citrate than for the other metabolites 
used. In the presence of fHSA for most metabolites the free metabolite concentration 
appears  to  reach  the  100  %  free  level  again.  Exceptions  are  formed  by  citrate  the 
strongest binder which does not reach the 100 %, the same applies for the strong binder 
phenylalanine which goes up to 80%; the weaker binder creatinine (and threonine) also 
remains  significantly  below  the  100  %  level.  To  further  characterize  the  metabolite 
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 metabolites in the filtrate, for the metabolite only sample as well as for both samples with 
fatted and non-fatted HSA present. Their concentrations are close or equal to the total 
metabolite  concentration  (Table  1,  ultra-filtrate  columns,  Metamix_ufil, 
Metmix_ufil+HSA, and Metmix_ufil+fHSA). However, the strongest binder citrate is the 
only metabolite that displays a significantly lower concentration in the filtrate when HSA 
is added (~ 34 %), Table 1. However, when fHSA is added the citrate signal is partly but  
not fully recovered (~ 76 %).  Thus, except for citrate which was found to bind very 
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strongly  to  HSA as  shown above,  all  other  metabolites,  which  bind  less  strong,  are 
released. 
Does saturation of binding sites occur upon increasing the metabolite 
concentration, i.e. the metabolite to HSA ratio?
We observe in the 1D 1H NMR spectra free metabolite despite their binding to HSA 
and [M] < [HSA]; this indicates that the binding sites on HSA are saturated. Saturation of 
the  binding  sites  on  HSA would  imply  that  upon  further  increasing  the  metabolite 
concentration  none  of  them would  bind  and  hence  the  free  metabolite  concentration 
would proportionally increase with the added extra metabolite. To find out, whether upon 
titration  this  indeed  occurs,  we  titrated  some  of  the  metabolites,  namely  the  strong 
binders, citrate, phenylalanine, lactate, and pyruvate as well as the slightly less strong 
binder histidine and the non-binders glutamine and valine.  In Figure 3,  we show the 
spiking graph for the strongest binder citrate. Most interesting is the lower slope of the 
trend line seen in the presence of HSA (Metmix_afil+HSA),  a slope which increases 
again when instead fHSA is present. In addition, the trend line has for some metabolites 
translated to lower concentrations when HSA is added. For instance, for lactate, but also 
for  citrate,  the  trend  line,  seen  when  HSA is  added,  has  translated  down  to  lower 
concentrations with respect to the Metabolite-only trend line (Metmix_afil). When fHSA 
is added this translation is much smaller or has even disappeared. The presence of free 
metabolite  indicates,  in  case  of  strong  binding  saturation  of  the  binding  sites,  see 
Materials  and  Methods.  Addition  of  metabolite,  would  then  lead  to  a  proportional 
increase in the free metabolite concentration, i.e. only translation of the trend line would 
then be expected. This does not occur, instead in the presence of HSA and fHSA a lower  
slope is seen in the trend line. This shows that upon addition of metabolite, additional 
binding sites become available on the HSA. On fHSA less such sites become available.  
Because the slopes are highly informative, they are presented in Table 2.
Table 2 shows the slope values of the fitted trend lines for the spiked mimics. A slope 
equal to 1 indicates that all added metabolites are free in solution, while a slope below 1 
indicates that some of the added metabolites become bound. In the presence of HSA, 
lowered slopes are obtained; ordered from low to high the slope values are for citrate, 
phenylalanine  pyruvate,  lactate,  lysine,  and  histidine.  Valine  and  glutamine 
concentrations are indeed little affected by the presence of HSA (slope near 1). Clear 
evidence of the influence of FAs on the metabolite-HSA binding is observed for most of 
the metabolites. For citrate the slope increases but remains below 1, while for lactate,  
lysine, phenylalanine and pyruvate the slope increases even up to 0.8 to 1.0. Histidine 
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binding to HSA appears, on the other hand, not so much affected by the presence of FAs. 
Together,  these  data  reveal  that  FAs  strongly  affect  many  of  the  HSA-metabolite 
bindings, and that fluctuations in FA concentration will cause significant fluctuations in 
free metabolites concentrations in plasma. 
Table 2 Free metabolite concentration relative to total concentration, calculated as the slope of  
the trend line in Figure 3. The error in the normalized free metabolite concentration is ~ 10%.
Metabolite Met only 
0.9 1.1 1.1
1 0.9 0.9
0.8 0.6 0.6
0.5 1
Lactate 0.9 0.3 0.8
0.9 0.2 0.8
Phenylalanine 0.9 0.1 0.8
Citrate 1.1 0.1 0.4
Met +HSAb Met+FA-HSAb 
Valine 
Glutamine 
Histidine 
Lysinea 1.3a
Pyruvate 
a The NMR-derived lysine concentration in the mimic with metabolite mixture is higher than the  
real concentration; this is likely due to overlap with the resonance of creatinine at 3.02 ppm. b 
The normalized metabolite concentrations close to 1 (>= 0.8) in the presence of HSA and fHSA  
are given in bold for clarity.
Inter-metabolite interactions and their potential effect on HSA binding
To investigate whether between metabolites competition for binding sites occurs or 
metabolite  induced  allosteric  effects  influence  the  metabolite-HSA  bindings,  we 
measured for the spiked metabolite also the concentration of the other metabolites. In 
Table  3,  we  compare  the  metabolite  concentrations  as  a  function  of  the  citrate 
concentration (spiked metabolite).  Citrate is  the metabolite  that binds the strongest  to 
HSA and is thus the metabolite that is most likely to affect the binding to HSA of other 
metabolites.  As can be seen,  for the non-spiked metabolites  that  do not  bind or bind 
weakly to HSA no significant change (change in metabolite concentration is within 20%) 
occurs upon addition of citrate. For the strong binders lactate and pyruvate no significant 
change is seen. Only histidine and also phenylalanine display some release from HSA 
upon addition of citrate. For the other spiked metabolites, it was observed that the spiked 
metabolite does not affect the free concentration of the other metabolites. This indicates 
that the spiked metabolites for the most part do not compete for the same binding sites on 
the  HSA.  Alternatively,  it  can  indicate  that  HSA is  flexible  enough to accommodate 
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several metabolites on one binding site or even that the binding of one metabolite brings 
about a change in conformation to provide for another binding site. These possibilities 
have all been observed between FA and drugs or with endogenous ligands and in mutated 
HSA  [28,29].  Competing  drugs  did  not  change  the  ratio  of  FA  bound  to  HSA. 
Alternatively, it was found that addition of a drug initially leads to increased FA binding 
initially, while further increase of the drug concentration reduced the FA binding. This is 
well explained by the observation in crystal structures, that drugs or FA binding induces 
conformational changes on the HSA, creating new binding sites in proximate clefts. 
Finally, in the mimic that contains only the metabolite mixture, the concentrations of 
non-spiked  metabolites  are  constant.  This  shows  that  there  is  no  evidence  for 
intermolecular  interactions  between  the  spiked  metabolites  and  any  other  present 
metabolites. An exception may be formed by histidine. Some degree of intermolecular 
interaction  appears  to  exist  towards  histidine  molecules;  as  can  be  seen  in  Table  2 
described above, the observed trend line upon histidine titration in the mimic with only 
metabolites (Metmix_afil) has a slope slightly smaller than 1 (slope is 0.8), pointing to 
some degree of interaction. 
Fast exchange regime and dilution to reach free-state chemical shift
We applied the dilution protocol to both the plasma mimic samples as well as to blood 
plasma samples  of  three  volunteers  (see  materials  and methods).  Figure  4 shows the 
profile of the chemical shift of histidine peak at 7.05 ppm throughout the dilution series 
of the three mimics. The change in chemical shift shows a steep slope at low dilution 
factor and goes towards saturation at higher dilution. This curve trend can be fitted using 
the relationship between the chemical shift values of the free and bound, and the dilution 
factor. To construct this equation we used the Hill equation to express the fraction bound 
and  fraction  free,  and  incorporate  these  in  the  chemical  shift  equation  for  binding, 
equation 1-6. The fitted parameters of equation 6 for the dilution of the various samples: 
the three mimics, volunteers F, O and P are shown in Table 4. We can see in Figure 4 that  
upon  dilution  in  all  three  mimics  the  chemical  shift  of  histidine  goes  towards  one 
common free value δf. The data also show δf can be determined with good accuracy (std 
~ 0.5 Hz). The chemical shift in the bound state, δb, is more difficult to determine and its  
error is larger, because δb (or δ = δf - δb) follows from fitting of equation 6 to the data  
points and is affected by the curvature and extrapolated to zero dilution. In addition, from 
fitting equation 6 to the data points one can determine an effective dissociation constant 
KDeff. 
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Table 3 Titration of citrate into the metabolite mimic with HSA added (Metmix_afil+HSA) to  
establish the potential  effect  of  the  strong HSA binder  citrate  on the  HSA binding of  other  
metabolites. For each metabolite, its free (NMR measured) concentration is shown at each one  
of the four titration points relative to its mean concentration in the titration series [M]av, i.e.  
shown is [M]/[M]av. The metabolite concentration was measured from the 1H 1D-NMR spectra  
recorded with zgcpmges sequence. 
176 440 616 1848
1.03/3.61 1.0 1.0 1.0 1.0
5.23 0.9 1.0 1.1 1.0
2.45 1.0 1.0 1.0 1.0
0.95 1.0 1.0 1.0 1.0
3.04 1.1 1.0 1.0 1.0
4.05 0.9 1.1 1.1 1.0
7.08/7.86 0.8 0.8 1.2 1.2
1.32 1.1 1.0 1.0 1.0
4.11 Lactate 1.0 1.1 1.0 1.0
2.36 1.0 1.0 1.0 1.0
7.37 Phenylalanine 0.8 0.8 1.2 1.1
2.55 0.2 0.6 0.8 2.4
3.58 1.0 1.0 1.0 1.0
1.7 1.0 1.0 1.0 1.0
3.98 0.8 1.2 1.1 0.9
1.9 1.0 1.0 1.0 1.0
Chemical shift 
(ppm) Metabolite name
a
Concentration of citrate titrated μM
Concentration normalized to mean valueb
Valine
α-glucose
glutamine/oxoglutarate
Leucine
Creatinine/lysine
Creatinine
Histidine
Lactate&threonine
Pyruvate
Citratec
Threonine
Arginine/leucine/lysine
Asparagine/histidine/ 
phenylalanine
Citrulline/arginine/lysine
aMetabolites are ordered as in Table 1 (names in bold, italic and grey boxed not, intermediate  
and strongly affected by HSA, respectively). bNumbers in bold: metabolite whose HSA binding is  
affected by citrate. cCitrate titration: numbers in bold and underlined.
Considering the histidine dilution data in some detail we note the following. Histidine 
still  shows a very small chemical shift change ∆δ (= δf – δb) of -2.9 Hz in the presence 
of metabolites only. This may indicate that a weak intermolecular interaction could exist 
with histidine molecules. Secondly, in the presence of HSA, ∆δ is larger (-7.5 Hz) and it  
is even larger in the presence of fHSA (-12.0 Hz). This difference in ∆δ indicates that 
histidine binds HSA differently. Thirdly, we find larger KDeff values in the presence of 
fHSA than  HSA:  23-62  µM  in  the  metabolites/fHSA mixture  and  9-35  µM  in  the 
metabolites/HSA mixture. This indicates weaker HSA interaction in the presence of fHSA 
than in  the  presence of  pure HSA. Fourth,  we estimated from the 3 mimics  that  the 
chemical shift free (δf) of histidine is 7.057 ± 0.002 ppm. Any deviation from this value 
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In Table 4, we summarize the results for the fittings with the most reliable outcomes, 
i.e.  those  metabolites  whose  chemical  shifts  change  significantly  upon  dilution. 
Significant chemical shift changes in the 3 different mimics and in the blood plasma are 
seen for citrate, histidine, lysine, phenylalanine, and tyrosine. For acetoacetate (in blood 
plasma only), lactate (in the mimic Meta_afil+HSA), and pyruvate (in mimics and blood 
plasma) we do observe chemical shift changes but they were too small (< ~0.5 Hz) to 
allow for fitting parameters. We stress that for the other metabolites under investigation 
(see Table 1) no significant chemical shift  changes were observed upon dilution. The 
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mimic  with  metabolite/fHSA is  the  closest  to  the 
blood plasma and one can try to compare these data, 
Table 4 
Table 4 Fitted parameter from equation 6 of δf for dilution  
series of the three mimics and the three volunteers. In the  
dilution  factor  ([LT]  /  [LT]o  ),  [LT]o  is  taken  as  the  
HMDB  normal  concentration  for  each  metabolite  
([tyrosine]  =  65  µM,  and  see  Table  S1  for  other  
metabolites concentration). The listed metabolites are all  
metabolites  in  the  plasma mimics  and  blood  plasma of  
volunteers that showed significant chemical shift changes  
and  were  well  fitted  upon  dilution,  i.e.  |∆δ|  >  1.5  Hz  
(citrate formed an exception; the peak at 2.54 ppm was  
included despite its small |∆δ| so as to compare with its  
other peak at 2.64 ppm). Note that the KD’s were, for all  
fittings, determined with a Hill coefficient set to 1 (α = 1;  
see Materials and Methods). Thus, the KD’s follow directly  
from the steepness of the initial binding/dilution curve as  
displayed for instance in Figure 4 [46].  ameta.+HSA-FA; 
bmeta.+HSA; ctyrosine peak 6.90ppm.
Considering these data in Table 4 some detail we 
highlight  the  following  aspects.  The  citrate  peak  at 
~2.64  ppm  in  blood  plasma  showed  the  largest 
chemical shift difference, average ∆δ = -25 ± 2 Hz. In 
the metabolite mimic with fHSA added ∆δ = -7 ± 3 
Hz, which is slightly smaller. This shows two different 
ways of HSA binding of citrate. In blood plasma the 
KDeff is  in  the  range  19-28  µM,  which  are  values 
falling in the range of 5-62 µM obtained in the mimic 
with metabolites/fHSA. Interestingly, the citrate peak 
at ~2.54ppm has a different chemical shift difference. 
The  KDeff could  not  be  determined  reliably.  These 
observations  from  citrate  suggest  that  the  different 
protons on citrate experience different weak binding, 
which can be related to the orientation of the molecule 
in the binding site. Interestingly, citrate shows similar 
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∆δ and KDeff for the 3 healthy volunteers. Histidine gave a negative ∆δ (-16.6 Hz) in the 
‘meta.+HSA-FA’ mimic and a positive ∆δ in volunteers’ blood plasma. This indicates that 
the chemical shift of bound histidine is not the same in the mimic and blood plasma, and 
thus the binding is not the same. Lysine showed chemical shift differences observed in 
blood plasma only; this could indicate that this metabolite binds to other proteins than 
HSA in blood plasma. Furthermore, tyrosine was not present in our mimics, but was in 
blood  plasma  and  was  observed  to  display  significant  chemical  shift  changes  in  all 
volunteers. In terms of affinity there is not a major difference between the metabolites 
and between the different systems. They are all in the range of tens of µM. However, like 
most metabolites the KDeff values vary from one volunteer to the other, except for citrate 
that showed to display similar KDeff values for all volunteers. 
DISCUSSION
In this study, we obtain an overview of the interactions of the most abundant plasma 
metabolites with HSA, the most abundant plasma protein and the main transporter of 
fatty acids and other blood plasma components [49]. Plasma mimics were prepared in 
PBS and contained a mixture of ~20 of the most abundant/common metabolites at normal 
plasma concentrations (see Materials and Methods). In addition, either HSA or fHSA was 
added with the HSA also at its normal plasma concentration (~ 0.75 mM). In addition, we 
studied three blood plasma samples. 
1H 1D NMR spectra were recorded of the plasma mimics and blood plasma samples 
and analyzed to derive NMR measured metabolite concentrations and chemical shifts. 
Each NMR spectrum was recorded with good signal to noise of each mimic to obtain a 
good measure of the analytical error. In the absence of HSA the measured concentrations 
in  the  plasma  mimic  can  be  directly  compared  with  the  real  concentrations  of  the 
metabolites  and  thus  the  analytical  error  can  be  determined.  We  then  find  that  the 
analytical error is 10 %. Thus, reliable comparisons can be made. 
In the plasma mimics with metabolites and HSA added, we observe for quite a number 
of  metabolites  a  strong  decrease  in  the  measured  concentration,  indicating  strong 
interaction with HSA. In summary, the most affected metabolites to the least affected 
ones  are  citrate>  phenylalanine>  pyruvate>  lactate>  histidine>  creatinine  >  leucine, 
alanine, glutamine, glucose, valine. In the plasma mimic of the metabolite mixture with 
fHSA added most metabolites show again a concentration close to the total concentration. 
A notable  exception  is  formed  by  citrate  that  still  displays  a  clearly  reduced  free 
concentration,  but  also  for  instance  phenylalanine,  creatinine  and  histidine  appear  to 
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show a somewhat reduced concentration. The data thus show that fatty acids bound to 
HSA strongly influence the binding of a number of metabolites, namely lactate, leucine, 
phenylalanine,  pyruvate and also citrate.  In the presence of fatty acids these affected 
metabolites are released from the HSA. 
The spiking experiments show that the trend line for the free metabolite concentration 
has a lower slope in the presence of HSA than in its absence. This implies that upon 
addition of metabolites new binding sites are created. When fatty acids are present the 
slope of the free metabolite trend line is larger but still lies below that in the metabolite 
mixture without HSA or fHSA. This shows that the fatty acid content in blood plasma can 
influence the concentration of transported metabolites by HSA. Finally, we do not find 
significant competition between metabolites with regard to binding to HSA or to fHSA. 
The dilution experiment showed chemical shift changes for some metabolites and thus 
established the presence of weak binding of metabolites to (fatted) HSA. We observe 
significant  chemical  shift  changes  for  citrate,  histidine,  phenylalanine,  lysine,  and 
tyrosine  upon  dilution,  such  that  the  dilution/binding  curves  could  be  analyzed  to 
determine an effective binding dissociation constants  (KDeff).  The other (less)  affected 
metabolites in terms of changes in chemical shift are acetoacetate (in blood plasma only), 
lactate  (in  the  mimic  meta.+HSA)  and  pyruvate  (in  mimics  and  blood  plasma).  No 
significant changes were for the other metabolites considered (Table 1).
The different resonances of citrate showed different chemical shift trends. This can be 
attributed to the orientation of the molecule in the binding site, i.e. that one extremity of 
the molecule would be turned towards the protein and the other extremity towards the 
surrounding  solution.  These  differences  in  chemical  shift,  from  signals  of  the  same 
molecule, were also seen for histidine, lactate and phenylalanine.
Previous  studies  showed  binding  of  acetoacetate,  citrate,  3-D-hydroxybutyrate, 
histidine, lactate, phenylalanine and tyrosine to the blood plasma protein matrix and to 
some specific proteins. To this list  we can now add from our experiments with HSA: 
creatinine, lysine and pyruvate.  These findings suggest that profiling studies of blood 
plasma by NMR need to be critical when any of the mentioned metabolites varies, as 
their concentrations may be related to change in the protein content and thus not only to 
dysfunction of metabolic pathways.
To  remove  protein  from  plasma  or  serum  the  most  commonly  used  approach  is 
ultrafiltration. This method has for example recently been used to establish the normal 
concentrations in serum for the human serum metabolome database [2]. Our data show 
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that with ultrafiltration the total metabolite concentration is recovered in the filtrate of all 
three  plasma  mimics,  i.e.  independent  of  whether  HSA or  fHSA is  added,  for  all 
investigated metabolites except the strongest binder citrate. It is interesting to note that in 
a  recent  comparison of  various  protein  recovery  methods  using  very  high  and equal 
metabolite concentrations compared to normal (2.5 mM) circa two-thirds is recovered 
[36].  We  employ  in  our  mimics  the  normal  metabolite  and  HSA  and/or  fHSA 
concentration and find that all  metabolites are recovered, except for citrate.  It  can be 
concluded  that  given normal  metabolite  concentrations  the  metabolites  are  recovered 
fully upon ultrafiltration except for extremely strongly binding metabolites. Finally, we 
note that we observe that  fatty acids are released as well.  Fatty acids bind with high 
affinity to HSA up to a HSA:FA ratio of circa 1:3. The other common FA sites display 
weaker affinity. It appears then likely that the latter fatty acids are partly released. 
In our experiments we focused on HSA as the most abundant protein in blood plasma. 
Lipoproteins are lipid-protein complexes and also important constituents of blood plasma 
and may interact  with metabolites.  However,  they are much less abundant than HSA 
(HSA makes up 60 % of protein in blood plasma, ~60 g/l, while lipoproteins make up 
only  ~1.4  g/l)  and  thus  metabolite  binding  to  HSA is  likely  to  overwhelm  that  to 
lipoproteins. Finally recent studies by Daykin et al. [11] showed that ibuprofen that bind 
at drug site 2 on bovine serum albumin (BSA) releases citrate. In our study fatty acids 
that compete for the latter binding site [15] affect citrate binding and partially release it. 
Thus  citrate  binding  can  be  either  in  direct  competition  or  allosterically  affected  by 
ligands of drug site 2 in albumin.
CONCLUSION
In conclusion, we observed and mapped slow exchange binding (strong binding) as 
well as fast exchange binding (weak binding) to the plasma protein matrix of a significant 
number of the metabolites commonly observed in NMR. As a result the measured (free) 
metabolite concentration was found to deviate significantly from the real concentration 
for these metabolites. Fatty acids release many of these metabolites.  The free metabolite 
concentration is thus affected strongly by the fatty acid content and by the HSA content. 
We  also  find  that  for  most  spiked  metabolites  their  free  concentration  increases 
proportionally with the overall  concentration; however,  the proportionality constant is 
below 1  when HSA or fHSA is  added.  We further  find  that  an increased  metabolite 
concentration does by and large not affect the free concentration of other metabolites, i.e. 
no  interaction  between  metabolites  or  apparent  competition  for  HSA binding.  These 
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results are interesting for two main reasons - 1) Significant quantification errors can be 
made due to the binding of metabolites to HSA or fHSA. 2) The binding  also provides 
opportunities  for  measuring  the  FA and/or  HSA concentrations  from  the  metabolite 
concentration. The metabolite profile of plasma can thus function as a reporter of FA 
and/or HSA content. This provides new opportunities to employ metabolite profiles as 
biomarkers or diagnostic, e.g. for trauma or cardiovascular diseases. In a follow-up study 
we investigate how and to which extent specific common fatty acids affect the HSA-
metabolite interactions. Finally, it is to be noted that after ultrafiltration (which removes 
plasma proteins) the correct total metabolite concentration is found for most metabolites, 
except for the strongest binder citrate.
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Table S1 Overview of metabolites in the non-filtrated and ultra-filtrated blood plasma mimics.
Number Metabolite
1 82
2 48
3 22
4 citrate 88
5 333
6 66
7 D-+-glucose 4520
8 612
9 86
10 lactate 1510
11 159
12 L-lysine 190
13 30
14 L-phenylalanine 61
15 pyruvate 63
16 150
17 231
Normal conc. 
Human1 (µM)
L-arginine
L-asparagine
L-aspartate
L-alanine2
creatinine
L-glutamine
L-histidine
L-leucine
Acetate2
threonine
valine
1data from HMDB, for normal adult  patients > 18 years old  [1–3]); 2 in  the blood plasma 
mimics employed in the spiking and dilution experiments L-alanine and acetate were replaced by  
citrulline (38 µM) and 2-oxoglutarate (9 µM) approximately to the given HMDB concentrations.
Table S2 Spiking of  selected metabolites  in  the three mimics,  the final  concentration of  the  
spiked metabolite is given at each step.
Molecule Spiking: final concentration (mM)1.000 2.000 3.000 4.000 5.000
0.600
Citrate 0.088 0.180 0.440 0.620 1.850
0.612 1.223 1.529 1.835 2.140
0.086 0.172 0.430 0.688 1.806
Lactate 1.510 2.265 3.020 4.530 6.040
Lysine 0.190 0.379 0.758 1.137 1.895
Phenylalanine 0.063 0.121 0.303 0.605 1.815
0.063 0.126 0.315 0.630 1.827
0.231 0.461 0.692 1.153 1.844
HSA or fatted-HSA
Glutamine
 Histidine
Pyruvate
Valine
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Table S3 Dilution of blood plasma using appropriate buffer to keep pH at 7.4±0.5 and ionic  
strength at 154 mM
Blood plasma Buffer Buffers’ pH
2 250 250 6.4
5 100 400 7
8.33 60 440 7.1
16.7 30 470 7.3
25 20 480 7.3
50 10 490 7.4
62.5 8 492 7.4
71.43 7 493 7.4
100 5 495 7.4
Volume (μL)
Dilution 
factor
Figure S1 Analytical error (RMSD) in NMR measurement of metabolite concentration versus  
metabolite  concentration:  Metabolite  only  mimics  for  the  non-filtrated  and  ultra-filtrated  
experiments were used and NMR measurement ‘zgcppr’ and ‘zgcpgmes’ for these mimic samples.  
The open diamond symbols are for the analytical error in the NMR concentration measurement.  
The  analytical  is  taken as  the  RMSD of  the  NMR concentration  measurements  of  the  three  
metabolite-only plasma mimics for non-filtrated experiments (three ‘zgcppr’ measurements and  
‘zgcpmges’ measurements)  and  the  three  metabolite-only  plasma  mimics  for  ultra-filtrated  
experiments (three ‘zgcppr’ measurements and ‘zgcpmges’ measurements). For this set of NMR  
measurements, the filled square symbols stand for the average absolute deviations between NMR  
concentration measurement and the normal (HMDB) concentration.                            .
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Table  S4 Annotation  for  blood  plasma  spectrum,  chemical  shift  calibrated  to  α-Glucose 
resonance at 5.23 ppm.
Annotation
0.69 cholesterol
[0.80 .. 0.90]
[0.97 .. 0.99]
[0.99 .. 1.01]
[1.02 .. 1.04]
[1.19 .. 1.36]
[1.31 .. 1.33] lactate
[1.46 .. 1.48] alanine
1.57
[1.69 .. 1.75] lysine
[1.86 .. 1.92] lysine
1.91 acetate
[1.96 .. 2.07] lipids
2.03
[2.10 .. 2.14]
2.22
[2.19 .. 2.26] lipid
[2.21 .. 2.29]
2.36 pyruvate
[2.38 .. 2.42] glutamate
[2.41 .. 2.48]
[2.50 .. 2.54] citrate
[2.66 .. 2.70] citrate
[2.67 .. 2.69]
[2.85 .. 2.86]
[2.90 .. 2.92]
[3.02 .. 3.03] lysine
3.04
3.21 choline
[3.23 .. 3.24]
[3.60 .. 3.61]
[3.63 .. 3.68]
[3.74 .. 3.76]
[3.74 .. 3.77]
[3.89 .. 3.91]
[3.95 .. 3.98]
4.05
[4.09 .. 4.13] lactate
[4.22 .. 4.31]
[4.67 .. 4.84] water
[5.17 .. 5.21]
[5.22 .. 5.24]
5.23
[5.25 .. 5.35] unsaturated lipids
5.77 urea
[6.87 .. 6.90] tyrosine
7.05
[7.17 .. 7.20] tyrosine
[7.30 .. 7.33]
[7.39 .. 7.44]
7.77
8.45
Chemical shift 
(ppm)
lipids[ldl+vldl]
valine
isoleucine
valine
lipids[ldl+vldl]
lipid[vldl]
glycoproteine
glutamine
acetoacetate
valine[m]
glutamine
aspartate
aspartate
asparagine[dd]/trimethylamine[s]
creatinine//creatine
arginine
valine//threonine
glycerole//ethanol
glutamine//arginine
arginine[not visible]
aspartate[not visible]
histidine
creatinine
threonine
glyceryl of lipids
alphaGlucose
glu
histidine
phenyalanine
phenyalanine
histidine
formate
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Figures  S2 Spectrum  annotation  of  blood  plasma,  chemical  shift  calibrated  to  α-Glucose  
resonance at 5.23 ppm.
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Figure S3 Correction factors used along spectra to compensate from water suppression and  
cpmg effects.
120
Chapter 3 - Metabolites Interacting with Fatted and Non-Fatted Human Serum Albumin
121
SUPPLEMENTARY MATERIAL
Figure S5 2D 1H J-resolved spectra of metabolites mixture. The labeling correspond to Table S1.
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Figure S6 2D 1H TOCSY spectrum of metabolites mixture. The labeling correspond to Table S1.
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CHAPTER 4
NMR Metabolomics Profiling of Blood Plasma Mimics shows that  
Medium- and Long-chain Fatty Acids Differently Release Metabolites  
from Human Serum Albumin
Marc Jupin, Paul Michiels, Frederic Girard, Manfred Spraul, Sybren Wijmenga
Journal of Magnetic Resonance (2014), Articles in Press
ABSTRACT
Metabolite  profiling  by  NMR  of  body  fluids  is  increasingly  used  to  successfully 
differentiate patients from healthy individuals. Metabolites and their concentrations are 
direct reporters of body biochemistry. However, in blood plasma the NMR-detected free-
metabolite  concentrations are also strongly affected by interactions with the abundant 
plasma proteins, which have as of yet not been considered much in metabolic profiling. 
We previously reported that many of the common NMR-detected metabolites in blood 
plasma bind to human serum albumin (HSA) and many are released by fatty acids present 
in  fatted  HSA.  HSA is  the  most  abundant  plasma  protein  and  main  transporter  of 
endogenous and exogenous  metabolites.  Here,  we show by NMR how the two most 
common fatty acids (FAs) in blood plasma - the long-chain FA, stearate (C18:0) and 
medium-chain FA, myristate (C14:0) - affect metabolite-HSA interaction. Of the set of 18 
common  NMR-detected  metabolites,  many  are  released  by  stearate  and/or  myristate, 
lactate appearing the most strongly affected. Myristate, but not stearate, reduces HSA-
binding  of  phenylalanine  and  pyruvate.  Citrate  signals  were  NMR  invisible  in  the 
presence of HSA. Only at high myristate-HSA mole ratios 11:1, is citrate sufficiently 
released to be detected. Finally, we find that limited dilution of blood-plasma mimics 
releases  HSA-bound  metabolites,  a  finding  confirmed  in  real  blood  plasma  samples. 
Based  on  these  findings,  we  provide  recommendations  for  NMR  experiments  for 
quantitative metabolite profiling.
Keywords: Metabolomics; NMR; Albumin; Fatty acids; Blood plasma; Interactions; 
Myristate; Stearate.
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INTRODUCTION
Metabolomics  of  biofluids  increasingly  contributes  to  disease  diagnostics  [1-5] 
through detection of disease-specific biomarkers [6-9].  NMR is, next to MS, the main 
analytical  platform,  contributing  about  one-third  of  the  total  of  metabolomics 
publications [6]. NMR is well suited for non-targeted quantitative metabolic profiling and 
for  detecting  metabolite-protein  interactions  (see  e.g.  [10,  11]).  In  metabolic  studies, 
metabolite-protein interactions have until now not much been accounted for (see below). 
However,  they  are  prominent  in  blood  plasma because  of  the  abundance  of  plasma 
proteins and important, because human serum albumin (HSA), the main plasma protein 
(~60% of total), is a main transporter of endogenous (metabolites and fatty acids) and 
exogenous (drugs) compounds. Furthermore, metabolites, fatty acids and proteins may 
mutually influence these interactions. In turn, these networks of metabolome, lipidome, 
and proteome are connected to the genome and its expression. The metabolite profile 
contains therefore in principle a wealth of information on these networks and it is of great 
interest  to  properly measure  and interpret  the  interactions  of  metabolites  with blood-
plasma proteins.
In  present  metabolics  studies  proteins  are  usually  physically  removed  by 
deproteination  techniques  [3,  12].  This  simplifies  the  NMR  spectra  thanks  to  the 
concomitant removal of  broad protein and lipid signals,  but holds the danger of also 
removing some of the protein-bound metabolites [10, 12].  More importantly,  to study 
protein-metabolite interactions in blood plasma requires retaining its protein component. 
The broad protein (and lipid) NMR signals can then be removed by employing CPMG 
sequences [3, 12]. ‘NMR-invisible’ metabolites in blood plasma or mimics thereof have 
been reported many years ago for lactate, 3-D-hydroxybutyrate, acetoacetate, tryptophan, 
tyrosine, phenylalanine and histidine [13-15],  showing complex metabolite interaction 
with HSA, i.e. non-specific multiple binding was proposed [15]. Recently, Daykin et al. 
[11]  introduced  i-metabolomics,  an  approach  to  non-targeted  study  of  metabolite 
interactions by diffusion-edited-NMR. Samples of ibuprofen mixed with 20 endogenous 
metabolites and HSA and mixed with blood plasma were investigated. Acetone, acetate 
and citrate were found to bind to HSA. We investigated [10] by 1D 1H NMR, also in a 
non-targeted manner, the binding to fatted- and non-fatted HSA in blood plasma mimics 
(and blood plasma) of the ~20 endogenous metabolites, commonly detected by NMR in 
blood plasma/serum. Of the ~20 metabolites, only some showed chemical shift changes, 
i.e. fast-exchange or weak binding to HSA. Many metabolites showed instead reduced 
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NMR  resonance  integrals  (reduced  free  concentration),  indicating  slow-exchange  or 
strong binding. However, the slow-exchange binding is complex and displays apparent 
weak binding, most likely caused by multiple conformations of HSA. Remarkably, HSA-
binding metabolites are released (increased integrals), in part or fully, by fatty acids (FAs) 
as evidenced by changes in NMR spectra of metabolite mixtures with non-fatted HSA 
versus  fatted  HSA added  [10].  However,  to  make  full  use  of  interactions  in  NMR 
metabolite  profiling  requires  a  clearer  understanding  of  what  guides  the  binding 
processes, which may also help to device new (applications of) NMR experiments.  An 
important question, we address here is, which specific FAs affect HSA binding of the 
metabolites considered? Thus, this work forms a continuation of our previous study [10].
What  is  known  of  the  binding  sites  on  HSA of  FAs  and  low  molecular-weight 
molecules? Under normal physiological conditions, HSA binds 0.1-2 mol of FA per mol 
protein [16]. However, the FA-HSA molar ratio can rise up to 6 or even higher, e.g.  in 
patients  with  diabetic  ketoacidosis  complicated  by  nephrosis [17].  Crystallographic 
analysis and NMR binding studies have delineated the location of the binding sites of 5 
saturated FAs, C10, C12, C14, C16 and C18, and 2 unsaturated FAs, C18:1 and C20:4. 
FAs share 7 common binding sites of which 3 are of high affinity and 4 of low affinity 
[18]. Further, 2 main drug binding sites (drug site 1 and 2) and a heme/bilirubin binding 
site  [18,  19]  are known.  Drug-site  2  (e.g.  binds  diazepam [19])  coincides  with high-
affinity site FA4 [18]. For FA4, the binding of FAs and drugs involves direct competition. 
Drug-site 1 (e.g. binds warfarin [19]) coincides with FA7, a low-affinity site [20]. Drugs 
displace the FA in this site except indomethacin [20]. The heme site on HSA coincides 
with FA1 and heme binding displaces FAs [19]. 
Apart  from  direct  competition,  also  allosteric  competition  for  HSA binding  takes 
place,  demonstrating  the  complex  ligand  binding  characteristics  of  HSA.  Allosteric 
competition is intimately related to the large number of different conformations that HSA 
displays at different salt conditions, pH, and on binding of FAs or other ligands [18]. For 
instance, binding of bilirubin to HSA increases when the FAs, laurate and myristate, are 
added at FA-HSA mole ratios 1 to 3. At higher ratios bilirubin binds less [21, 22]. Similar 
observations were made for progesterone and testosterone in conjunction with laurate 
[21, 22]. Finally, myristate (C14:0) competes directly with the hormone thyroxine on all 
its four binding sites on HSA [23]. However, excess myristate induces conformational 
changes that create a fifth thyroxine site, which explains why HSA retains a high-affinity 
site for thyroxine even in the presence of excess FA [18, 19, 24]. 
This study involves two aspects. First, the study investigates by NMR how binding to 
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HSA of myristate (C14:0) and stearate (C18:0) affects HSA-metabolite interaction. These 
FAs were chosen because they are common in blood-plasma and posses well-established 
but common and different HSA binding sites and affinities. The seven common sites are 
FA1 to FA7, while myristate shows at high FA-HSA ratios four additional low-affinity 
sites [15, 18, 25]. Further, the HSA affinity tends for long FAs, like stearate, to be higher 
than for medium- and short-chain FAs, like myristate [26, 27]. We expect (see above) 
direct- and/or allosteric competition between these FAs and metabolites for binding on 
HSA, which can be assessed by following the free metabolite concentration by NMR as 
function of increasing FA-HSA molar ratio. In this way, a better understanding of the 
molecular mechanisms underlying FA/HSA/metabolite interactions is obtained. Secondly, 
we  also  find  that  limited  dilution  of  blood-plasma  mimics  leads  to  release  of  HSA-
interacting  metabolites,  which  helps  to  detect  metabolite/HSA  interactions.  These 
findings are confirmed in blood plasma. We provide recommendations as to how these 
findings  can  be  translated  into  productive  usage  (measurement  and  interpretation)  in 
quantitative metabolic NMR profiling.
MATERIAL AND METHODS
Materials
All chemical products were purchased at Sigma-Aldrich. The Human serum albumin 
stock was essentially globulin and fatty-acid free (~0.005%, product no. A 3782 ).
Preparation of plasma mimic, metabolite mixture 
The plasma mimics were prepared largely as described previously [10]. Briefly, for the 
plasma  mimics,  18  metabolites  (Table  S1)  were  chosen  and  mixed  at  normal 
concentrations. They should be previously identified in 1D 1H NMR blood plasma [28, 
29]. Further they were selected based on criteria as used in [10].  We note that in the 
recent Serum HMDB [30],  NMR spectra were recorded of serum samples of healthy 
individuals  and  of  patients  with  a  heart  transplant.  Per  sample  32  metabolites  were 
identified of which 21–25 were seen in every sample. The metabolites in our plasma 
mimics correspond to 18 of these compounds.
For each selected metabolite a stock solution was prepared by dissolution in 7.0 mM 
Phosphate buffered saline (PBS stock) of pH 7.4 (~0.8% NaCl, ionic strength of buffer 
154 mM) and a stock solution mixture of the selected metabolites was made at 20 times 
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their normal concentration in blood plasma (data from HMDB, Table S1) and stored at 
-20 °C. 
Preparation of HSA solution and HSA/metabolite mixtures
Stock solution of human serum albumin (HSA) was also prepared in PBS stock to a 
final concentration of about 50 mg/mL HSA and was filtered using Millex® GP 0.22 μm. 
The  concentration  was  measured  with  a  Cary300  spectrophotometer.  We  used  an 
absorbance of 5.3 for 1% solution of protein at 280 nm. The buffered protein solution 
was stored at 4 °C if not used immediately. 
The  HSA/metabolite  mixture  was  prepared  by  adding  stock  metabolite  mixture 
(concentration  20  x  normal)  to  the  HSA  stock  solution  (50  mg/ml)  to  a  final 
concentration  of  HSA  of  40  mg/ml  (normal  concentration  in  blood  plasma)  and 
metabolite  concentrations  corresponding  to  those  found  in  normal  blood  plasma  as 
described in the previous section. The ultimate HSA/metabolite mixture was dissolved in 
PBS stock. The samples were put in a water bath at 37 °C for 1 hour to equilibrate, and 
then left at room temperature for 1 hour before measurements. The pH of all samples was 
adjusted to 7.4 ±0.05 using concentrated NaOH and HCl.
Preparation of fatty-acid-HSA-metabolite mixtures
Sodium salts of myristate (C14:0) and stearate (C18:0) were dissolved in PBS (pH 7.4) 
by warming in a  water  bath  up to  75  °C and 85  °C,  respectively,  and shaking until 
optically clear solutions were obtained. The myristate and stearate stock concentrations 
were 2.4 mM and 0.8 mM, respectively. These stock solutions were allowed to cool down 
before mixing with HSA (40 mg/mL ≈ 0.6 mM)/metabolite mixtures. Subsequently, the 
HSA/metabolite-FA mixtures were put in a water bath at 37 °C for 1 hour to equilibrate 
and  then  rested  at  room  temperature  for  1  hour  before  measurement.  If  not  used 
immediately, the fatty-acid stock solutions were kept at room temperature. Because they 
became turbid over time, they were warmed again prior to use as described above. The 
pH of all samples was adjusted to 7.4 ±0.05 using concentrated NaOH and HCl. 
HSA/metabolite-FA mixtures were prepared with FA-HSA molar ratio ranging from 1 
to 11 for myristate and 1 to 6 for stearate. These mixtures are called the ‘test’ samples.  
Note that the overall HSA/metabolite concentration may decrease for the higher FA-HSA 
ratios, but the HSA-metabolite ratio remains constant. For the control mixture, FAs were 
replaced by the equivalent volume of PBS so as to account for the effect of dilution due 
to the preparation protocol, but again the HSA-metabolite ratio remains constant. These 
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mixtures are called the ‘control’ samples (Myristate: dilution factors were at mole ratio 1 
= 1.04, 3 = 1.54, 5 = 2.04, 7 = 2.54, 9 = 3.04, 11 = 3.54; Stearate: dilution factors were at 
mole ratio 1 = 1.57, 2 = 2.3, 3 = 3.03, 4 = 3.78, 5 = 4.51, 6 = 5.24).  
Preparation for citrate titration
Citrate titration was performed in combination with stearate and myristate addition to 
the metabolite mixtures using the previous stearate-HSA ratios (1 to 6) and myristate-
HSA ratios  (1  to  11).  For  each  FA-HSA ratio  three  test  and  control  samples  were 
prepared. The samples with different FA-HSA ratios were prepared as described above 
with citrate added prior to FA addition, so that the dilution associated with FA addition 
does not affect the citrate-HSA ratio. Citrate was added to reach a final concentration of 
1, 6, 11, 16 and 22 times the normal blood concentration, i.e. concentrations of 88, 528, 
968, 1408 and 1936 µM; this was done for both test and controls. For stearate-HSA molar 
ratios 4, 5, and 6, one of the three ‘test’ samples and one of the three control samples was 
replaced with a different citrate concentration range. For stearate-HSA ratio 4 the citrate 
concentrations were then 88, 1060, 2110, 3170, 4440 µM; for stearate-HSA ratio 5 they 
were 88, 860, 1729, 2580, 3610 µM, and for stearate-HSA ratio 6, 88, 760, 1520, 2270, 
3180 µM. 
Blood plasma dilution
Blood plasma samples of 5 volunteers were collected at the hospital. They were pre-
treated and buffered at pH 7.4 as previously described [10]. The samples were measured 
without dilution and or once diluted with PBS stock to maintain ionic strength and pH. 
NMR measurements
Always 500  µL of sample was put in the 5 mm NMR tubes. For lock signal 2 mm 
coaxial tubes containing D2O and TSP were used. The  TSP signal was not used in the 
present work, but can be and was used as external reference (see [10]). We used glucose 
and valine  signals  for  chemical  shift  referencing and quantification,  respectively (see 
below). For the citrate titration the lock signal was obtained by adding 50 μL of D2O to 
reach a final volume of 550 μL in the 5 mm NMR tubes. Measurements were carried out 
on  a  600  MHz  Bruker  Avance  III  spectrometer  equipped  with  a  cryoprobe  (Triple 
Resonance:  1H,  13C,  15N;  z  gradient;  and  high  sensitivity  1H  detection  and  13C 
detection). 
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The 1D 1H NMR spectra were all recorded at 298 K using the following ‘CPMG-ES’ 
pulse sequence: RD-90°-(τ-180°-τ)n-ES-acquisition. After the relaxation delay (RD) of 
3.5s,  a  1H  90°  excitation  pulse  is  applied  followed  by  a  T2-filter  to  remove 
macromolecular NMR signals.  The T2-filter is composed of a Carr-Purcell-Meiboom-
Gill  (CPMG)  sequence  [31,  32]  with  τ  set  to  830  µs  and  n  equal  to  128.  Prior  to 
acquisition the water signal is suppressed by means of an excitation sculpting sequence 
(ES) [33, 34]. The ES sequence consists of two pulse sequence blocks, each consisting of 
a water selective (sinc-shaped) 180° inversion pulse of 2 ms followed by a non-selective 
180° pulse. These two 180° pulses are bracketed by two equal sign pulse-field gradients 
(shape: square with rounded top) of 1 ms duration. The pulse-field gradients in the first 
and second block are 31% and 11% of the  maximum gradient  strength,  respectively. 
Acquisition was equal  to  3s.  Pulse  calibrations  were  done for  each sample  to  assure 
proper quantification. The 1D 1H NMR spectra were analyzed using Bruker Topspin 3.0. 
Chemical  shift  calibration  was  on  the  α-H1-D-glucose  signal  at  5.23ppm.  Metabolite 
concentrations were calculated from the resonance integrals using the L-valine doublet at 
1.033ppm as reference. We found L-valine not to bind to HSA [10]. 
The  T2-filter  and  excitation  sculpting  to  suppress  H2O signal  in  the  ‘CPMG-ES’ 
sequence affect the integrals of the metabolite resonances and a correction is needed to 
obtain correct quantification. NMR spectra were therefore also recorded using the regular 
presat-1D-noesy  (RD-90-t1-90-tm-90-acquire).  We  then  compared  the  metabolite 
concentrations from ‘CPMG-ES’ with those from ‘presat-1D-noesy’ to make a correction 
list for each metabolite resonance integral (Supplementary Material). This correction thus 
includes the effects from both T2 relaxation and excitation-sculpting water-suppression 
(for  further  details  see  also  [10]).  In  Supplementary  Material  it  is  shown  that  this 
approach gives reliable outcomes. For instance, for the metabolite mixture without HSA 
where  the  NMR-measured  free  metabolite  concentration  equals  the  known  total 
concentration, correct values were obtained. This also implies that relaxation delay (RD) 
and acquisition time were sufficiently long to prevent occurrence of saturation effects 
upon accumulation of transients (see also [10]).  However, signals close to water and 
signals with poor signal to noise ratio gave bigger standard deviation.
Statistics
All samples were prepared in triplicate and each measured at least once. Further, the 
total  metabolite  concentrations,  from  metabolite  mixture  at  dilution  factor  1,  were 
measured  5  and 6  times  during  stearate  and myristate  titration,  respectively  (Figures 
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S3a,b).  These  measurements,  done  during  the  experimental  process,  were  used  to 
estimate the standard deviation in the total concentration. A 95% confidence interval for 
the  difference  between means  for  the  ‘test’ and ‘control’ samples  was taken and the 
margin  of  error  calculated  from there  [35].  It  was  assumed that  errors  show normal 
distributions (since the sample sizes are relatively small, a t score as the critical value was 
used).
RESULTS
Stearate addition to blood plasma mimics
Figure 1 1D 1H NMR spectra at pH 7.4, ionic strength 154 mM, and 298 K of (a) metabolite  
mixture without HSA, (b) metabolite mixture with HSA, and (c-h) metabolites mixtures with HSA  
and stearate added in FA-HSA mole ratios 1 to 6, respectively. The c-h samples were called ‘test’  
samples. With increasing FA-HSA mole ratio is associated a certain degree of dilution (see main  
text; dilution factor at mole ratio 1 = 1.57, 2 = 2.3, 3 = 3.03, 4 = 3.78, 5 = 4.51, 6 = 5.24). The  
spectra were recorded as described in Materials and Methods, using a T2 filter to remove the  
broad  HSA resonances.  The  spectral  regions  display  resonances  of  leucine  (1;  two  nearly  
overlapping  methyl  doublets  giving  appearance  of  a  triplet),  valine  (2;  two doublet  methyl  
signals,  internal  reference,  see text),  lactate  (3; doublet),  alanine (4; doublet),  pyruvate (5),  
glutamine (6; multiplet), citrate (7; doublet of doublets), histidine (8 and 10; singlet of different  
aromatic protons), and phenylalanine (9, multiplets of aromatic protons signals). The annotation  
at the top (e.g. x8) indicates the vertical expansion of each spectral region. The spectral signals  
heights are calibrated relative to valine at 1.033 ppm.
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Figure  2 Effect  of  stearate  addition  on  HSA  binding  of  selected  metabolites.  (a,  c,  e)  
Concentration (NMR measured) of free lactate, phenylalanine and pyruvate in test and control  
samples  as  function  of  stearate-HSA mole  ratio  (and  associated  dilution  factor,  see  legend  
Figure 1). (b, d, f) Difference in concentration between test and control samples (FA-induced  
free metabolite concentration, see main text) as function of stearate-HSA mole ratio. 
Figure 1 shows 1D  1H NMR metabolite  spectra of metabolite  mixtures at  various 
stearate-HSA mole ratios, ratios at which all stearate molecules are expected to bind to 
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HSA [25]. In preparing the samples, called test samples, the system is inescapably diluted 
to  some  degree  (Table  S2,  Materials  and  Methods),  due  to  the  necessarily  low 
concentration of stearate stock (0.8 mM). To deconvolute the effects of stearate binding 
and  dilution,  we  also  prepared  control  samples  with  equivalent  dilution  factor  but 
substituting  the  stearate  solution  with  PBS.  In  all  samples,  the  ratio  of  HSA  to 
metabolites was kept constant and to enable proper quantification valine at 1.033 ppm 
was used as internal reference. Comparison of Figure 1a (absence of HSA) versus Figure 
1b (presence of  HSA) shows that  citrate,  lactate,  phenylalanine and pyruvate bind to 
HSA.  For  citrate  and  phenylalanine  the  signals  are  no  longer  visible  in  the  NMR 
spectrum when HSA is present, while for lactate and pyruvate the signals have decreased 
considerably. In addition, acetate, creatinine, histidine, leucine, lysine (data not shown) 
show a minor decrease in signal intensity. We observe that the signals of HSA-bound 
metabolites increase upon addition of stearate (Figures 1c-h), indicating their progressive 
release from HSA. Citrate remains invisible (HSA bound) under all  these conditions. 
Note that the release seen in Figures 1c-h could be caused in part also by dilution, as 
mentioned. .
A more quantitative view of the effect of stearate on metabolite binding to HSA is 
given in Figure 2 for lactate, phenylalanine and pyruvate. Figs. 2a, c, and e show the free 
metabolite  concentrations  as  function of  stearate-HSA molar  ratio  in  test  and control 
samples. As described above, the test samples become somewhat diluted upon fatty acid 
addition and thus the free concentration in the test samples incorporates the effects of 
both.  The  control  samples  show  the  effect  of  only  dilution.  The  difference  in  free 
metabolite  concentration  between  test  and  control  samples  shows  then  the  effect  of 
addition  of  fatty  acid  alone  (Figs.  2b,  d,  f).  This  difference  will  for  convenience  be 
referred to as the FA-induced free concentration. The test and control sample data in Figs 
2a,c, and e are the average value of three measurements (n = 3; Materials and Methods) 
done at different times with freshly prepared HSA and stearate solutions and the error bar 
represents the standard deviation on the data points. The error bars in Figs. 2b, d, and f  
represent the 95 % confidence level in the difference.
Figure  2a  shows  that  the  free  lactate  concentration  increases  more  steeply  in  the 
presence  of  stearate  (test  samples)  than  in  the  absence  of  stearate  (control  samples). 
Consequently,  the  FA-induced  free-lactate  concentration  (Figure  2b)  increases  with 
increasing FA-HSA molar ratio and reaches a significant release at mole ratios 5 and 6.  
The  term  ‘significant’ refers,  here  and  throughout,  to  a  deviation  beyond  the  95% 
confidence  limit.  For  phenylalanine  and pyruvate,  the  free  concentrations  in  test  and 
control  samples  essentially  overlap  (Figures  2c  and  2e).  Their  FA-induced  free 
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concentrations do therefore not significantly deviate from zero (Figures 2d and 2f). 
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Figure  3 Effect  of  myristate  addition  on  HSA  binding  of  selected  metabolites.  (a,  c,  e)  
Concentration of (NMR measured) free lactate, phenylalanine and pyruvate in test and control  
samples as function of myristate-HSA mole ratio (associated dilution factors at mole ratio 1 =  
1.04, 3 = 1.54, 5 = 2.04, 7 = 2.54, 9 = 3.04, 11 = 3.54). (b, d, f) Difference in concentration  
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between test and control as function of myristate-HSA mole ratio with error bar indicating 95 %  
confidence interval. 
Thus,  stearate  appears  not  to  affect  phenylalanine  and  pyruvate  binding  to  HSA. 
However, dilution has a different effect on the free concentration of these two molecules. 
For  phenylalanine,  the  free  concentration  (Figure  2c)  steadily  grows  with  increasing 
dilution. In contrast, for pyruvate it reaches the total concentration already at a dilution 
factor corresponding to FA-HSA ratio 2 (Figure 2e).
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Figure 4 NMR-measured free citrate concentration as function of total citrate concentration in  
the blood plasma mimic in  the presence of  myristate  (myristate-HSA mole ratio  11:1; filled  
shaped markers) or absence of myristate (crosses and star markers). The citrate concentrations  
are given relative to the HSA concentration. In these samples the plasma mimics are all diluted  
by a factor of 3.54 with respect to the original; the highest concentration of citrate used is then  
522 μM.
Citrate is the strongest HSA binding metabolite as found here and in our previous 
study [10]. We measured here the concentration of free citrate as a function of total citrate 
concentration  for  different  stearate-HSA  ratios  and  corresponding  dilution  factors 
(Figures S8-11). The titration curves show that approximately one citrate binds per HSA 
molecule (see legend of Figure S8). No clear distinction can be made between the free 
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concentration in test and control samples, indicating that addition of stearate has no effect 
on citrate-HSA binding. Titration curves at small and larger dilution overlap indicating 
that  also  the  degree  of  dilution  does  not  affect  the  binding  under  limited  dilution 
conditions. Finally, we investigated whether increasing the citrate-HSA ratio affects the 
HSA binding of other metabolites  for  the different FA-HSA ratios by following their 
signals.  Essentially  no  changes  due  to  increased  citrate  concentration  were  observed 
(Figures S9-S11).
Myristate addition to blood plasma mimics
Myristate  (C14:0)  was  studied  in  the  same  way  as  stearate  (C18:0).  However,  to 
account for the additional HSA binding sites of myristate compared to stearate, 11 sites 
instead of 7 [25], the maximum myristate-HSA molar ratio was increased to 11. 
Figures 3a, 3c, and 3e show as above the concentrations of free lactate, pyruvate and 
phenylalanine as function of myristate-HSA molar ratio for test and control samples. In 
the  test  samples  (combined  effect  of  FA and  dilution)  the  free  lactate  and  pyruvate 
concentrations at first show a steep increase, after which a plateau is reached at molar 
ratio 5. In the controls (effect of dilution only), the free 
concentrations steadily increase. At molar ratio 11, the test and control converge at the 
level of the total amount of metabolite. For phenylalanine, except at molar ratio 1, we 
observe a more-or-less constant difference of ~12 μM between test and control (see also 
Figure 3d). For lactate and pyruvate, the difference between test and control (Figs. 3b, f) 
shows a  maximum at  mole  ratios  7 and 5-6,  respectively.  This  shows that  myristate 
affects HSA binding of these three metabolites differently than stearate.
Finally,  the  citrate  concentration  was  titrated  to  22  times  its  normal  blood 
concentration for each of the different myristate-HSA molar ratios (Figures S12-15). At 
the highest ratio of 11, we observe an evident difference in free citrate concentration 
between test and control samples when [citrate]/[HSA] >> 1 (Figure 4). This indicates 
release of citrate by myristate. At the highest total citrate concentration, free and total 
citrate concentration become nearly equal in the test sample, i.e. myristate releases nearly 
all  citrate.  In contrast,  at normal concentrations ([citrate]/[HSA] << 1),  citrate signals 
were not observed in the test and control samples.
Blood plasma dilution
To validate the metabolite release from HSA by dilution seen in blood plasma mimics 
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in  real  blood  plasma,  we  collected  samples  from  5  volunteers  and  measured  the 
metabolite  NMR  spectra  at  the  original  concentration  and  once  diluted  with  PBS 
(Materials and methods).  The spectra are shown Figure 5, calibrated with respect to the 
methyl signal of valine of A1,  so that  signal intensity changes upon dilution become 
evident. For instance, the lactate signal of E2 is much higher than that of E1, indicating 
release of lactate upon dilution. The same holds for the other lactate signals. Note the 
considerable variation in lactate signal height between volunteers. Pyruvate also shows a 
signal increase upon dilution for all volunteers. Citrate signals also become more intense 
upon dilution, the effect appearing strongest for A, C, and E. For creatine and creatinine 
release is evident as well (see e.g. C1 to C2). Also, tyrosine signals are more intense upon 
dilution for volunteers C and D, while the formate peak is evidently more intense only for 
volunteers A and E. In conclusion, dilution of blood plasma leads to a relative increase in 
signal  intensities  for  many  of  the  NMR  accessible  metabolites  in  accordance  with 
observations made in blood plasma mimics. It is also evident that for some metabolites 
the degree of release varies between volunteers,  while for others it  appears relatively 
constant. 
Figure 5 Regions from 1D 1H NMR spectra of blood plasma of 5 volunteers (A to E) at original  
concentration (A1 to E1) and once diluted with PBS (A2 to E2). In both the pH was adjusted to  
7.4 using concentrated HCl and NaOH. The 1D 1H NMR spectra were obtained using excitation  
sculpting with T2-filter to remove broad resonances as for blood plasma mimics (see Materials  
and Methods). The spectra display resonances of valine (1; doublet), lipid (2, broad), lactate (3;  
doublet),  alanine  (4;  doublet),  pyruvate  (5),  glutamine  (6;  multiplet),  citrate  (7;  doublet  of  
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doublets), creatine/creatinine (8, two closely spaced singlets), tyrosine (9, multiples), histidine  
(10; singlet of different aromatic protons), and formate (11, singlet). The spectral heights are  
calibrated with respect to methyl signals of valine (1, doublet; 4, doublet) of A1.
DISCUSSION
Release of HSA-bound metabolites by dilution
Dilution was found to release bound HSA metabolites to a significant degree. The 
dilution  factor  was  kept  limited  to  maintain  good  analytical  accuracy  (error  in  the 
concentration ≤10 %) on the NMR-measured metabolite concentrations. To illustrate the 
dilution effect,  we consider in more detail  the NMR metabolite  concentrations in  the 
‘control’ samples of myristate with dilution factor 3.04 and 3.54 (see legend Figure 3) 
and  of  stearate  with  dilution  factor  3.03  and  3.78  (see  legend  Figure  2).  The 
concentrations are averaged to further reduce the analytical error. Their values relative to 
the total concentration are shown in Figure 6 (see also Table 1). For comparison, Figure 6 
includes the free metabolite concentrations in mimics with non-fatted and fatted HSA as 
determined in our previous study [10]. 
First, we note that in the presence of HSA the free concentration of most common 
NMR-detected metabolites is significantly reduced (~85 % threshold) compared to that in 
the absence of HSA. Valine, glucose, threonine; alanine, glutamine, and leucine, form an 
exception. They are not much affected by the presence of HSA. These results confirm the 
findings of the previous study both in terms of order and quantitative degree of binding 
[10]. 
Secondly, we find that a dilution factor of ~3.3 increases the relative free concentration 
for  essentially  all  binding  metabolites  considered.  For  some  binding  metabolites  the 
relative free concentration reaches nearly 100 %, acetate and histidine it lies over 90 %, 
while for pyruvate and creatinine it is well over 80%.The free concentration approaches 
at dilution factor ~3.3 nearly 100 % for 10 out of the 18 considered common metabolites  
taking a ~20 % deviation as cut-off, namely for valine*, glucose*, threonine*, alanine*, 
glutamine*, leucine*, acetate, histidine, pyruvate and creatinine; the list includes the 6 
metabolites (*) not binding to HSA. Note that the composite signal ‘creatinine/lysine’ lies 
also above 90 %. We can conclude that limited dilution may thus be employed for these 
listed metabolites to obtain correct quantification of their total concentration. 
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Figure 6 Bar chart comparing free metabolite concentration relative to its total concentration  
for plasma mimics of different composition: metabolite-HSA mixture in present (Met+HSA) and  
previous  study  [10]  (Met+HSA_Jupinetal_ref10),  in  present  study  diluted  ~3.3  times  
(Met+HSA_diluted~3.3), in present study with myristate added in myristate-HSA ratio 10 and  
diluted ~3.3 times (Met+HSA:Myristate 1:10 dilution~3.3), in previous study [10] with fatted  
HSA  instead  of  HSA  (Met+fHSA_Jupinetal_ref10).  The  free  metabolite  concentrations  for  
‘Met+HSA_diluted~3.3’are averaged over stearate ‘control’ samples with mole ratios 3 and 4,  
dilution factor 3.03 and 3.78, and myristate ‘control’ samples with mole ratios 9 and 11, dilution  
factor 3.04 and 3.54.. For ‘Met+HSA:Myristate 1:10 dilution~3.3’ the free concentrations are  
average of myristate ‘test’ samples with mole ratios 9 and 11. Metabolites signals affected by  
water suppression or poor signal to noise or not observed (e.g. citrate) were omitted from this  
graph.
Thirdly, for more strongly-binding metabolites the relative free concentration is taken 
to remain at dilution factor ~3.3 below the 80 % limit and is ordered from low to high as, 
citrate  (see  below) < phenylalanine < lactate  < creatinine < pyruvate.  Citrate  signals 
remain invisible in the NMR spectra even upon this  dilution (Figure 1),  indicating a 
stronger  HSA binding  affinity  for  citrate  than  for  the  other  metabolites,  as  noted 
previously [10]. As before [10] we do not find that citrate or other metabolites considered 
mutually  affect  their  binding  to  HSA.  The  signals  of  arginine,  asparagine,  aspartate, 
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lysine, and citrulline overlap with other signals. Their composite signals remain below 
100 %. However, it is not possible to say with certainty for these individual metabolites 
whether dilution affects their concentration or not, because of their relatively low normal 
concentrations. 
Finally, in real blood plasma 1D 1H NMR signals of free lactate and pyruvate were 
also observed to be more intense upon dilution in all  5 different samples (Figure  5). 
Citrate, creatine/creatinine, tyrosine, and formate signals were also more intense but not 
to the same degree in each volunteer, indicating variations in interactions. Nevertheless, 
dilution of real blood plasma brings about release of metabolites. Release of metabolites, 
e.g. of citrate, was previously observed in blood plasma [36]. 
Interpretation of dilution data in terms of HSA-metabolite interaction
Fast-exchange interactions may lead to broadening of the metabolite resonances or 
chemical  shift  change  but  do  not  affect  their  integrals.  In  contrast,  slow-exchange 
interactions lead to separate resonance signals of the free and bound metabolites, with the 
signal  of  the  bound  metabolite  may  be  broadened  beyond  detection.  Weak  binding 
(dissociation constant KD > µM) is usually associated with fast-exchange, whereas strong 
binding (KD <<  µM) is associated with slow-exchange. Together this leads to various 
concentration regimes depending on the relative values of KD and metabolite and protein 
concentration (see for instance theoretical discussion of [10]). 
In  our previous study [10] and in the  present study,  we observe for  the set  of  18 
common NMR detected endogenous metabolites in blood plasma and its mimics complex 
interactions with HSA. First, some metabolites display both fast - and slow-exchange 
interactions with HSA ([10]). Secondly, most metabolites display reduced integrals as a 
result of interaction with HSA, indicating slow exchange and thus strong binding  (KD 
<<µM) (theoretical  section  of  [10]).  However,  at  the  same  time  titration  shows  that 
metabolite binding to HSA (~0.6 mM) does not saturate in the ‘above µM’ regime (see 
[10] and Figure 4) as it should for a simple strong binding interaction (see  [10]). The 
apparent KD’s of the metabolites appear thus higher than µM (apparent fast exchange 
regime, [10]). This conclusion also follows from the dilution data presented above. Upon 
dilution the metabolite and protein concentrations remain above µM. Given KD << µM, 
the bound metabolites should then stay bound (see theoretical section of [10]) and the 
free  metabolite  concentrations  would  then  linearly  follow  the  dilution.  Instead,  one 
observes free metabolite concentrations that increase with respect to this linear trend for 
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many considered metabolites (Figure 5 and Table 1). Again, the apparent KD’s of the 
slow-exchanging metabolites are higher than µM (apparent fast exchange regime). 
Table  1 Comparing  effect  of  dilution  and  myristate  titration  on  metabolite  mixture  in  the  
presence of HSA.
molecule signal(s) Met+HSA
M
et
ab
ol
ite
s o
rd
er
ed
 a
s F
ig
ur
e 
5 
fo
r c
om
pa
ris
on
3.61 229.1 ± 1.7 233.1 ± 4.3 238.5 ± 3.2 236.4 ± 6.8
1.03 230.5 ± 0.0 230.5 ± 0.0 230.5 ± 0.0 230.5 ± 0.0
3.58 108.9 ± 4.0 107.7 ± 2.6 114.8 ± 1.5 114.7 ± 2.4
2.45 535.9 ± 12.3 479.3 ± 15.6 500.9 ± 3.9 496.8 ± 11.9
alanine 1.47 355.5 ± 14.4 315.7 ± 20.3 339.6 ± 6.6 331.4 ± 16.2
0.95 193.8 ± 6.5 156.4 ± 4.6 184.0 ± 2.3 183.7 ± 1.8
3.98 59.2 ± 4.0 47.6 ± 7.5 48.0 ± 4.0 65.0 ± 15.4
3.04 62.4 ± 1.4 47.9 ± 1.2 57.1 ± 0.4 57.0 ± 1.7
acetate 1.91 48.2 ± 2.0 33.9 ± 2.4 47.3 ± 0.9 51.6 ± 1.4
4.05 45.1 ± 1.3 31.6 ± 3.1 38.1 ± 1.4 48.0 ± 4.1
7.78 63.0 ± 2.3 39.3 ± 1.8 62.0 ± 1.3 50.9 ± 1.4
1.90 233.7 ± 7.9 133.6 ± 9.0 181.6 ± 5.5 169.1 ± 4.1
1.70 176.9 ± 12.6 99.7 ± 12.7 137.9 ± 7.1 123.4 ± 10.3
lactate 4.11 1136.7 ± 61.7 575.5 ± 50.8 924.0 ± 16.3 1133.5 ± 9.0
pyruvate 2.36 15.4 ± 0.4 7.6 ± 0.5 13.4 ± 0.2 13.9 ± 0.9
1.32 1520.7 ± 46.3 637.2 ± 26.9 1140.7 ± 6.5 1481.8 ± 47.6
phenylalanine 7.37 43.3 ± 1.2 7.1 ± 0.6 23.9 ± 0.5 35.7 ± 0.8
Measured metabolites concentration in various samples (nM)
Center of 
integration 
area(ppm)
Metmix Met+HSA diluted ~3.3
Met+HSA:Myr
istate 1:10 di-
luted~3.29
valine
valine(ref)
threonine
glutamine/oxoglutarate
leucine
asparagine/histidine/ 
phenylalanine
creatinine/lysine
creatinine
histidine
citrulline/arginine/ 
lysine
arginine/leucine/lysine
Lactate&threonine
This observation is in accordance with KD’s between 1 to 100 µM for HSA ligands 
measured  by  other  methods  [22,  37].  Further,  disappearance  or  reduction  of  lactate 
resonances in NMR spectra have been reported for blood plasma [13, 14] and further 
investigated in solutions of bovine serum albumin [15]. This led to the conclusion that the 
decreased ‘NMR visibility’ of lactate in proteinaceous solutions is due to non-specific 
binding to albumin [15]. Indeed, to understand this complex metabolite-HSA binding one 
has to consider the multimeric and flexible nature of HSA to explain its multitude of 
allosteric binding effects [19, 37-43].  HSA samples its  many different conformations, 
leading to closing and/or opening of certain binding sites, which in turn leads to many 
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slightly different KD values and thus to apparent KD‘s > µM. One potential cause for 
conformational changes likely involves interaction of chloride ions with HSA which bind 
at drug site 2 and affect allosterically or via direct competition binding of drugs and other 
ligands [37-43].  In our study, ionic strength is kept constant so that upon dilution the 
chloride-HSA ratio  changes  and  changes  in  HSA binding  of  the  chloride  ion  may 
similarly affect metabolite binding.
Release of HSA-bound metabolites from HSA by specific FAs 
The 1D 1H NMR spectra for FAs-HSA-metabolites samples with increasing FA-HSA 
molar ratios (ranging up to 11) provided a method for observing the effect of binding of 
specific FAs to HSA on the binding metabolites. Under normal conditions the FA-HSA 
molar ratio lies in blood plasma between 0.1 and 2, but may for certain disease can rise 
up to 6 or even higher [17]. Therefore, the employed FA-HSA molar ratios largely cover 
what may occur in biological samples and may provide an impression of the variations in 
measured (free) metabolite concentrations observed in a metabonomic study.
Effect of FA on metabolite-HSA binding at high FA-HSA molar ratio 
Figure 5 and Table 1 give an overview of metabolite release by myristate at myristate-
HSA ratio 10 (average of 9 and 11), the highest ratio considered. Of the 18 metabolites, 6 
to 8 do not bind to HSA or are already fully released at dilution factor ~3.3 (see above). 
They are of course not further released by myristate. Myristate releases to completion 
lactate and creatinine, to near completion phenylalanine and to lesser extent also acetate. 
Finally, some metabolites are not affected by addition of myristate, namely the composite 
NMR signals from citrulline/argenine/lysine and from argenine/leusine/lysine. Stearate 
(C18:0) only releases lactate at the highest FA-HSA ratios considered. 
Stearate and myristate titrations
At low stearate-HSA molar ratios (<4) no differences are observed between the free 
concentrations  of  lactate,  phenylalanine,  and  pyruvate  (Figure  2)  in  test  and  control 
samples. At higher mole ratios, i.e. ratios 5 and 6, stearate only releases lactate. 
For  myristate,  lactate  and  pyruvate  are  completely  released  from HSA in  the  test 
samples, beyond mole ratios 5 and 7, respectively (Figure 3). This is evident in the test 
samples  from  the  concentration  plateau  that  equals  the  total  concentration  of  these 
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metabolites. As evident from the control samples, the dilution effect in the test samples is 
such that at myristate-HSA molar ratio 11 the free concentration approaches the total 
concentration (Fig 3). For phenylalanine one observes from mole ratio 3 to 11 a constant 
difference  of  ~12±4  μM  (95  %  confidence  interval)  between  test  and  control.  The 
constancy indicates that, from mole ratio 3 onwards, myristate has no longer an effect. 
The value itself indicates that part of phenylalanine is still bound to HSA. Upon dilution 
phenylalanine is released from these sites, because from mole ratio 3 to 11 in the control 
the free fraction concentration still increases. 
Interpretation in terms of occupation by metabolites of FA binding sites on HSA
According to Simard et al. [44], Hamilton et al. [45] and Cistola et al. [46, 47] two classes of 
fatty-acid binding-site affinities exist on HSA and Bovine serum albumin (BSA, 75% identical to 
HSA in amino acid sequence):  three high-affinity sites and the rest  low-affinity  sites.  Seven 
common binding  sites exist of which five contain basic amino-acid side-chains that form salt-
bridge interactions with the fatty acids’ carboxyl group [44]. The three high-affinity sites show 
this  carboxyl  group  interaction  apart  from their  enclosed  hydrophobic  binding  environment 
which allows the methylene tail of fatty acids to bind in a nearly linear conformation. The low-
affinity sites are either exposed to solvent or energetically unfavourable. 
The endogenous metabolites commonly detected by NMR are polar or aromatic and water 
soluble. This contrasts with most drug molecules which tend to be hydrophobic.  One therefore 
does  not  a  priori  expect  the  endogenous  metabolites  to  directly  compete  for  the  fatty  acid 
(hydrophobic) high affinity sites. They may instead compete for lower affinity sites or interact 
with the polar part of high affinity sites. On the other hand, fatty acids induce conformational 
changes in HSA as observed in crystallographic studies on drugs/metabolites and fatty acids 
binding to HSA [19, 22, 25, 44, 48-50]. Thus, binding of metabolites to HSA might be affected 
directly or allosterically by FA-HSA binding.
Stearate, releases lactate from HSA at the higher stearate-HSA mole ratios of 5 and 6 
(Figure 2a and b).  Since, three high-affinity FA binding sites exist,  this indicates that 
release of lactate is due to FA binding to its low affinity sites (e.g. FA7, which coincides 
with drug site 1, or FA3, FA1, FA6). 
The free concentrations of lactate and pyruvate plateau at their total concentration at 
myristate-HSA mole ratios ≥5 (Figures 3a and 3e). Hence, neither lactate nor pyruvate 
still  binds  to  HSA at  these  ratios.  The  fact  that  the  myristate-HSA ratio  is  above  5 
indicates that low affinity myristate sites on HSA are involved. However, lactate is partly 
released  already  at  FA-HSA  ratio  3.  Thus,  lactate  is  also  released,  directly  or 
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allosterically,  due  to  myristate  binding to  a  high-affinity  site  on  HSA.  Inversely,  the 
myristate-induced free concentration of phenylalanine plateaus for myristate-HSA ratios 
≥3  (Figure  3d).  Hence,  in  the  myristate  titration  only  the  high  affinity  site(s)  are 
responsible for displacing phenylalanine. 
Finally, citrate binds with high affinity to HSA and is not affected by either stearate or 
myristate at normal FA-HSA ratios. The citrate is released only at the highest myristate-
HSA ratio of 11 (Figure 4). Thus, myristate binding to low affinity sites on HSA causes 
release of citrate.
CONCLUDING REMARKS
We find that only 6 out of the 18 common NMR-detected plasma metabolites are not 
bound to HSA: valine, glucose, threonine, alanine, glutamine, and leucine. Upon limited 
dilution by a factor of ~3.3, acetate and histidine become also completely released, while 
creatinine and pyruvate are nearly completely released. Other metabolites remain partly 
bound, e.g. lactate, phenylalanine, citrate. The release of metabolites by limited dilution 
as seen in the mimics is confirmed in real blood plasma samples. 
Fatty acids are found to release metabolites from HSA. Stearate (C18:0) affects mainly 
the binding of lactate to HSA and that  at  high FA-HSA molar ratios,  indicating low-
affinity sites being involved.. Myristate (C14:0) affects HSA binding of more metabolites 
than stearate.  Phenylalanine and lactate are affected when myristate binds to its HSA 
high-affinity sites. Pyruvate and lactate (again) are released when myristate binds to its 
HSA low-affinity sites. The mechanism of metabolite release from HSA is thus different 
for stearate and myristate.
Together,  these results also provide opportunities to improve quantitative metabolic 
profiling  of  blood  plasma  by  accounting  for  metabolite-protein  interactions.  First,  to 
obtain data on the total concentration of each metabolite, we recommend the following. 
Simply diluting the samples by a limited degree,  by a factor of at least  4,  should be 
enough to release most metabolites - commonly detected by NMR - from HSA and thus 
provide for them the total metabolite concentration. Alternatively, plasma proteins can be 
removed by ultracentrifugation  to  obtain  the  total  metabolite  concentration  for  NMR 
measurable metabolites, as we and others found that ultracentrifugation does not lead to a 
reduction in NMR-measurable metabolite concentration, except for very strong binders 
like  citrate  [10].  Second,  these  results  provide  an  opportunity  to  extract  valuable 
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information regarding the presence of (specific) fatty acids in plasma from the NMR-
measured metabolic profiles. For instance, lactate, phenylalanine and pyruvate can act as 
probes for high FA concentrations. The FA content can simply be estimated from the 
concentration of these metabolites in the whole blood sample compared to their  total 
concentration in diluted or ultra-filtrated samples. 
The clinical importance of such quantitative NMR metabolic and interaction profiling, 
is well illustrated in diabetes or obesity metabolomics studies, where it is seen that lactate 
concentration is higher in patients [51-53] or animal models [54-56] than in controls, 
either in blood plasma or urine. Since the FA-HSA ratios are usually ~3 times higher in 
diabetes, one should be careful in directly interpreting higher free lactate as  increased 
lactate metabolism.
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I Preparation of plasma mimics, i.e. metabolite mixtures
Table S1 Selected metabolites used in the blood plasma mimics and their respective normal  
concentrations to make up the metabolite mixture that mimics blood plasma. The metabolite  
mixture that mimics blood plasma contains the commonly NMR measured metabolites at normal  
blood/plasma concentrations and with salt and buffer added to an ionic strength of ~150 mM  
and  a  pH  set  to  ~  7.0  (see  Materials  and  Methods).  The  metabolite  concentration  values  
correspond to those of healthy (normal) adults 18 or more years old as found in the HMDB  
(HMDB.ca website; the corresponding references are number 34 and 35 in the main text). 
Metabolites
Concentration (mM)
normal adult human (>=18 years)
HMDB
L-arginine 0.082
L-asparagine 0.048
L-aspartate 0.0215
citrate 0.088
citrulline 0.038
creatinine 0.066
D-+-glucose 4.52
L-glutamine 0.6115
L-histidine 0.086
lactate 1.51
L-leucine 0.1585
L-lysine 0.1895
L-phenylalanine 0.0605
pyruvate 0.063
threonine 0.15
valine 0.2305
alanine 0.333
acetate 0.03
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II Methodology - NMR: Correction of resonance integrals for the effect of 
Excitation Sculpting water suppression and (CPMG T2-filter) on the 
recorded 1D 1H NMR spectra to obtain proper metabolites 
concentrations 
To suppress  the  water  signal  without  potential  saturation  of  metabolite  resonances 
signal in the NMR spectra and to remove the broad resonance signal from plasma protein 
and fatty acids the 1D  1H NMR spectra of the metabolites mixture were ultimately all 
recorded using the excitation sculpting (ES) to suppress water signal [1] in combination 
with a T2-filter-CPMG sequence [2,3] (‘cpmgesgp’ sequence); these data were compared 
with those from the NOESY sequence with presaturation (‘noesypr1d’).  We note that 
here,  where  we  check  on  correct  NMR  concentration  measurement  and  establish 
correction factors for ES profiles and CPMG effects (see below), three or more samples 
were  prepared  and  measured  for  each  condition.  Each  sample  contained  the  pure 
metabolite mixture that mimics blood plasma, i.e. the mixture contains the commonly 
NMR measured metabolites  at  normal blood/plasma concentrations  and with salt  and 
buffer added to an ionic strength of ~150 mM and a pH set to ~ 7.0 (see Materials and 
Methods); the metabolite mixtures used here for the corrections and testing are called 
pure as they are prepared without HSA and fatty acids. For chemical shift referencing and 
amplitude calibration purposes also 130 μM TSP is added and 10% D2O for field locking. 
The water suppression profile due to excitation sculpting [1] is centered at the ~4.7 
ppm  (water  resonance  position  at  room  temperature)  and  reduces  resonance  signals 
significantly up to ~ 1 ppm away from this center (~ 3.7 ppm and ~ 5.7 ppm); the T2-
filter (CPMG) reduces broad protein signals  but may also reduce the much narrower 
metabolite signals to some degree; in addition, the relative amplitudes of some metabolite 
resonances may in part also be affected by the J-coupling [4].
The  resonance  integrals  of  pure  metabolite  mixtures  (several  separately  prepared 
samples of blood plasma mimics without the HSA and/or fatty acids)- obtained by 1D 1H 
NMR using ‘cpmgesgp’ – were translated into metabolite concentrations and compared 
with  the  known  metabolite  concentration  as  well  as  with  those  obtained  with  the 
‘noesypr1d’ sequence. To obtain the correct metabolite concentration, i.e. to correct for 
the excitation sculpting profile and for (small) signal reduction due to CPMG sequence, 
correction factors were applied to the signals of the 1D 1H NMR spectra recorded with 
the ‘cpmgesgp’ sequence; the correction factors were calculated as the ratio of resonance 
integrals  of  ‘noesypr1d’ and  ‘cpmgesgp’ sequence  average  over  3  samples  of  pure 
metabolite mixtures. 
To establish the quality/correctness of the NMR concentration determinations we first 
compared in these pure metabolite mixtures the NMR measured metabolite concentration 
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via ‘noesypr1d’ (and ‘presaturation 1d’, data not shown) with the real known metabolite 
concentration (Table S2, Figure S1a). We find a high correlation between measured and 
total  concentration  (Figure  S1a,  correlation  coefficient  ~1);  over  the  3  samples,  the 
relative standard deviation is ~10% for high metabolite concentration values and reaches 
for small metabolite concentration value a minimum of ~ 10  µM; similar numbers are 
obtained for the relative and absolute deviations with respect to the total concentration. 
These to that obtained earlier in our previous study [5]. 
The ES-profile water suppression can be obtained by simulation or as we did here 
experimentally. We took for this  - for a number of pure metabolite mixtures - the average 
ratios  of  the  metabolite  concentrations  from  1D  1H  NMR  spectra  recorded  with  a 
‘noesypresat’ sequence over the metabolite concentrations from 1D 1H NMR recorded 
with ES water suppression alone. The experimental ES water suppression thus obtained is 
displayed in Figure S1b. We first note that the profile is similar to that obtained earlier 
when we compared ES water suppression with straightforward presaturation (composite 
pulse) to suppress the water [5]. Note further that indeed only within 1 ppm of the center 
significant signal suppression still occurs. 
As mentioned above, to obtain the correct metabolite concentration from 1D 1H NMR 
spectra recorded with ‘cpmgesgp’ sequence, thus where in addition to ES suppression 
also a T2-filter (CPMG) is active, correction factors need to be applied; these correction 
factors were calculated as the ratio of resonance integrals of ‘noesypr1d’ and ‘cpmgesgp’ 
sequence averaged over 3 samples of pure metabolite mixtures. Because the ‘noesypr1d’ 
sequence gives the correct total metabolite concentration (Figure S1a), application to the 
concentrations derived from the ‘cpmgesgp’ sequence should also lead to correct overall 
concentrations. The final ‘cpmgesgp’ correction factor values are shown in Figure S1b. 
Note that the CPMG associated correction factors are less then ~+/-30 %.
The  correction  factors  for  thus  obtained  were  tested  on  two  sets  of  other  freshly 
prepared samples of pure metabolite mixture (these were prepared to ultimately be used 
for the myristate and stearate interaction studies; the results are shown Figures S2 and 
S3). Most signals were found to be highly reproducible and correct concentrations were 
obtained.  We  find  that  the  error  in  the  concentration  estimate  is  ~  15  %  (mostly 
integration  error)  for  the  higher  concentration  and  for  the  lower  concentrations  the 
absolute error reaches a plateau of ~ 17 µM. 
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Table S2 Testing of metabolite concentration determination from 1D 1H NMR spectra recorded  
with a pulse sequence with NOESY presaturation (3 pure metabolite mixtures). The metabolite  
concentrations, determined  from 1D 1H NMR spectra recorded with the ‘noesypr1d’ sequence  
for  3  samples  of  pure  metabolite  mixtures,  were  compared with  the  known total  metabolite  
concentration in the pure metabolite mixture (see also text description with regard to relative  
and absolute error size; vertical error bars indicate the error). 
Metabolite 
Chemical Shift
(ppm)
Center  
Integral
Normal HMDB 
concentration  
(µM)
(and as used in  
samples)
NMR measured 
Metabolite  
Concentration
(uM) ‘noesypr1d’
Average of 3 pure 
metabolite  
mixtures
Stdev
(µM)
Stdev
(%)
Nr
(see 
Fig 
S2)
Name
1 L-leucine 0.96 158.5 151 1 1
2 L-valine 1.03 230.5 226
3 Lactate/L-
threonine
1.34 1510 1535 139 9
4 L-alanine 1.47 333 357 0 0
5 L-arginine/L-
leucine/L-lysine
1.70 189.5 192 2 1
6 acetate 1.90 30 55 2 3
7 citrulline/L-
arginine/L-lysine
1.91 189.5 328 7 2
8 pyruvate 2.37 18 21 1 6
9 Glutamine 
(oxoglutarate)
2.45 611.5 622 4 1
10 citrate 2.55 88 80 5 6
11 L-lysine 3.02 189.5 229$1 2 1
12 creatinine/L-lysine 3.04 66 85 1 1
13 citrulline/L-
histidine/L-
phenylalanine
3.13 70 76 7 9
14 L-threonine 3.58 150 190 19 10
15 L-valine 3.61 230.5 269 18 7
16 L-asparagine/L-
histidine/L-
phenylalanine
3.98 70 87 23 26
17 creatinine 4.05 66 63 13 20
18 lactate 4.11 1510 1437 139 9
19 L-threonine 4.25 150 174 73 41
20 A-glucose$2 5.23 1620 1683 278 16
21 L-histidine 7.06 86 91 2 2
22 L-phenylalanine 7.37 60.5 63 1 1
23 L-histidine 7.79 86 91 2 3
$1L-lysine resonance appears at this ppm position to overlap and was not further considered;  
$2The D-glucose consists of A-glucose with a signal 5.23 ppm (concentration 1620 µM) and B-
glucose at 4.66 ppm (concentration ~2900 µM); the latter is too close to the H2O signal to give  
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reliable concentration  values and was not further considered; the A-glucose signal at 5.23 ppm  
leads apparently to correct concentrations when recorded with the ‘noesypr’ sequence (see this  
Table S2 above), but requires significant correction when excitation sculpting is employed for  
water suppression and is then less reliable for concentration quantification (see below). 
Figure  S1a Testing  of  metabolite  concentration  determination  from  1D  1H  NMR  spectra  
recorded with a pulse sequence with NOESY presaturation (3 pure metabolite mixtures). The  
metabolite  concentrations  were  determined  from  1D  1H  NMR  spectra  recorded  with  the  
‘noesypr1d’ sequence for 3 samples of pure metabolite mixtures. They were compared with the  
known total metabolite concentration in the pure metabolite mixture (see also text description  
with regard to relative and absolute error size; vertical error bars indicate the error). 
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Figure S1b Correction factors to compensate for the effect of Excitation Sculpting and CPMG  
T2-filtering  to  obtain  correct  metabolite  concentration.  The  correction  faction  factors  were  
obtained by comparing for a number of pure metabolite mixtures the concentrations obtained  
using the ‘cpmgesgp’ pulse sequence and the ‘noesypr1d’ pulse sequence, as described above.
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Figure  S2a Testing  of  metabolite  concentration  determination  from  1D  1H  NMR  spectra  
recorded with a pulse sequence with Excitation Sculpting and CPMG T2-filtering (stearate pure  
metabolite mixture samples). The metabolite concentrations were determined from 1D 1H NMR  
spectra recorded with the ‘cpmgesgp’ sequence for a number of  samples of  pure metabolite  
mixtures and employing the average correction factors of Figure S1. They were compared with  
the  known  total  metabolite  concentration  in  the  pure  metabolite  mixture  (see  also  text  
description with regard to relative and absolute error size).
[see below Figures S2b and S3]
III Overview of concentration effects of HSA, fatty acid (stearate and myristate), 
and dilution on the free concentration of all metabolites in the plasma 
mimic
The binding capacity of HSA for metabolites and how myristate and stearate affect  
HSA-metabolite interactions.
In Figures S4 and S6 is given for all measured metabolites in the plasma mimic their 
free concentration in (1) the metabolites mixture itself, (2) in the presence of HSA, and 
(3) then at different mole ratio of myristate-HSA (Figure S4) and stearate-HSA (Figure 
S6). The data for the control samples (fatty acid volume replaced by PBS to account for 
dilution effect) are given in Figure S5 (myristate, control) and S7(stearate, control). In the 
controls the volume of myristate and stearate were replaced by phosphate buffer saline 
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(PBS) (see in the paper and Table S2). The data in the figures represent the average value 
for 3 measurements and their corresponding standard deviation. The data indicates that in 
the presence of HSA, acetate, citrate, creatinine, lactate, leucine, lysine and phenylalanine 
show a reduction in their free concentration. Therefore, HSA binds these molecules. The 
free concentration increases with increasing fatty acid-HSA mole ratio and/or dilution 
factor.  Citrate shows no increase in free concentration upon increased fatty acid-HSA 
ratio. Lactate shows the strongest increase in free concentration in the presence of fatty 
acids. Note that threonine and valine signals display a slight increase instead reduction in 
free concentration upon addition of HSA is present; this has to do with HSA signals that 
are not filtered out completely and contribute to their integration. 
[see below Figures S4 – S7]
IV Citrate titration: how an increase in the citrate concentration affects the free 
concentration of citrate and some selected metabolites in the 
presence/absence of HSA and how this is affected by addition of fatty 
acid (stearate and myristate) and by dilution.
Titration of citrate into the metabolite mixture (1) with stearate and HSA present in 
stearate-HSA ratios ranging from 1:1 to 6:1 (test samples) and (2) as (1) with stearate 
volume replaced with PBS buffer (control samples); the free citrate concentration (a) and 
the free concentration of lactate, phenylalanine and pyruvate (b) are followed.
a) The free citrate concentration as a function of the total citrate concentration provides 
an indication of the stoichiometry of the citrate-HSA binding. 
b) The free citrate titration curves for in the test samples and control samples at the 
different stearate-HSA ratios indicate whether dilution and/or stearate addition affects the 
binding citrate to HSA. 
c) Lactate, phenylalanine and pyruvate concentrations are used to establish whether 
an increase of citrate concentration in the different fatty acids-HSA mole ratios has 
any influence on the free concentration of the other metabolites (i.e. releases them 
from HSA).
[see below Figures S8 – S15]
156
Chapter 4 - Myristate and Stearate Differently Release Metabolites from Human Serum Albumin
Fi
gu
re
 S
2b
 T
es
tin
g 
of
 m
et
ab
ol
ite
 c
on
ce
nt
ra
tio
n 
de
te
rm
in
at
io
n 
fro
m
 1
D
 1
H
 N
M
R 
sp
ec
tr
a 
re
co
rd
ed
 w
ith
 a
 p
ul
se
 s
eq
ue
nc
e 
w
ith
 E
xc
ita
tio
n 
Sc
ul
pt
in
g 
an
d 
C
PM
G
 T
2-
fil
te
ri
ng
 (s
te
ar
at
e 
pu
re
 m
et
ab
ol
ite
 m
ix
tu
re
 s
am
pl
es
). 
Th
e 
m
et
ab
ol
ite
 c
on
ce
nt
ra
tio
ns
 w
er
e 
de
te
rm
in
ed
 fr
om
 1
D
 1
H
 N
M
R 
sp
ec
tr
a 
re
co
rd
ed
 w
ith
 t
he
 ‘
cp
m
ge
sg
p’
 s
eq
ue
nc
e 
fo
r 
a 
nu
m
be
r 
of
 s
am
pl
es
 o
f 
pu
re
 m
et
ab
ol
ite
 m
ix
tu
re
s 
an
d 
em
pl
oy
in
g 
th
e 
av
er
ag
e 
co
rr
ec
tio
n 
fa
ct
or
s o
f F
ig
ur
e 
S1
. 
N
ot
e 
th
at
 A
-g
lu
co
se
 a
t 5
.2
3 
pp
m
 n
ea
r t
he
 w
at
er
 si
gn
al
 is
 st
ill
 si
gn
ifi
ca
nt
ly
 u
nd
er
es
tim
at
ed
 in
 th
es
e 
te
st
s.
157
SUPPLEMENTARY MATERIALS
Fi
gu
re
 S
3 
Te
st
in
g 
of
 m
et
ab
ol
ite
 c
on
ce
nt
ra
tio
n 
de
te
rm
in
at
io
n 
fro
m
 1
D
 1
H
 N
M
R 
sp
ec
tr
a 
re
co
rd
ed
 w
ith
 a
 p
ul
se
 se
qu
en
ce
 w
ith
 E
xc
ita
tio
n 
Sc
ul
pt
in
g 
an
d 
C
PM
G
 T
2-
fil
te
ri
ng
 (m
yr
is
ta
te
 p
ur
e 
m
et
ab
ol
ite
 m
ix
tu
re
 sa
m
pl
es
 w
er
e 
us
ed
 h
er
e)
. T
he
 m
et
ab
ol
ite
 c
on
ce
nt
ra
tio
ns
 w
er
e 
de
te
rm
in
ed
 fr
om
 1
D
 1
H
 
N
M
R 
sp
ec
tr
a 
re
co
rd
ed
 w
ith
 th
e 
‘c
pm
ge
sg
p’
 se
qu
en
ce
 fo
r a
 n
um
be
r o
f s
am
pl
es
 o
f p
ur
e 
m
et
ab
ol
ite
 m
ix
tu
re
s a
nd
 e
m
pl
oy
in
g 
th
e 
av
er
ag
e 
co
rr
ec
tio
n 
fa
ct
or
s o
f F
ig
ur
e 
S1
.
158
Chapter 4 - Myristate and Stearate Differently Release Metabolites from Human Serum Albumin
Fi
gu
re
 S
4 
M
yr
is
ta
te
 ti
tr
at
io
n 
(te
st
 s
am
pl
es
). 
Th
e 
m
et
ab
ol
ite
s 
ar
e 
ar
ra
ng
ed
 h
or
iz
on
ta
lly
 a
s 
in
 fi
gu
re
s 
S2
b 
to
 S
3.
 T
he
 tw
o 
fir
st
 c
ol
um
ns
 fr
om
 le
ft 
to
 
ri
gh
t, 
fo
r e
ac
h 
m
et
ab
ol
ite
 si
gn
al
, a
re
 fo
r t
he
 m
et
ab
ol
ite
 m
ix
tu
re
 a
nd
 th
e 
m
et
ab
ol
ite
 m
ix
tu
re
 in
 th
e 
pr
es
en
ce
 o
f H
SA
. T
he
 la
st
 si
x 
ar
e 
fro
m
 le
ft 
to
 ri
gh
t 
fo
r t
he
 m
et
ab
ol
ite
 m
ix
tu
re
 w
ith
 m
yr
is
ta
te
 a
nd
 H
SA
 p
re
se
nt
 in
 m
ol
e 
ra
tio
s 1
, 3
, 5
, 7
, 9
 a
nd
 1
1.
159
SUPPLEMENTARY MATERIALS
Fi
gu
re
 S
5 
M
yr
is
ta
te
 ti
tr
at
io
n 
(c
on
tro
l s
am
pl
es
). 
Th
e 
m
et
ab
ol
ite
s a
re
 a
rr
an
ge
d 
as
 in
 fi
gu
re
s S
2b
 to
 S
3.
 T
he
 tw
o 
fir
st
 c
ol
um
ns
 fr
om
 le
ft 
to
 ri
gh
t, 
fo
r 
ea
ch
 m
et
ab
ol
ite
 si
gn
al
, a
re
 th
e 
m
et
ab
ol
ite
s m
ix
tu
re
, t
he
 m
et
ab
ol
ite
s m
ix
tu
re
 in
 th
e 
pr
es
en
ce
 o
f H
SA
. T
he
 la
st
 si
x 
ar
e 
fro
m
 le
ft 
to
 ri
gh
t t
he
 c
on
tro
ls
 
fo
r m
yr
is
ta
te
-H
SA
 m
ol
e 
ra
tio
s 1
, 3
, 5
, 7
, 9
an
d 
11
, i
n 
th
e 
pr
es
en
ce
 o
f t
he
 m
et
ab
ol
ite
s m
ix
tu
re
. I
n 
th
e 
co
nt
ro
ls
 th
e 
vo
lu
m
e 
of
 m
yr
is
ta
te
 w
as
 re
pl
ac
ed
 b
y 
ph
os
ph
at
e 
bu
ffe
r s
al
in
e 
(P
BS
), 
so
 a
s t
o 
ac
co
un
t f
or
 th
e 
di
lu
tio
n 
fa
ct
or
s t
ha
t w
er
e 
at
 m
ol
e 
ra
tio
 1
 =
 1
.0
4,
 3
 =
 1
.5
4,
 5
 =
 2
.0
4,
 7
 =
 2
.5
4,
 9
 =
 3
.0
4,
 1
1 
=
 
3.
54
.
160
Chapter 4 - Myristate and Stearate Differently Release Metabolites from Human Serum Albumin
Fi
gu
re
 S
6 
St
ea
ra
te
 ti
tr
at
io
n 
(te
st
 s
am
pl
es
). 
Th
e 
m
et
ab
ol
ite
s 
ar
e 
ar
ra
ng
ed
 h
or
iz
on
ta
lly
 a
s 
in
 fi
gu
re
s 
S2
b 
to
 S
3.
 T
he
 tw
o 
fir
st
 c
ol
um
ns
 fr
om
 le
ft 
to
 
ri
gh
t, 
fo
r e
ac
h 
m
et
ab
ol
ite
 si
gn
al
, a
re
 th
e 
m
et
ab
ol
ite
s m
ix
tu
re
, t
he
 m
et
ab
ol
ite
s m
ix
tu
re
 in
 th
e 
pr
es
en
ce
 o
f H
SA
. T
he
 la
st
 si
x 
ar
e 
fro
m
 le
ft 
to
 ri
gh
t t
he
 
st
ea
ra
te
-H
SA
 m
ol
e 
ra
tio
s 1
, 2
, 3
, 4
, 5
 a
nd
 6
, i
n 
th
e 
pr
es
en
ce
 o
f t
he
 m
et
ab
ol
ite
s m
ix
tu
re
.
161
SUPPLEMENTARY MATERIALS
Fi
gu
re
 S
7 
St
ea
ra
te
 ti
tr
at
io
n 
(c
on
tro
l s
am
pl
es
). 
Th
e 
m
et
ab
ol
ite
s 
ar
e 
ar
ra
ng
ed
 h
or
iz
on
ta
lly
 a
s 
in
 fi
gu
re
s 
S2
b 
to
 S
3.
 T
he
 tw
o 
fir
st
 c
ol
um
ns
 fr
om
 le
ft 
to
 r
ig
ht
, f
or
 e
ac
h 
m
et
ab
ol
ite
 s
ig
na
l, 
ar
e 
th
e 
m
et
ab
ol
ite
s 
m
ix
tu
re
, t
he
 m
et
ab
ol
ite
s 
m
ix
tu
re
 in
 th
e 
pr
es
en
ce
 o
f H
SA
. T
he
 la
st
 s
ix
 a
re
 fr
om
 le
ft 
to
 r
ig
ht
 
th
e 
co
nt
ro
ls
 fo
r s
te
ar
at
e-
H
SA
 m
ol
e 
ra
tio
s 
1,
 2
, 3
, 4
, 5
 a
nd
 6
, i
n 
th
e 
pr
es
en
ce
 o
f t
he
 m
et
ab
ol
ite
s 
m
ix
tu
re
. I
n 
th
e 
co
nt
ro
ls
 th
e 
vo
lu
m
e 
of
 st
ea
ra
te
 w
as
 
re
pl
ac
ed
 b
y 
ph
os
ph
at
e 
bu
ffe
r s
al
in
e 
(P
BS
), 
so
 a
s t
o 
ac
co
un
t f
or
 th
e 
di
lu
tio
n 
fa
ct
or
s t
ha
t w
er
e 
at
 m
ol
e 
ra
tio
 1
 =
 1
.5
7,
 2
 =
 2
.3
, 3
 =
 3
.0
3,
 4
 =
 3
.7
8,
 5
 
=
 4
.5
1,
 6
 =
 5
.2
4.
162
Chapter 4 - Myristate and Stearate Differently Release Metabolites from Human Serum Albumin
Figure S8 Plots of the free concentration of citrate as function of the total citrate 
concentration in samples of stearate-HSA mole ratios 1:1 to 6:1 in the test samples (filled 
shaped markers) or control samples (stearate replaced by PBS buffer; effect of dilution 
alone; crosses and star markers). At the different stearate-HSA mole ratios the associated 
dilution factors are: 1 = 1.57, 2 = 2.3, 3 = 3.03, 4 = 3.78, 5 = 4.51, 6 = 5.24. The free and 
total citrate concentrations are given in units of [HSA] (0.6 mM). The notations Sample1, 
Sample2, and Sample3 stand for the test samples, i.e. the metabolite mixtures with stearate 
and HSA added (with stearate:HSA mole ratio as given in the title) and Control1, 
Control2, and Control3 stand for the control samples, i.e. the mixtures where the volume of 
stearate was replaced by phosphate buffer saline (to account for the effect of dilution in the 
test samples). Finally (1), note that when the total citrate concentration is above ~2 the 
free and total citrate concentration increase more or less linearly; the corresponding trend 
line extrapolates to a total citrate concentration value of ~1 at a free citrate concentration 
of 0; thus, the stoichiometry of the citrate binding to HSA is ~1. Finally (2), the titration 
curves of the citrate in test and control are essentially overlapping for all stearate-HSA 
ratios and dilution factors, showing that stearate addition and dilution has a limited effect 
on the citrate binding. This observation points to a strong citrate-HSA interaction and that 
stearate does not replace citrate.
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Figure S9 Citrate titration as in Figure S8: Lactate free fraction concentration against 
total citrate concentration. Sample1, Sample 2, and Sample3 represent as before the test 
samples that contain stearate and HSA in the different stearate:HSA mole ratios and 
Control1, Control2, and Control3 are the control samples in which the volume of 
stearate was replaced by PBS (phosphate buffer saline) to account for effect of dilution 
always associated with increasing the stearate-HSA ratio.
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Figure S10 Citrate titration as in Figure S8: Phenylalanine free fraction concentration 
against increase in total citrate concentration. 
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Figure S11 Citrate titration in as Figure S8: Pyruvate free fraction concentration 
against increase in total citrate concentration.
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Figure S12 Plots of citrate free fraction concentration as function of the total citrate 
concentration in samples of myristate-HSA mole ratio 1:1 to 11:1 (filled shaped 
markers) or dilution factor (crosses and star markers), the dilution factors were at 
mole ratio 1 = 1.04, 3 = 1.54, 5 = 2.04, 7 = 2.54, 9 = 3.04, 11 = 3.54. 
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Figure S13 Citrate titration as Figure S12: Lactate free fraction concentration 
against increase in total citrate concentration.
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Figure S14 Citrate titration as Figure S12: Phenylalanine free fraction concentration 
against increase in total citrate concentration.
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Figure S15 Citrate titration as in Figure S12: Pyruvate free fraction concentration 
against increase in total citrate concentration.
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CHAPTER 5
Prostatic Fluid Mimic: Metabolite Interactions revealed by 1H NMR
Marc Jupin, Sybren Wijmenga, Arend Heerschap
In preparation
ABSTRACT
The composition  of  prostatic  fluid  may change  during the  development  of  cancer. 
Some major components of this fluid are the metabolites,  spermine, citrate and myo-
inositol, which may interact with each other depending on the composition of the fluid. 
To  study these  interactions  we investigated  a  prostatic  fluid  mimic  by  1D  1H NMR 
spectroscopy  using  T2  and  chemical  shift  as  markers  for  binding.  We  showed  that 
spermine and citrate interact and both bind to BSA present in the system. When metallic 
ions, Na+, K+, Ca++, Zn++ and Mg++ are added to the metabolites, the T2 relaxation values 
of citrate and spermine protons are lowered by factors of 3 and 2, respectively. For myo-
inositol, the T2 values decreased with increasing zinc concentration or in the presence of 
BSA. The formation of spermine-metal ion-citrate-BSA complex lowered spermine and 
citrate T2s by factors of 4 and 6, respectively. Citrate is the most affected metabolite in 
the  presence of  BSA and metallic  ions.  During  the  development  of  cancer,  zinc  and 
citrate  concentrations  decrease  while  the  protein  composition  (and  probably 
concentration) changes, hence it is expected that the T2 relaxation of citrate changes as a 
result of mutual binding.
Keywords: Prostatic fluid, Prostate cancer, Metabolites, Metal ions, Bovine serum 
albumin (BSA).
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INTRODUCTION
In vivo magnetic resonance spectroscopy (MRS) of the prostate can be used to report 
on metabolites dominant in the intracellular space, e.g. choline and creatine, or in the 
luminal  space,  e.g.  citrate  and  spermine  [1,2].  Ratios  of  these  metabolites  are  often 
employed to assess the severity of prostate cancer (PCa) as expressed in Gleason scores 
[3,4]. About 70 % of prostate cancers arise in the peripheral zone (PZ)  [5], in which 
epithelial cells reside that contribute to prostatic fluid secretions. This is of interest as the 
composition of this fluid changes according to the prostate tissue state, as was shown by 
NMR for  the  concentrations  of  the  main  fluid  metabolites:  citrate,  myo-inositol  and 
spermine [6]. The authors of this paper also found a correlation between the secretion of 
citrate and spermine and suggested that these compounds may occur as a complex. The 
measurement of citrate concentrations has been shown to outperform the prostate specific 
antigen (PSA) test for detecting PCa  [7], especially in the differentiation from benign 
prostatic hyperplasia [8]. Apart from that of citrate, also the prostatic fluid levels of myo-
inositol and spermine are decreased in the presence of PCa [6,9,10].
Metal ions such as Ca++, Mg++ or Zn++ affect the proton NMR signals of citrate and 
spermine  [11,12].  In  particular  the  effect  of  zinc  on the  citrate  chemical-shift  and J-
coupling may be relevant as the zinc concentration (9 mM in healthy volunteers) has been 
shown to be 90-95 % lower in both prostatic tissue and in prostatic fluid of PCa patients 
[13,14].  And a colorimetry test  for  prostate  cancer  based on zinc concentration from 
expressed prostatic  fluid  has  been proposed  [15].  Free  proteins  are  another  group of 
molecules that are produced by the prostate epithelial cells  [16,17], of which the major 
ones  are:  PSA,  prostatic  acid  phosphatase  and  PSP-94  [18].  Proteomics  and 
transcriptomics studies of transformed epithelial cells in PCa have shown modifications 
in protein expression and mRNA regulation. Thought no proper proteomic quantitative 
studies have been performed for prostatic fluid, it is important to notice that the protein 
content changes in composition and probably in concentration [19–23]. The proton NMR 
properties of spermine are known to be influenced by proteins, metal ions, temperature 
and pH [12]. These conditions also affect proton NMR parameters of citrate [11,24].
All in vitro studies essentially only addressed the interactions of single compounds in 
isolation,  while  in  reality  prostatic  fluid  is  composed  of  a  mixture  of  compounds. 
Therefore, in this study, we examined how the NMR signals of citrate,  spermine and 
myo-inositol,  are  influenced  by  metal  ions  and  protein  concentrations  in  a  mixture 
mimicking the composition of prostatic fluid. We used BSA to mimic its protein content. 
This  approach  should  reveal  to  what  extent  the  formation  of  complexes  affects  the 
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metabolites  signals.  Moreover,  changes  in NMR parameters  of  metabolites  associated 
with  tumor  conditions  (e.g.,  when  zinc  concentration  becomes  lower)  could  provide 
handles for MRS diagnostics of PCa. In addition, as signal shape and integral, in MRS, 
depend on the echo time of the pulse sequence and the estimated T2, a change in NMR 
properties may affect these signals. If for instance, the citrate T2 severely drops due to 
physiological interactions, then modification in the timing and design of pulse sequences 
may be desirable for optimal assessments.
METHODS
Sample preparation
All  products  were  obtained  from  Sigma-Aldrich.  Stock  solutions  of  spermine 
tetrahydrochloride (C10H26N4, 4HCl), myo-inositol (C6H12O6), tri-sodium citrate dihydrate 
(HOC(COONa)(CH2COONa)2, 2H2O), zinc di-chloride (ZnCl2), calcium di-chloride di-
hydrated (CaCl2, 2H2O), magnesium di-chloride (MgCl2) and potassium chloride (KCl) 
were all dissolved in MiliQ water to reach a final concentration of 253.8 mM, 528.5 mM, 
581.3  mM,  1467  mM,  1360.4  mM,  2100.6  mM,  2682.8  mM,  respectively.  Stock 
solutions of spermine tetrahydrochloride, myo-inositol, tri-sodium citrate were stored at 4 
°C. A stock solution of bovine serum albumin (BSA) was prepared in potassium buffer 
saline (PBS, ~0.8% NaCl, salt  concentration of 154 mM, pH of 7.4) to reach a final 
concentration  of  100  g/L  BSA and  was  filtered  using  Millex®  GP 0.22  μm.  The 
concentration was measured with a Cary300 spectrophotometer using an absorbance of 
6.5 for 1% solution of protein at 280 nm. The buffered protein solution was stored at 4 
°C, if not used immediately.
Spermine tetrahydrochloride, myo-inositol, tri-sodium citrate, calcium di-chloride di-
hydrated, magnesium di-chloride and potassium chloride had a final concentration of 18 
mM, 11 mM, 90 mM, 18 mM, 15 mM, 61 mM, respectively, according to the average 
cation composition of expressed human prostatic fluid  [25]. Zinc di-chloride and BSA 
were used at different concentrations (see Result section). Each sample contained 10% 
D2O for an NMR lock signal and the rest was MiliQ water (samples were not buffered 
with  PBS  as  precipitations  are  formed).  The  pH  was  adjusted  to  7.1  ±  0.05  using 
concentrated HCL and NaOH. All samples were measured after 12 hours of equilibrium.
NMR spectroscopy
The 600 μL samples of different composition were measured in 5 mm NMR tubes on a 
Bruker Avance III spectrometer operating at 500 MHz and equipped with a Bruker smart 
probe BBO 500 MHz S2. The 1D 1H NMR spectra were all recorded at 298 K using a 
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simple pulse acquire sequence: RD - 30° - acquisition. After a relaxation delay (RD), a 1H 
30°  excitation  pulse  was  applied  followed by acquisition.  Acquisition  and  relaxation 
delays were set to 5 s and 6 s, respectively. For T2 measurements a CPMG sequence was 
used: RD – cw1 – cw2 – 90° -(t1 – 180° - t1 – 180° - t1)n – acquisition. RD was set to 2 
s, cw1 and cw2 are water saturation pulses applied for 3 s each, followed by a 90°. The  
CPMG block was repeated n times with a t1 delay of 100 µs. The n values were 119, 238,  
357, 476, 595, 714, 833, 952, 1071, 1190, 1310, 1429 and 1548. Pulse calibrations were 
done for each sample to assure proper quantification and the gain value was fixed to 
assure  comparison  between  spectra.  The  1D  1H NMR spectra  were  processed  using 
Bruker  Topspin  1.2  and  ACDlabs  12.0.  Processing  involved  apodisation,  phasing, 
baseline  correction (the baseline was constructed by taking the first  16 points  of  the 
FID.), peak picking and integration. The T2 slopes were fitted using a mono-exponential 
equation, Intensity(t) = A exp(t/T2), in Matlab (Math Works) R2010a.
RESULTS
The one dimensional 1H NMR spectra of the prostatic fluid mimic as measured at 500 
MHz  showed  clearly  resolved  signals  for  the  selected  metabolites  (Figure  1).  The 
spermine proton signals at 3.1 ppm were assigned using 2D 1H/13C NMR at 800 MHz at 
pH 9.4. As shown previously this pH gives a better separation of spermine signals [12]. 
This revealed that the furthest left signal at 3.1 ppm (down field) belong to spermine 
protons labeled 1 (spm1) (see Figure 1 and Supplementary materials). As inflammation 
can  rise  the  prostate  temperature,  we  followed  the  spectral  profile  of  spermine  as  a 
function of temperature. It was observed that all spermine signals shift to the left (0.01-
0.02 ppm down field with respect to TSP), when the temperature is increased from 37 to 
42 °C (Supplementary materials).
To quantify the effect of interactions on the different metabolite signals we measured 
the  T2,  peak  area,  peak  height,  chemical  shift  and  J-coupling  in  different  mixtures. 
Though all these parameters can be used to identify interactions, the relaxation rates are 
most valuable because they are most sensitive to binding [26]. In terms of interaction, we 
expected to observe fast-exchange regime profiles because the BSA concentration was 15 
times less than the metabolite concentrations, (fraction free metabolites >> binding sites). 
And because there may be more than one binding site the measured T2 will be an average 
value.
Different  solution  compositions  were  made  by  mixing  the  metabolites  with  (a) 
inorganic  ions,  commonly  found  in  the  prostatic  fluid,  (b)  a  variety  of  zinc 
concentrations, as this metal ion is known to be essential in characterizing PCa, and (c)  
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the protein BSA to determine the effect of unspecific binding to prostatic fluid proteins 
(BSA was used as an index protein).
Figure 1 1D 1H NMR spectrum obtained at 500 MHz of the prostatic fluid mimic at 298 K. The  
labeling of the protons on the molecules correspond to the numbers at the end of  the signal  
abbreviations  -  cit:  citrate;  myo:  myoinositol;  spm:  spermine.  Citrate  doublets  are  labeled  
cit_down and cit_up to represent the doublets resonating downfield and upfield, respectively.
T2 relaxation
The T2 relaxation times calculated for the different spermine or myo-inositol signals in 
the NMR spectrum differed by less than a factor of 2 for the different solution condition 
tested.  To study the  effect  of  solution  components  we  chose for  spermine  and myo-
inositol the multiplets at 1.77 ppm (spm5) and 4.05 ppm (myo5), respectively, as their 
T2s are most sensitive to interactions, their resonance positions are rather isolated and 
their scalar couplings are small. Citrate downfield doublet (cit_down) and upfield doublet 
(cit_up) signals have T2 values that are not equal. The cit_up signals could not be fitted 
for a T2 calculation in some mixtures containing zinc and protein as the signals became 
negative with long echo time. The latter mixtures contained: 4 mM zinc and 50 g/L BSA, 
9 mM zinc and 30 g/L BSA, and 9 mM zinc and 50 g/L BSA (Figure 2). Therefore, we 
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focused on the T2 relaxation time as derived for the signals of cit_down, myo5 and spm5.
Figure 2 Part of the 1H NMR spectra of prostate fluid mimic showing only the citrate signals.  
The spectra were obtained with a CPMG sequence with an echo time of 0.63 s. The spectra are  
from samples with the following composition (a) metabolites mixture of citrate, myo-inositol and  
spermine (met_mix) [27]; (b)  met_mix and all metallic ions with Zn at 9 mM [25]; (c) met_mix  
and all metallic ions with Zn at 4 mM and 50 g/L BSA [1]; (d) met_mix and all metallic ions  
with Zn at 9 mM and 5 g/L BSA [22]; (e) met_mix and all metallic ions with Zn at 9 mM and 15  
g/L BSA [2]; (f) met_mix and all metallic ions with Zn at 9 mM and 30 g/L BSA [1]; (g) met_mix  
and all metallic ions with Zn at 9 mM and 50 g/L BSA [2]. Metallic ions are: Ca++, Mg++, K+,  
Na+ and Zn++. The number in square bracket (e.g., [2]) indicates the vertical expansion of each  
spectral region with respect to spectrum (c). myo5 was used as chemical shift reference at 4.05  
ppm.
First  we  mixed  individually  citrate,  myo-inositol  and  spermine  at  constant 
concentration to metallic ions (Ca++, Mg++, K+ and Na+ were at constant concentration, 
while Zn++ was increased) (Figure 3a). Then BSA was added to the mixtures (Figure 3c).  
We focused on zinc as it has been shown to be the most relevant metal ion in prostate  
cancer diagnosis [15,27,28]. Citrate T2 decreases as zinc concentrations increases, while 
spermine T2 stays relatively constant at ~0.66 s before dropping by a factor of 2 at 9 mM 
of zinc. On addition of 15 g/L of BSA the T2 of citrate and spermine in the different  
mixtures  drops  by factors of  6  and 3,  respectively.  Myo-inositol  T2 decreases as  the 
concentration of zinc increases. Interestingly, myo-inositol signal in the absence of metal 
ions is broad, we explain this phenomenon in the discussion section. 
ppm
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b
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g
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Figure 3 T2 relaxation times of citrate (cit_up), myo-inositol (myo5) and spermine (spm5). The  
metabolites are measured individually (a,c) or mixed (b,d). The x-axis represents the presence of  
metal ions calcium, magnesium, potassium, sodium and zinc. Zinc concentration was varied. In c  
and d, 15 g/L BSA was added.
Secondly, mixtures of two metabolites were prepared: spermine and citrate, spermine 
and myo-inositol, and citrate and myo-inositol. Spermine T2 value decreased to ~0.37 s 
in the presence of citrate (Table 1). Myo-inositol does not affect the T2 of spermine and 
citrate. However, myo-inositol T2 value is slightly lower in the presence of citrate than 
spermine (Table 1).
Thirdly,  a  metabolite  mixture  of  citrate,  myo-inositol  and spermine  (met_mix)  was 
prepared. In the latter mixture Spermine T2 value dropped to ~0.37 s (Figure 3b). Then 
met_mix  was  mixed  with  metal  ions  with  increasing  zinc  concentration.  Citrate  T2 
decreases  with  increasing  zinc  concentration,  while  spermine  T2  stayed  relatively 
constant before further dropping to ~0.17 s (factor of 2 lower) at [Zn] of 9 mM (Figure 
3b). Similar to spermine, myo-inositol T2 stayed constant at ~0.88 s with increasing zinc 
concentration and then decrease to ~0.44 s at 9 mM zinc.
Forth, we incorporated BSA in the above preparations. We observed again a drop in T2 
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values for the metabolite spin systems (Figure 3d). Spermine T2 is slightly lower in the 
met_mix (~0.16 s) than when not mixed with other metabolites (~0.26 s).
Table  1 T2 values of spermine (spm5), citrate (cit_down) and myo-inositol (myo5) in different  
sample compositions.
Signals
Metal ions BSA (g/L) Spm5 Cit_down Myo5
N
ot
 m
ix
ed
 m
et
ab
ol
ite
s No ions
0
0.657 0.719 0.338
ions,no Zn 0.669 0.543 1.029
ions,[Zn]=4mM 0.663 0.493 0.440
ions,[Zn]=9mM 0.303 0.224 0.434
No ions
15
0.246 0.179 0.355
ions,no Zn 0.278 0.157 0.382
ions,[Zn]=9mM 0.241 0.110 0.412
M
ix
ed
 M
et
ab
ol
ite
s
spm+cit
0
0.372 0.720
spm+myo 0.661 1.079
cit+myo 0.823 0.828
No ions 0.372 0.721 0.894
ions,no Zn 0.363 0.468 0.897
ions,[Zn]=4mM 0.370 0.404 0.854
ions,[Zn]=9mM 0.173 0.190 0.437
No ions 15 0.165 0.188 0.422
io
ns
,n
o 
Zn 5 0.167 0.187 0.434
15 0.163 0.158 0.429
30 0.156 0.134 0.440
50 0.148 0.114 0.417
5 0.172 0.166 0.417
15 0.166 0.132 0.424
30 0.160 0.104 0.437
50 0.152 0.082 0.423
5 0.166 0.156 0.434
15 0.163 0.121 0.415
30 0.158 0.093 0.417
50 0.153 0.069 0.416
io
ns
,
[Z
n]
=4
m
M
io
ns
,
[Z
n]
=9
m
M
Finally, we note that cit_up is quite sensitive to variation in both zinc or BSA 
concentration (Figure 4b). Its T2 drops by a factor of ~2 either when increasing BSA 
from 5 to 50 g/L or increasing metal ion concentration (Figure 4b). Myo-inositol and 
spermine, on the other hand, showed relatively little change with respect to variation in 
BSA and zinc concentration (Figure 4a,c).
Peak Intensity and Integral
To better appreciate the changes of peak intensity or integral we normalized our data 
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relative to the metabolite peaks from the mixture containing no metal ions and BSA. The 
spectrum baseline was made from the first 16 points of the FID to remove the broad 
signals from BSA.
5 15 30 50
0.050
0.100
0.150
0.200
(a) Mixed Spermine, Myo-inositol and Citrate,
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Figure  4 Combined  effect  of  zinc  and  BSA concentration  on  the  T2  of  mixed  metabolites  
(met_mix). All mixtures contained spermine tetrahydrochloride, myo-inositol, tri-sodium citrate,  
calcium  di-chloride  di-hydrated,  magnesium  di-chloride  and  potassium  chloride  at  
concentrations of 18 mM, 11 mM, 90 mM, 18 mM, 15 mM, 61 mM, respectively. Zinc and BSA  
concentration are given in the figures legend and x-axis, respectively.
The citrate peak height was the most affected, its intensity lowered by ~62% in the 
presence of metal ions. Further decrease (down to 30 %) was observed when mixed with 
both metal ions and 50 g/L BSA (Table 2). Spermine and myo-inositol showed a decrease 
in peak height of 79% and 54% respectively, in the presence of metal ions with 4 mM 
zinc and 50 g/L BSA.
Normalized integral values of the metabolite signals showed no changes upon different 
sample  compositions  (Table  3).  This  conclusively  shows  that  peak  height  changes 
observed are related to changes in peak width and thus changes in T2-times.
Table 2 Intensities normalized relative to metabolites peaks of mixture without metal ions and  
BSA.
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Signals intensities
BSA (g/L) Spermine Citrate
No ions
0
1.00 1.00 1.00
ions,no Zn 0.94 0.63 0.87
ions,[Zn]=4mM 0.94 0.63 0.87
ions,[Zn]=9mM 1.05 0.62 0.87
No ions 15 0.98 0.66 0.87
io
ns
,n
o 
Zn
5 1.05 0.60 0.87
15 0.94 0.57 0.87
30 0.94 0.48 0.87
50 0.87 0.45 0.87
5 0.94 0.56 0.87
15 1.05 0.52 0.87
30 0.94 0.46 0.87
50 0.79 0.30 0.54
5 1.05 0.58 0.87
15 1.05 0.51 0.87
30 1.05 0.41 0.87
50 1.02 0.34 0.87
Myo-inositol
io
ns
,
[Z
n]
=4
m
M
io
ns
,
[Z
n]
=9
m
M
Table 3 Integral signal values normalized relative to metabolite peaks of mixture without metal  
ions and BSA.
Signals integrals
BSA (g/L) Spermine Citrate
No ions
0
1.00 1.00 1.00
ions,no Zn 1.02 1.04 0.95
ions,[Zn]=4mM 1.02 1.04 0.95
ions,[Zn]=9mM 1.02 1.03 0.97
No ions 15 1.00 1.02 0.95
io
ns
,n
o 
Zn 5 1.04 1.05 1.02
15 1.01 1.02 1.01
30 0.95 0.97 0.95
50 0.92 0.96 0.98
5 0.99 0.99 0.95
15 1.01 1.02 0.99
30 1.00 1.01 1.00
50 0.97 0.97 1.04
5 1.02 1.01 0.99
15 1.02 1.01 0.99
30 1.02 0.99 1.00
50 0.99 0.97 1.00
Myo-inositol
io
ns
,
[Z
n]
=4
m
M
io
ns
,
[Z
n]
=9
m
M
181
RESULTS
Chemical shift and J-coupling
The presence of BSA in the mixtures made it impossible to use TSP as an internal 
reference, as it binds to BSA [29]. As myo-inositol showed the most stable T2 relaxation 
time in met_mix for all the different preparations, it apparently interacts least with other 
components. Thus, we used the chemical shift of the well isolated signal myo5, as an 
internal reference (Figure 1).  In this analysis we compared the chemical shifts of the 
metabolite peaks from those in the mixtures containing no metal ions and BSA.
Table 4 Chemical shift change in Hz compared to peaks from the sample without metal ions and  
absence of BSA. All samples contain metabolite mixtures of citrate, myo-inositol and spermine.  
The signal myo5 (Figure 1) was used as internal reference.
BSA (g/L) Spm5 Spm2 Cit_down Cit_up Spm3/4 Spm1 Myo2 Myo4/6 Myo1/3
No ions
0
1.79 2.1 2.54 2.64 3.09 3.15 3.28 3.54 3.62 ppm
ions,no Zn -5 -2 1 12 3 2 1 1 0
Hz
ions,[Zn]=4mM -5 -2 1 12 3 2 1 1 0
ions,[Zn]=9mM -6 -3 6 17 2 2 1 1 0
No ions 15 0 0 0 1 0 1 0 0 0
io
ns
,n
o 
Zn
5 -5 -2 1 12 3 2 1 1 0
15 -5 -2 1 12 3 2 1 1 -1
30 -5 -2 0 12 3 2 1 1 -1
50 -4 -2 0 12 2 3 1 1 -1
5 -6 -3 5 17 3 3 1 1 0
15 -6 -3 5 16 2 3 1 1 -1
30 -5 -3 4 16 2 3 1 1 -1
50 -5 -2 3 15 2 3 1 1 -1
5 -7 -3 8 20 3 3 1 1 -1
15 -6 -3 8 20 3 3 1 1 -1
30 -6 -2 7 19 3 3 1 1 -1
50 -5 -2 5 18 3 3 1 1 -1
Signals Chemical shift wrt Myo2
io
ns
,
[Z
n]
=4
m
M
io
ns
,
[Z
n]
=9
m
M
Increased metal ion concentration caused an obvious change in chemical shift of both 
citrate  and  spermine.  Spermine  and  citrate  signals  showed  different  chemical  shift 
changes. The difference between spm5 and spm1/3/4, and cit_down and cit_up were ~10 
Hz. In the presence of 15 g/L BSA, without metal ions, no chemical shift change was 
observed, compared to the mixture free of both metal ions and BSA. Samples containing 
both BSA and metal ions showed a further change in chemical shift of citrate resonances 
as zinc concentration increases.
Overall, the least to most affected metabolite signals were spm1, spm3/4 < spm2 < 
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cit_up < spm5 < cit_down upon increasing metal ion and BSA concentration (Table 4). 
Since  the  citrate  methylene  protons  showed  different  T2  values  it  was  important  to 
compare their J-couplings (Table 5). Upon increasing metal ion and BSA concentration 
the J-coupling increased by 1 Hz (15 to 16 Hz).
Table 5 Difference in chemical shift between citrate methylene and their respective J-coupling  
(Hz).
J-coupling
BSA (g/L) Cit_down Cit_up
No ions
0
64.5 15.1 15.1
ions,no Zn 75.7 15.8 15.7
ions,[Zn]=4mM 76.3 15.9 15.9
ions,[Zn]=9mM 77.0 16.1 16.0
No ions 15 65.2 15.1 15.1
io
ns
,n
o 
Zn 5 76.0 15.8 15.8
15 76.2 15.8 15.8
30 76.7 15.8 15.8
50 77.0 15.8 15.8
5 76.6 15.9 15.9
15 76.7 15.9 15.9
30 77.0 15.9 15.9
50 77.5 15.9 15.9
5 77.1 16.1 16.0
15 77.4 16.0 16.0
30 77.6 16.0 16.0
50 78.0 16.0 16.0
Δδ between 
methylenes
io
ns
,
[Z
n]
=4
m
M
io
ns
,
[Z
n]
=9
m
M
DISCUSSION
The  1H  NMR  spectra  of  prostatic  fluid  mimics  are  similar  to  those  of  prostate 
secretions  previously  measured  by  Lynch  et  al.  [6,30].  These  authors  suggested 
interaction between spermine and citrate, which we demonstrate here using T2 relaxation 
times. In addition, the changes in T2 relaxation suggest that the citrate-spermine complex 
binds to metal ions, such as zinc [31], and interacts with BSA. Other NMR parameters, 
such  as  citrate  peak  chemical  shift,  J-coupling  and  height  were  also  sensitive  to 
interactions, while peak integrals were not affected by any added component.
The T2 values of spermine protons dropped by a factor of 2 when mixed with 90 mM 
citrate,  suggesting  binding  between  spermine  and  citrate.  Moreover,  the  citrate  T2 
relaxation value decreases with increasing bivalent metallic ions indicating that citrate 
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interacts  with  metallic  ions.  Further,  citrate  T2  values  are  lower  in  the  presence  of 
spermine and increasing zinc concentration (Table 1). Overall this strongly suggest the 
formation of a spermine-metal-ion-citrate complex. These observations confirm previous 
studies  showing  that  polyamines,  as  spermine,  stabilize  metal-citrate  complexes  by 
secondary sphere interactions [32,33]. Further, zinc forms a zinc-ligand, as zinc-citrate as 
reviewed by Costello [34], and this is considered the main form of zinc found in biofluids 
either intra- or extra-cellularly. It is under the zinc-ligand form that zinc is involved in 
transport and reactivity (the concept of direct zinc exchange from the zinc-ligand donor 
to  the  acceptor  protein  without  any  requirement  for  the  presence  or  involvement  of 
production of free zinc ions). Previous studies showed that in semen zinc is transferred 
from high molecular weight (HMW) compounds to citrate, and when inorganic phosphate 
is added zinc is transferred from citrate to HMW compounds  [32,33]. This can explain 
the  formation  of  a  precipitate  (e.g.,  zinc-phosphate)  that  we  observed  when  using 
phosphate buffer saline during our trial setup. 
First, to compare the effect of BSA and metallic ions we used mixtures containing 15 
g/L BSA (average protein content in prostatic fluid [35]) and the metal ions included in 
this study, except zinc. Citrate, myo-inositol and spermine bind individually to BSA, with 
T2 values reduced to 0.16, 0.40 and 0.28 s, respectively. When metabolites are mixed, 
spermine T2 is lowered to 0.16 s, while citrate and myo-inositol T2s are more or less the 
same. To explained why spermine T2 decreases but not that of citrate, as they form a 
complex, we refer to the difference in fraction bound and free spermine and citrate, in the 
fast exchange regime [26].
T2obs = T2b∗F b+T2 f∗F f (1)
Here, the observed T2, T2obs, depends on the fraction bound (Fb, spermine-metal ion-
citrate complex) and free (Ff, the individual metabolites); T2b is the T2 in the bound state, 
i.e. in/of the complex, and T2f is the T2 in the free state. Spermine, with its concentration 
being 5 times lower than citrate, will thus be more affected by Fb upon binding (Eq. 1).
Secondly we compared the effect of varying both BSA and zinc concentration. Myo-
inositol  and spermine T2 values are barely affected by a further the increase in BSA 
concentration above 5 g/L and are not affected by increasing zinc concentration. If this 
amount of BSA binds most myo-inositol and spermine (in a spermine-metal-ion-citrate 
complex),  no  more  free  myo-inositol  and  spermine  (Ff)  will  be  available  for  further 
binding. This is different for citrate, which is present at a high total concentration of 90 
mM compared to the 11 mM and 18 mM of myo-inositol and spermine, respectively. And 
citrate T2 drops by a factor of 2 either by increasing BSA concentration from 5 to 50 g/L 
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or by increasing zinc from 0 to 9 mM. Thus citrate, apart from the spermine-metal ion-
citrate complex, has free citrate, Ff, available to form further complexes with zinc and to 
interact with BSA. Parallelly, since increased zinc concentration did not lower spermine 
T2, it appear that any metal ion present was adequate to form the spermine-metal ion-
citrate complex [11]. For the T2 value of spermine signal at 1.8 ppm (spm5) when mixed 
with 15 g/L BSA and metal ions (with zinc at 9 mM) we measured 0.24 s compared to 
0.32 s from Spencer et al.  [12]. This difference is expected as the authors did not use 
potassium, the second highest concentrated metal in the prostatic fluid  [25]. And thus 
they had less metal ions to form the spermine-metal ion-citrate complex.
The T2 relaxation times differs  for cit_up and cit_down signals  in the presence of 
metallic ions and BSA. This suggests  that these two signals  reflect  different types of 
binding, which can be related to the citrate orientation in the binding site of BSA. This  
agrees with previously observed data on citrate chemical shifts and J-couplings in the 
presence of metallic ions [11], and albumin [36].
Interestingly,  when spermine is  mixed with metal  ions  at  9 mM zinc its  T2 value 
decreases by a factor of 2. It is possible that the addition of zinc dichloride contributes to 
higher levels of chlorine ions that bind to spermine. Another intriguing phenomenon is 
the short myo-inositol T2, of ~0.34 s, when dissolved in MiliQ water, but, mixed with 
metal ions (without zinc) its T2 is higher, ~1 s. This indicates that myo-inositol is more 
free to tumble in presence of metal ions. This can be understood when realizing that the 
solution of the uncharged myo-inositol in MiliQ water will have a very low ionic strength 
(< 1mM) which leads to a Debye-Huckel screening-length  κ-1 that is very long of over 
100 Å and thus the coulombic interactions equal to the thermal energy reaching over this 
distance  (κ2 =  8πQI;  where  Q is  the  Bjerrum length  of  7  Å and I  is  ionic  strength 
expressed in ions per unit volume of Angstrom, see for instance Wu et al. and references 
therein) [37]. In contrast, in the presence of metal ions ( > 10 mM) κ-1 has dropped below 
30 Å and the charge interactions are screened, and the myo-inositol are free to tumble. 
This is consistent with experimental findings of Zhao et al. who have previously reported 
evidence of increasing partial molar volume of myo-inositol in aqueous solution of alkali 
metal salt [38]. This is due to interactions between myo-inositol and metal ions [39].
The T2 value of 0.12 s obtained for citrate (cit_down) in the presence of metal ions 
(with zinc at 9 mM) and 15 g/L BSA comes close to the T2 value of 0.17 ± 0.05 s  
measured for citrate in the human prostate [40] (note that T2 is relatively insensitive to 
field strength). For the T2 value of the spermine protons resonating at 1.8 ppm no data is 
available from prostate tissue, but  for the T2 of these protons we observed a higher value 
then that reported for spermine in human prostatic fluid  0.16 s against 0.056 s [12]. Our 
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higher  T2 value can be explained by the  fact  that  in  prostate  it  is  problematic  to  to 
measure the T2 of spermine, due to overlap of its signals with other resonances (e.g.,  
polyamines and cratine) [12]. For myo-inositol protons no T2 values from prostate tissue 
are available yet.
Peak height and integral were normalized to the metabolite peaks from the mixture 
containing  no  metal  ions  and  no  BSA.  Myo-inositol  and  spermine  showed  only 
significant  decrease  in  peak intensity,  down to  54  % and  79 %,  respectively,  in  the 
presence of 50 g/L BSA and 4 mM zinc. This composition seems to be the optimum for 
binding in our study. In contrast, citrate showed a decrease in intensity in the presence of 
metallic ions down to 63 %. When 50 g/L BSA and 4 mM zinc are added the citrate peak 
height dropped further to 30 %. Overall, citrate showed to be the signal that is the most  
affected through the different sample compositions. Since peak height is related to T2 
relaxation (half-width ≈ 1/T2), these data confirm that interactions seem to affect citrate 
signals more than those of other metabolites.
Peak  integrations,  which  represent  the  total  concentration  of  free  metabolites, 
remained constant throughout all different sample compositions. Since the concentrations 
of the metabolites are much higher than of BSA ([metabolites] >> [BSA]) we observe 
only  fast-exchange  regime  interactions,  where  the  peak  integral  reflects  the  total 
metabolite concentration, i.e. the sum of free and bound metabolite concentrations.
On addition of metallic ions spermine and citrate signals shifted up-field and down-
field,  respectively,  with respect to  myo-inositol.  Increasing BSA concentration caused 
citrate  signals  to  shift  further  down-field.  However,  the  two  citrate  doublet  signals 
chemical shift changes are not equivalent: cit_up shifted by 19 Hz and cit_down by 8 Hz. 
This parallels the citrate T2 data and indicates a preferential orientation of citrate for 
binding  to  BSA and/or  in  the  spermine-metal-ion-citrate  complex.  How  the  citrate 
molecules are exactly oriented towards the protein is difficult to understand because the 
CH2 groups cannot be distinguished from the simple NMR 1/2D 1H and 13C experiments 
employed  here.  The  J-coupling  of  citrate  methylene  protons  increases  by  1  Hz  with 
increasing metal-ion and BSA concentration, and thus represents another NMR parameter 
for binding [11].
CONCLUSION
In this study the T2 relaxation time of metabolite proton spins was found to be the best 
NMR parameter to identify interactions in a mimic of prostatic fluid. The formation of a 
spermine-metal ion-citrate complex was observed and the complex was found to bind to 
BSA. While myo-inositol binds to metal ions and BSA. The high citrate concentrations 
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make it certain that this metabolite can be found complexed with metal ions, BSA and 
spermine. Thanks to the interactions being in the fast exchange regime the citrate signal 
unites information on all the different complexes. The formation of these complexes is 
reported  by  the  lower  T2  relaxation  values  of  citrate  protons.  The  variation  in  peak 
heights follow the trends seen for T2 relaxation. However,  citrate methylenes are not 
equivalent and generate unsymmetrical signals upon bindings. Finally, the constant peak 
integral values of all metabolites for all mixtures confirm that the interactions are in the 
fast-exchange regime. The composition of prostatic fluid may be a factor affecting the in 
vivo  assessment  of  prostate  pathologies  by  1H MRSI  of  metabolites  ratios  in  which 
citrate, myo-inositol and spermine is included.
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SUPPLEMENTARY MATERIALS
F
igure S1 Spermine 1D 1H at 800 MHz at pH 9.4.
Figure S2 Spermine 2D 1H HSQC at 500 MHz at pH 7.1.
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Figure S3 Spermine 2D 1H  J-resolve at 500 MHZ at pH 7.1.
Figure S4 Spermine 2D 1H  TOCSY at 500 MHz at pH 7.1.
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Figure S5 Temperature effect on spermine signals.
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SUMMARY
This  thesis  focuses  on the  study of  molecular  interactions  in  biofluids  by Nuclear 
Magnetic  Resonance  (NMR) a  relatively  new area  within  the  field  of  metabolomics. 
Biofluids  are  complex  water-dissolved  mixtures  of  metabolites,  proteins,  and  lipids, 
which category includes fatty acids, as well as ions, drugs, nutrients, and other cellular 
components. In parallel to the name given to the collection of genes, the genome, the 
collections of metabolites, proteins, and lipid, are called the metabolome, proteome, and 
lipidome, respectively. Their respective fields of study are then termed metabolomics, 
proteomics, and lipidomics. Biofluids surround and flow through tissues and organs of 
the whole body and reflect therefore their biochemistry. And, thanks to this close contact 
biofluids  play  an  important  role  in  active  regulation,  i.e.  homeostasis,  of  the  body. 
However, “The whole is more than the sum of its parts” (Aristotle ca. 350 BC). Not only 
the  molecular  composition  of  biofluids  is  important,  also  interactions  between  the 
molecules need to be considered. Several types of interactions can occur, e.g. between 
metabolites and proteins, between fatty acids and proteins, etc. These interactions in turn 
influence the transport and delivery of metabolites, nutrients and drugs; enzyme-mediated 
biotransformations;  metal  complexation;  and  micellular  compartmentalization  of 
metabolites.  All  these  interactions  can  be  influenced  by  pH,  salt  concentration, 
temperature,  competition  for  binding  sites  or  allosteric  effects  (change  in  protein 
conformation).  Molecular  interactions  of  metabolites,  which  have  not  been  much 
considered in metabolomics, form the main focus of this thesis.
In the introductory Chapter 1 an overview and background is given on various aspects 
of biofluids and metabolomics. Also, the basic theory of NMR is treated, one of the main 
analytical techniques for studying biofluids. Biofluids are very complex in composition 
and qualitative and quantitative measurements both require careful attention to sample 
preparation. In this chapter we  explain how the use of different buffers or complexing 
agents can improve measurement reproducibility of biofluid samples. It is also explained 
how enzymatic activities and small molecule transport  will eventually affect metabolite 
concentration.  But  can  measurements of  metabolite  concentrations  in  crude  biofluids 
reveal these activities? For instance, what is the free concentration of a metabolite or drug 
in  blood  plasma?  And  what  are  the  biological  consequences  of  binding  to  plasma 
proteins?  If a drug or metabolite has a high renal extraction ratio due to active tubular 
secretion, then plasma protein binding will promote drug elimination by transporting the 
drug to the kidney. Similarly, binding processes, such as metabolites binding to Human 
Serum Albumin (HSA), play an enhancing  role in hepatic uptake of  small molecules. 
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Serum albumin,  the  main  transporter  protein  in  plasma,  is  presented  and  its  role  is 
discussed. To measure crude biofluids for determining interactions NMR is the favored 
spectroscopic technique. In the second part of chapter 1, the NMR basic theory in liquid 
media is given, including an overview of the different components of the frequency shift, 
which determines analyte signal positions in NMR spectra. Special attention is paid to the 
aspect of bulk magnetic susceptibility (BMS) and how this affects chemical shift.
Most plasma proteins are transporters and/or enzymes. Thus, they have a crucial role 
in interactions with metabolites and knowledge of protein concentration is essential if one 
wants to measure their impact. In Chapter 2 we propose a new method to measure the 
protein concentration in blood plasma. It is based on the protein-induced bulk magnetic 
susceptibility  (BMS)  that  results  in  a  frequency  shift  change.  This  phenomenon  is 
observed when external referencing is employed, instead of the usual internal chemical-
shift. We used a coaxial setup: an insert containing the external reference solution (TSP) 
and  the  outer  tube  containing  the  proteinated  sample,  e.g.  the  biofluid  sample.  The 
chemical shift change between sample and insert reference signals is proportional to the 
difference  in  BMS,  which  in  turn  is  proportional  to  the  protein  concentration  in  the 
sample. Our aim was to demonstrate and validate that  via the proposed BMS method, 
accurate metabolite  and total  protein quantification can indeed be achieved from one 
single NMR measurement for blood plasma. We specifically investigated the following 
aspects. (1) In a blood-plasma-like environment we assessed the size of the chemical-
shift change by BMS as a function of protein concentration. We also established which 
metabolite resonances are best suited to probe this change, i.e. which metabolites have 
well-accessible  chemical  shifts  that  are  not  affected  by  exchange-interactions  with 
protein. (2) We validated the method by determining the total protein concentration by 
protein-induced BMS in blood plasma of five volunteers and compared it to the total 
protein  concentration  derived  by  standard  colorimetric  methods.  The  error  in  the 
proposed BMS method is estimated to be ≤ 5 %, which is comparable to the ~4 % error 
of the standard colorimetric method used in the clinic. The BMS error is estimated as the 
mean absolute difference in concentration as measured by the standard colorimetric and 
BMS methods. Assuming an error of 0.3 Hz in the chemical-shift determination, one can 
estimate that a meaningful (> 3σ) concentration determination can be performed at and 
above ~10 g/L.  Hence, these results show that BMS is reliable in protein quantification 
for liquid state NMR.
Focusing on the interactions in blood plasma, we studied binding of metabolites to 
HSA. It makes up 60% of all protein content in blood plasma and is known for its ability 
to transport nearly everything in blood plasma. It primarily transports fatty acids (FAs), 
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for  which it  has  seven common binding sites.  In  Chapter 3 we investigate in  blood 
plasma mimics (and blood plasma) by 1D 1H NMR in a non-targeted manner, the binding 
to fatted- and non-fatted HSA of the ~20 endogenous metabolites, commonly detected by 
NMR in blood plasma/serum. Of these ~20 metabolites, only some showed chemical shift 
changes, i.e. fast-exchange or weak binding to HSA with KD in the µM regime. Many 
metabolites  showed  instead  reduced  NMR  resonance  integrals  (reduced  free 
concentration), indicating slow-exchange or strong binding. However, the slow-exchange 
binding is complex and displays apparent weak binding, most likely caused by multiple 
conformations of HSA. Remarkably,  HSA-binding metabolites  are released (increased 
integrals), in part or fully, by fatty acids (FAs) as evidenced by changes in NMR spectra 
of  metabolite  mixtures  with  non-fatted  HSA  versus  fatted  HSA  added.  Further, 
ultrafiltration  is  commonly  used  to  remove  the  protein/lipid  complement  from  the 
biofluid samples. Although protein/lipid removal  simplifies the NMR spectra thanks to 
the concomitant removal of their broad signals, it holds the danger of also removing some 
of the protein-bound metabolites. We therefore tested this aspect of ultrafiltration in the 
blood-plasma mimics.  It  was  found  that  for  most  metabolites  ultrafiltration  does  not 
affect their  concentration. An exception is formed by the tightly bound citrate,  which 
does show a lowered concentration after ultrafiltration.
In Chapter 4, we show by NMR how the two most common fatty acids (FAs) in blood 
plasma - the long-chain FA, stearate (C18:0) and medium-chain FA, myristate (C14:0) - 
affect metabolite-HSA interaction. Of the set of ~20 common NMR-detected metabolites, 
many  are  released  by  stearate  and/or  myristate,  lactate  appearing  the  most  strongly 
affected. Myristate, but not stearate, reduces HSA-binding of phenylalanine and pyruvate. 
Citrate signals were NMR invisible in the presence of HSA. Only at high myristate-HSA 
mole  ratios  11:1,  is  citrate  sufficiently  released  to  be  detected.  Finally,  we  find  that 
limited  dilution  of  blood-plasma  mimics  releases  HSA-bound  metabolites,  a  finding 
confirmed  in  real  blood  plasma  samples.  Based  on  these  findings,  we  provide 
recommendations for NMR experiments for quantitative metabolite profiling.
In Chapter 5 we explore the binding of endogenous metabolites to metal ions and to 
BSA in prostatic fluid. Prostatic fluid composition may change through the development 
of cancer. In vivo magnetic resonance spectroscopy (MRS) of the prostate issued to report 
on metabolites dominant in the intracellular space, e.g. choline and creatine, or in the 
luminal space, e.g. citrate and spermine. Ratios of these metabolites are often employed 
to  assess  the  severity  of  prostate  cancer  (PCa).  Furthermore,  about  70% of  prostate 
cancers arise in the peripheral zone (PZ). PZ' epithelial cells contribute to prostatic fluid 
secretions. This is interesting as the composition of this fluid changes  according to the 
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prostate tissue state, as shown previously by NMR for the  concentrations of the main 
metabolites: citrate, myo-inositol and spermine. Furthermore, metals ions and proteins 
concentrations are affected as part of prostate malignant growth and transformation. This 
chapter describes a study of how NMR parameters of prostatic metabolites, like citrate 
and spermine are affected when they are mixed in the presence or absence of metal ions 
and what influence protein, here BSA, has on this complex formation. These aspects are 
studied in mimics of prostatic fluid. It is found that upon addition of metal ions, like Na+, 
K+, Ca++, Zn++ and Mg++, the T2-relaxation values of spermine and citrate are lowered by 
factors of 2 and 3, respectively. This indicates formation of a spermine-metal-ion-citrate 
complex. We further find that the spermine-metal-ion-citrate complex binds to BSA. The 
effect of the zinc ion is of specific interest as the zinc concentration in PCa has been 
shown to be ~90 % lower in both prostatic  tissue and in prostatic  fluid.  We suggest 
therefore that the T2-relaxation of citrate or spermine may act as a marker of prostate 
cancer  development.  Also,  adjustment  of  pulse  sequences  to  take  account  of  the  T2 
values and the phase evolution of the spins appears required.
In brief the main aspects of interaction profiling in metabolic profiling of blood plasma 
that have been addressed in this thesis are the following. (a) A method is presented that 
allows the total protein concentration in blood plasma to be reliably measured on the 
same sample and at the same time as the metabolite profile. In this way, more complete 
interpretation  of  metabolite  interaction  data  is  achieved,  e.g.  estimate  reduction  in 
metabolite  concentration  due  to  binding  to  proteins.  It  provides  disease  diagnostics 
information related to protein concentration, e.g. for diabetes and inflammation. (b) Many 
metabolites  are  shown to  bind  HSA in  blood plasma and many of  them are  (partly) 
released by fatty acids. The biophysics of the metabolite-HSA interaction is found to be 
complex.  (c)  Ultrafiltration  -  commonly  used  to  remove  proteins  from  a  biofluid  – 
releases most of the bound metabolites. (d) It is shown that the medium-length fatty acid 
myristate and the long-chain fatty acid stearate release metabolites from HSA, each in 
their  own specific way.  These data  together with those from (b)  provide insight  into 
mechanism of metabolite-FA-HSA interaction. They also provide new opportunities to 
assess metabolism and estimate protein and fatty acid content in blood plasma, which is 
of  relevance  for  disease  diagnostics,  e.g.  diabetes.  (e)  It  is  also  shown  that  limited 
dilution  of  blood  plasma  releases  metabolites,  which  may  help  to  establish  total 
metabolite  concentration. (f)  It  is  shown that  in prostatic fluid complexes are formed 
between  spermine  and  citrate,  and  metal  ions,  like  zinc.  This  complexation  leads  to 
reduced  T2-relaxation  times  of  spermine  and/or  citrate.  In  prostatic  cancer,  the  zinc 
concentration is reduced and thus also this complexation is reduced. Consequently, the 
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T2-relaxation of spermine and/or citrate might act as an alternate marker for prostatic 
cancer.
In  conclusion,  interactions  between  biofluid  analytes  form  informative  probes  of 
biologically  relevant  biochemical  processes.  Understanding  and  studying  these 
interactions can help to better delineate the body’s physiology or regulatory mechanisms 
and provide  new markers  in  disease  diagnostics.  Thus,  interactions  between analytes 
form a highly relevant and informative new aspect of metabolite profiling. Accounting for 
interactions in metabolic profiling broadens the toolbox of metabolomics and as a future 
perspective may open up new avenues for disease diagnostics.
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Dit proefschrift  is  een studie naar de moleculaire interacties in biovloeistoffen met 
behulp van kernspinresonantie (Nuclear Magnetic Resonance, NMR), een relatief nieuw 
onderzoeksgebied  binnen  het  veld  van  de  metabolomics.  Biovloeistoffen  zijn 
ingewikkelde, in water opgeloste mengsels van metabolieten, eiwitten en lipiden zoals 
vetzuren, alsmede ionen, medicijnen, voedingsstoffen en andere cellulaire componenten. 
Zoals  de  verzameling  van  alle  genen  het  genoom  is,  zo  kunnen  de  complete 
verzamelingen  van  metabolieten,  eiwitten  en  lipiden  het  metaboloom,  proteoom  en 
lipidoom  genoemd  worden.  De  bestudering  hiervan  heet  dan  ook  respectievelijk 
metabolomics, proteomics en lipidomics. Biovloeistoffen omgeven en stromen door alle 
organen en weefsels van het lichaam en geven daardoor hun biochemie weer. En dankzij 
dit  nauw contact  spelen biovloeistoffen een belangrijke rol  in de homeostase van het 
lichaam. Echter, “Het geheel is meer dan de som der delen” (Aristoteles, circa 350 v. 
Chr.)  Niet alleen is de moleculaire samenstelling van biovloeistoffen belangrijk,  maar 
ook  de  interacties  tussen  moleculen.  Er  zijn  verschillende  interacties  mogelijk, 
bijvoorbeeld tussen metabolieten en eiwitten tussen vetzuren en eiwitten, enzovoorts. Op 
hun  beurt  beïnvloeden  deze  interacties  weer  transport  en  afgifte  van  metabolieten, 
voedingsstoffen  en  medicijnen;  enzym-gekatalyseerde  biotransformaties;  metaal-
complexen;  en  micellaire  compartimentering  van  metabolieten.  Al  deze  interacties 
worden  beïnvloed  door  pH,  zoutconcentratie,  temperatuur,  competitie  voor 
bindingsplaatsen  en  allosterische  effecten  (de  verandering  van  eiwitconformatie).  De 
moleculaire interacties van metabolieten zijn niet vaak overwogen in metabolomics en 
zijn de focus van dit proefschrift.  
In het introducerende Hoofdstuk 1 wordt een overzicht en achtergrond gegeven van 
de verschillende aspecten van biovloeistoffen en metabolomics. Tevens behandelt het de 
basale NMR-theorie, één van de belangrijkste analytische methodes voor het bestuderen 
van  biovloeistoffen.  Biovloeistoffen  zijn  zeer  complex  in  samenstelling  en  voor 
kwalitatieve  en  kwantitatieve  metingen  is  aandacht  voor  monstervoorbereiding 
noodzakelijk. In dit hoofdstuk beschrijven we hoe het gebruik van verschillende buffers 
of complexeringsmiddelen de reproduceerbaarheid van de metingen van biovloeistoffen 
kunnen verbeteren.  Het  legt  eveneens  uit  hoe enzymatische  activiteit  en  transport  de 
metabolietconcentratie beïnvloedt. Echter, kunnen metabolietconcentratie bepalingen in 
onbehandelde biovloeistoffen deze activiteiten bloot leggen? Bijvoorbeeld, wat is de vrije 
concentratie van een metaboliet of medicijn in bloedplasma? En wat zijn de biologische 
consequenties van het binden aan plasma-eiwitten? Als een medicijn of metaboliet een 
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hoge extractieratio van de nieren door actief tubulaire secretie heeft,  dan zal  plasma-
eiwitbinding  de  uitscheiding  van  het  medicijn  via  de  nieren  bevorderen.  Evenzo, 
bindingsprocessen,  zoals  die  van metabolieten  aan  Humaan Serum Albumine  (HSA), 
verhogen  de  leveropname  van  kleine  moleculen.  Serum  albumine,  het  voornaamste 
transporteiwit  in plasma, wordt geïntroduceerd en zijn rol  bediscussieerd.  NMR is de 
voorkeursmethode voor het bepalen van interacties in onbehandelde biovloeistoffen. In 
het tweede deel van hoofdstuk 1 wordt de basistheorie van NMR in vloeistoffen gegeven, 
inclusief een overzicht van de verschillende componenten van de frequentieverschuiving 
die de signaalpositie  in het  NMR-spectrum van een analyt  bepaalt.  Extra aandacht is  
gegeven aan de bulk magnetische susceptibiliteit  (BMS) en het effect op de chemical 
shift.
De meeste  plasma-eiwitten zijn transporters  en/of  enzymen en hebben daarom een 
cruciale  rol  in  interacties.  Ze  hebben  een  belangrijke  rol  in  de  interacties  met 
metabolieten en kennis van de eiwitconcentratie is derhalve essentieel wanneer men hun 
effect wilt meten. In Hoofdstuk 2 stellen wij een nieuwe methode voor het meten van de 
eiwitconcentratie  in bloedplasma voor.  Het is  gebaseerd op de frequentieverschuiving 
door  eiwit-geïnduceerde bulk magnetische susceptibiliteit (BMS). Dit fenomeen wordt 
waargenomen wanneer een externe referentie-oplossing wordt gebruikt in plaats van een 
interne  referentie.  Wij  hebben  een  coaxiale  setup  gebruikt;  een  binnenste  buis  (een 
zogenoemde ‘insert’) met de externe referentie-oplossing en een buitenste buis met het 
eiwit bevattende monster, bijvoorbeeld het monster van lichaamsvloeistof. De  chemical 
shiftverandering van de signalen van de insert en het monster is proportioneel met het  
verschil in BMS, die op zijn beurt weer proportioneel is met de eiwitconcentratie in het 
monster.  Ons doel was om aan te tonen en te valideren dat met behulp van de BMS 
methode  nauwkeurige  metaboliet-  en  eiwitkwantificatie  mogelijk  is  met  één  enkele 
bloedplasma NMR-meting. We hebben specifiek de volgende aspecten bestudeerd. (1) 
We hebben de grootte van de BMS geïnduceerde chemical shiftverandering gemeten als 
functie  van  de  eiwitconcentratie  in  een  bloedplasma-achtig  medium.  We hebben  ook 
vastgesteld welke metabolieten  het  best  geschikt  zijn  om deze  verandering  te  meten, 
d.w.z.  metabolieten  die  goed  te  bepalen  chemical  shifts  hebben  en  die  niet  worden 
beïnvloed door eiwit-interacties. (2) We hebben de methode gevalideerd door de totale 
eiwitconcentratie  in  bloedplasma  van  vijf  vrijwilligers  te  bepalen  met  de  eiwit-
geïnduceerde BMS methode en met de standaard colorimetrische methode. De geschatte 
fout in de voorgestelde BMS methode is ≤ 5 %, vergelijkbaar met de ~4% fout voor de 
standaard colorimetrische methode die gebruikt wordt in de kliniek. De fout in de BMS 
methode is geschat als het gemiddelde absolute verschil in concentratie ten opzichte van 
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de  colorimetrische  methode.  Als  een  fout  van  0.3  HZ  in  the  chemical  shift  wordt 
aangenomen,  dan  kan  men  afschatten  dat  een  betekenisvolle  bepaling  kan  worden 
uitgevoerd bij een concentratie van ~10 g/L of hoger. Dus deze resultaten laten zien dat 
BMS een betrouwbare vloeistof NMR methode is voor eiwitconcentratie bepalingen.
Voor  het  bestuderen  van  interacties  in  bloedplasma  hebben  wij  ons  gericht  op  de 
binding  van  metabolieten  aan  HSA.  Het  is  goed  voor  60%  van  alle  eiwitten  in 
bloedplasma en HSA staat  bekent om het vermogen om vrijwel  alles  in het  bloed te 
transporteren.  Het  transporteert  voornamelijk  vetzuren  en  heeft  hiervoor  7 
gemeenschappelijke bindingsplaatsen. In Hoofdstuk 3 hebben we op ongerichte wijze in 
bloedplasma  imitaties  (en  bloedplasma)  met  1D  1H-NMR  de  binding  van  de  ~20 
endogene metabolieten die algemeen worden waargenomen met NMR aan vervette en 
niet-vervette HSA onderzocht. Slechts enkele van deze ~20 metabolieten lieten chemical 
shift veranderingen zien, d.w.z. hebben ‘snelle uitwisseling’ of zwakke binding aan HSA, 
met  een  dissociatie  constante  KD in  het  µM  regime.  In  plaats  daarvan  lieten  veel 
metabolieten een afgenomen signaalintegraal  zien (afgenomen vrije  concentratie),  wat 
een  indicatie  is  voor  ‘langzame  uitwisseling’ of  sterke  binding.  Echter,  binding  via 
langzame uitwisseling is complex en vertoont schijnbare zwakke binding, waarschijnlijk 
geïnduceerd  door  verschillende  conformaties  van  HSA.  Het  is  opmerkelijk  dat  HSA 
gebonden metabolieten gedeeltelijk of geheel vrijkomen (toegenomen integralen) door 
vetzuren,  getuige de verschillen in NMR spectra van de metabolietmengsels  met niet 
vervette  HSA versus  vervette  HSA.  Ultrafiltratie  wordt  algemeen  gebruikt  om  de 
eiwit/lipid componenten van biovloeistoffen te verwijderen. Hoewel het verwijderen van 
de eiwit/lipid componenten de NMR-spectra vereenvoudigt omdat de brede signalen uit 
het spectrum verdwijnen, brengt dit het gevaar met zich mee dat ook de eiwitgebonden 
metabolieten  worden  verwijderd.  Wij  hebben  daarom  dit  aspect  van  ultrafiltratie  in 
bloedplasma-imitaties  getest.  Het  bleek  dat  ultrafiltratie  voor  de  meeste  metabolieten 
geen effect heeft op de concentratie. Eén uitzondering is het sterk gebonden citraat, dat 
wel een verlaagde concentratie na ultrafiltratie laat zien.
In  Hoofdstuk  4,  laten  we  met  NMR  zien  hoe  de  twee  in  bloedplasma  meest 
voorkomende vetzuren – de lange keten stearaat (C18:0) en de kortere myristaat (C14:0) 
–  de  metaboliet/HSA  interactie  beïnvloedt.  Veel  van  de  ~20  algemeen  NMR-
waargenomen metabolieten komen vrij door stearaat en/of myristaat, waarbij het effect 
het  grootst  lijkt  bij  lactaat.  Myristaat,  en  niet  stearaat  verlaagt  de  HSA binding  van 
fenylalanine en pyruvaat. Citraatsignalen waren NMR onzichtbaar in aanwezigheid van 
HSA.  Slechts  bij  hoge  molaire  myristaat-HSA  ratio’s  11:1,  is  citraat  voldoende 
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vrijgekomen om te worden opgepikt. Tot slot, zien we dat bij beperkte verdunning van 
bloedplasma  imitaties  de  HSA  gebonden  metabolieten  vrijkomen  en  dit  is  verder 
bevestigd in echt bloedplasma. Op basis van deze bevindingen geven we aanbevelingen 
voor NMR experimenten voor kwantitatieve bepaling van het metabolietprofiel. 
In  Hoofdstuk  5  onderzoeken  we  de  binding  van  endogene  metabolieten  aan 
metaalionen en BSA in prostaatvloeistof. Gedurende de ontwikkeling van prostaatkanker 
kan  de  samenstelling  van  prostaatvloeistof  veranderen.  In  vivo  kernspinresonantie-
spectroscopie  (magnetic  resonance  spectroscopy,  MRS)  wordt  gebruikt  om  de 
voornaamste metabolieten in de intracellulaire ruimte, bijvoorbeeld choline en creatine, 
en in de luminale ruimte, bijvoorbeeld citraat en spermine, te bepalen. Om de ernst van 
prostaatkanker (prostate cancer, PCa) vast te stellen worden ratios van deze metabolieten 
vaak gebruikt. Bovendien ontstaat ongeveer 70% van de PCa in de perifere zone (PZ). 
PZ-epitheelcellen dragen bij aan de afscheiding van prostaatvloeistof. Dit is interessant 
omdat de samenstelling van de prostaatvloeistof verandert als gevolge van de toestand 
van  de  prostaat,  zoals  eerder  is  laten  zien  met  NMR voor  de  concentraties  van  de 
voornaamste metabolieten: citraat, myo-inosytol en spermine. Bovendien veranderen de 
metaalion- en eiwitconcentraties als gevolg van kwaadaardige groei en verandering van 
de  prostaat.  Dit  hoofdstuk  beschrijft  een  studie  naar  hoe  NMR-parameters  van 
prostaatmetabolieten, zoals citraat en spermine, veranderen door de aan- of afwezigheid 
van metaalionen en wat de invloed is van eiwitten, in dit geval BSA, op de vorming van 
deze complexen. Deze aspecten zijn in prostaatvloeistof-imitaties bestudeerd. Het blijkt 
dat  het  toevoegen  van  metaalionen  zoals  Na+,  K+,  Ca++,  Zn++ en  Mg++ de  T2-
relaxatiewaarden van spermine en citraat respectievelijk met een factor 2 en 3 verlaagd. 
Dit duidt op een spermine-metaalion-citraat complex. We vinden verder dat dit spermine-
metaalion-citraat  complex  aan  BSA bindt.  Het  effect  van  het  zink-ion  is  bijzonder 
interessant omdat de zinkconcentratie in het geval van PCa met ~90% afneemt zowel in 
prostaatweefsel  als  in  prostaatvloeistof.  We  stellen  daarom  voor  dat  de  T2-
relaxatiewaarden van spermine  of  citraat  als  een  kenmerk  voor  de  ontwikkeling  van 
prostaatkanker  kan  dienen.  Bovendien  lijken  aanpassingen  van  pulssequenties 
noodzakelijk om rekening te houden met de T2-relaxatiewaarden en de fase-evolutie van 
de kernspins. 
In het kort zijn de belangrijkste aspecten van het bepalen van het interactieprofiel van 
het metabole profiel van bloedplasma die in dit proefschrift zijn behandeld de volgende. 
(a)  Een  methode  is  gepresenteerd  die  de  totale  eiwitconcentratie  in  bloedplasma 
betrouwbaar kan bepalen op hetzelfde monster en tijdens hetzelfde experiment als voor 
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de bepaling van het metabolietprofiel. Op deze manier kan er een volledigere interpretatie 
van  de  metaboliet-interactie  data  worden  bereikt,  bijvoorbeeld  de  afname  van 
metabolietconcentraties  als  gevolg  van  eiwitbinding.  Dit  geeft  informatie  voor  de 
diagnoses  van  ziekten  waar  de  totale  eiwitconcentratie  veranderd,  bijvoorbeeld  bij 
diabetes en ontsteking. (b) Veel metabolieten in bloedplasma blijken aan HSA te binden 
en velen hiervan komen (gedeeltelijk) vrij door vetzuren. De biofysica van metaboliet-
HSA blijkt  erg  complex.  (c)  Bij  utrafiltratie  –  algemeen  gebruikt  om  eiwitten  te 
verwijderen van biovloeistoffen – komen de meeste gebonden metabolieten vrij. (d) Het 
blijkt  dat  met  het  middellange  vetzuur  myristaat  en  het  lange  vetzuur  stearaat  de 
metabolieten vrijmaken van HSA, ieder op zijn eigen wijze. Deze data samen met die van 
(b) geven inzicht in het mechanisme van metaboliet-vetzuur-HSA interactie. Zij geven 
tevens nieuwe mogelijkheden om het metabolisme en eiwit- en vetzuurconcentraties te 
bepalen, wat van belang is voor de diagnose van ziekten zoals diabetes. (e) Het blijkt ook 
dat het beperkt verdunnen van bloedplasma leidt tot het vrijkomen van metabolieten wat 
kan helpen bij de bepaling van de totale metabolietconcentratie. (f) Het laat ook zien dat 
er  complexen  worden  gevormd  in  prostaatvloeistof  tussen  citraat  en  spermine  en 
metaalionen  zoals  zink.  Deze  complexvorming  leidt  tot  een  reductie  in  de  T2-
relaxatiewaarden  van spermine  en/of  citraat.  In  prostaatkanker  is  de  zinkconcentratie 
gereduceerd  en  dus  is  ook  de  complexvorming  afgenomen.  Daarom  kunnen  T2-
relaxatietijden wellicht als een alternatief kenmerk voor prostaatkanker dienen.
Concluderend, de interacties tussen lichaamsvloeistof-analyten geven een goede inkijk 
in de biologisch relevante biochemische processen. Het begrip en de studie van deze 
interacties  kan  helpen  bij  het  ontrafelen  van  de  fysiologie  van  het  lichaam  en  de 
regulatiemechanismen en voorziet in nieuwe kenmerken voor de diagnose van ziekten. 
Daarom vormen de interacties tussen analyten een zeer relevant en informatief nieuw 
aspect in de bepalingen van metabolietprofielen. Bepalingen van deze interacties is een 
nieuw  instrument  in  metabolomics  en  kan  als  toekomstperspectief  dienen  voor  de 
diagnose van ziekten.
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